

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:23 ; Search time 38 Seconds
(without alignments)
995.873 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKPSLELPQWYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_101002.*

- 1: /SID22/gcgdata/geneseq/geneseqp-embl/AA1980.DAT.*
- 2: /SID22/gcgdata/geneseq/geneseqp-embl/AA1981.DAT.*
- 3: /SID22/gcgdata/geneseq/geneseqp-embl/AA1982.DAT.*
- 4: /SID22/gcgdata/geneseq/geneseqp-embl/AA1983.DAT.*
- 5: /SID22/gcgdata/geneseq/geneseqp-embl/AA1984.DAT.*
- 6: /SID22/gcgdata/geneseq/geneseqp-embl/AA1985.DAT.*
- 7: /SID22/gcgdata/geneseq/geneseqp-embl/AA1986.DAT.*
- 8: /SID22/gcgdata/geneseq/geneseqp-embl/AA1987.DAT.*
- 9: /SID22/gcgdata/geneseq/geneseqp-embl/AA1988.DAT.*
- 10: /SID22/gcgdata/geneseq/geneseqp-embl/AA1989.DAT.*
- 11: /SID22/gcgdata/geneseq/geneseqp-embl/AA1990.DAT.*
- 12: /SID22/gcgdata/geneseq/geneseqp-embl/AA1991.DAT.*
- 13: /SID22/gcgdata/geneseq/geneseqp-embl/AA1992.DAT.*
- 14: /SID22/gcgdata/geneseq/geneseqp-embl/AA1993.DAT.*
- 15: /SID22/gcgdata/geneseq/geneseqp-embl/AA1994.DAT.*
- 16: /SID22/gcgdata/geneseq/geneseqp-embl/AA1995.DAT.*
- 17: /SID22/gcgdata/geneseq/geneseqp-embl/AA1996.DAT.*
- 18: /SID22/gcgdata/geneseq/geneseqp-embl/AA1997.DAT.*
- 19: /SID22/gcgdata/geneseq/geneseqp-embl/AA1998.DAT.*
- 20: /SID22/gcgdata/geneseq/geneseqp-embl/AA1999.DAT.*
- 21: /SID22/gcgdata/geneseq/geneseqp-embl/AA2000.DAT.*
- 22: /SID22/gcgdata/geneseq/geneseqp-embl/AA2001.DAT.*
- 23: /SID22/gcgdata/geneseq/geneseqp-embl/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	1525	100.0	284	22	AAB62695
2	1525	100.0	2143	21	AAB38108
3	1525	100.0	2259	21	AAB38107
4	1525	100.0	2260	21	AAB38106
5	1525	100.0	2261	21	AAB38082
6	1525	100.0	2261	21	AAB38105
7	1525	100.0	2261	21	AAB38109
8	1525	100.0	2261	21	AAB38110
9	1525	100.0	2261	21	AAB38111
10	1525	100.0	2261	21	AAB38112

11	1525	100.0	2261	21	AAB38113	Human ABC1 cholest
12	1525	100.0	2261	21	AAB38114	Human ABC1 cholest
13	1525	100.0	2261	21	AAB38116	Human ABC1 cholest
14	1525	100.0	2261	21	AAB38117	Human ABC1 cholest
15	1525	100.0	2261	21	AAB38117	Human ABC1 cholest
16	1525	100.0	2261	22	AAB381361	Amino acid sequenc
17	1525	100.0	2261	22	AAB381362	Amino acid sequenc
18	1525	100.0	2261	22	AAB381363	Amino acid sequenc
19	1525	100.0	2261	22	AAB381365	Amino acid sequenc
20	1525	100.0	2261	22	AAB381366	Amino acid sequenc
21	1525	100.0	2261	22	AAB381367	Amino acid sequenc
22	1525	99.8	2261	21	AAB38115	Human ABC1 cholest
23	1513	99.2	2130	22	AU002190	Human ABC1 mutant
24	1513	99.2	2201	21	AAV79380	Human ATP binding
25	1513	99.2	2201	22	AAE13021	Human ATP binding
26	1513	99.2	2201	22	AAW50227	Human ATP binding
27	1513	99.2	2261	21	AAB38104	Human ABC1 cholest
28	1513	99.2	2261	22	AAE13022	Human ATP binding
29	1513	99.2	2261	22	AAW50228	Human ATP binding
30	1513	99.2	2261	22	AAW78550	Human protein SEQ
31	1513	99.2	2261	22	AAU02176	Human ABC1. Homo
32	1513	99.2	2261	22	AAU02177	Human ABC1 mutant
33	1513	99.2	2261	22	AAU02181	Human ABC1 mutant
34	1513	99.2	2261	22	AAU02182	Human ABC1 mutant
35	1513	99.2	2261	22	AAU02183	Human ABC1 mutant
36	1513	99.2	2261	22	AAU02186	Human ABC1 mutant
37	1513	99.2	2261	22	AAU02189	Human ABC1 mutant
38	1513	99.2	2261	23	AB881578	Human ABC-A-1-1 pr
39	1513	99.2	2261	23	AAE23000	Human ABC1 full-le
40	1513	99.2	2263	22	AB911956	Human ABC1 homolo
41	1513	99.2	2263	22	AB9179534	Human protein SEQ
42	1510	99.0	2261	22	AAU02188	Human ABC1 mutant
43	850	55.7	1525	22	AAU02187	Human ABC1 mutant
44	733.5	48.1	2273	19	AAW70398	ATP binding casset
45	663.5	43.5	1873	22	AAW04484	Human PD-ATP-bind

ALIGNMENTS

RESULT 1

AAB62695

ID AAB62695 standard; peptide; 284 AA.

AC AAB62695;

DT 06-AUG-2001 (first entry)

DE ABC1 protein external domain TM7-TM8 fragment (residues 1371-1654).

KW ABC1; antilipemic; cholesterol; inhibitor; low density lipoprotein; LDL.

OS Homo sapiens.

PN WO200132184-A2.

PD 10-MAY-2001.

PF 01-NOV-2000; 2000WO-US530109.

PR 01-NOV-1999; 99US-0162803.

PR 30-JUN-2000; 2000US-0215564.

XX (WISC) WISCONSIN ALUMNI RES FOUND.

XX Attle AD, Cook M, Gray-Keller MP, Hayden MR, Plimstone S;

PI Brooks-Willson A;

XX WPI; 2001-335779/35.

XX New method for inhibiting cholesterol uptake in the gut comprises

PT administration of an inhibitor of an ABC1 protein -

XX

PS Disclosure: Page 9; 41pp; English.

XX The invention relates to a new method for inhibiting cholesterol uptake

CC in the gut that comprises administration of an inhibitor of an ABC1

CC protein. The method is useful for: lowering levels of LDL (low density

CC lipoprotein) cholesterol by reducing the activity of ABC1 protein in the

CC intestinal cells and the abundance of the ABC1 protein in the individual

CC by inhibiting the activity of the protein; identifying drugs that can

CC lower serum cholesterol and LDL levels comprising assaying the drug to

CC test if it can bind to an ABC1 protein; testing LDL cholesterol lowering

CC agents; and for modulation of ABC1 biological activity. Sequences

CC AAB62692-97 represent predicted external domain of ABC1 protein.

XX

XX Sequence 284 AA;

XX

Query Match 100.0%; Score 1525; DB 22; Length 284;

Best Local Similarity 100.0%; Pred. No. 2.3e-144;

Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 60

DB 1 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 60

QY 61 AGEETWTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPCAGGLPPPPQRK 120

DB 61 AGEETWTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPCAGGLPPPPQRK 120

QY 121 QNTADILQDLTGRTSDYLKTYVQIITAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 180

DB 121 QNTADILQDLTGRTSDYLKTYVQIITAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 180

QY 181 VNDATKQMKKHLKAKDSADRFNLGSRFTGLDTRNNYKVFNNKGWHAISSEFLNVIN 240

DB 181 VNDATKQMKKHLKAKDSADRFNLGSRFTGLDTRNNYKVFNNKGWHAISSEFLNVIN 240

QY 241 NAILRANLQKGNPSHYGITAFNHLPLNLTQOOLSEVALMTTSVD 284

DB 241 NAILRANLQKGNPSHYGITAFNHLPLNLTQOOLSEVALMTTSVD 284

RESULT 2

AAB38108

ID AAB38108 standard; Protein: 2143 AA.

XX

AC AAB38108;

XX

DT 29-JAN-2001 (first entry)

XX

DE Human ABC1 cholesterol transporter PHA-1 mutant protein (R2144STOP).

XX

KW Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cardiovascular disease; coronary artery disease; coronary stenosis;

KW cerebrovascular disease; peripheral vascular disease;

KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

KW mutin.

XX

OS Homo sapiens.

XX

PN WO20005318-A2.

XX

PD 21-SEP-2000.

XX

PF 15-MAR-2000; 2000WO-IB00532.

XX

PR 15-MAR-1999; 99US-0124702.

PR 08-JUN-1999; 99US-0138048.

PR 17-JUN-1999; 99US-0139600.

PR 01-SEP-1999; 99US-0151977.

XX

PA (UYBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.

XX

PI Hayden MR, Wilson AR, Pimstone SN;

XX

DR WPI: 2000-587528/55.

DR N-PSDB; AAC69389.

XX

PT New ABC1 polypeptide is useful for treating diseases associated with

PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's

PT disease and cancer -

XX

PS Examples; Page -: 229pp; English.

XX

CC The invention relates to the human ABC1 cholesterol transporter protein

CC (B3802) and to nucleic acid sequences (C69120) which encode it. ABC1 is

CC a member of the ATP-binding cassette (ABC transporter) superfamily of

CC proteins, and plays a crucial role in cholesterol transport, particularly

CC intracellular cholesterol trafficking in monocytes and fibroblasts, being

CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is

CC located on chromosome 9q31, and mutations in this gene are associated

CC with two genetic HDL (high density lipoprotein) deficiency disorders,

CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases

CC are distinguishable in that TD is an autosomal recessive disorder, while

CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good

CC cholesterol") in the blood correlate with a high risk of cardiovascular

CC disease, particularly coronary artery disease, but also cerebrovascular

CC disease, coronary stenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against

CC cardiovascular disease. The invention provides genetic constructs and

CC transgenic cells and non-human animals comprising human ABC1 nucleic

CC acids, and methods of gene therapy for the treatment or prevention of

CC cardiovascular disease comprising the administration of an expression

CC vector encoding ABC1 or an active fragment thereof. The invention also

CC encompasses compounds which mimic ABC1 activity, compounds which

CC stimulate ABC1 expression and methods of screening for such compounds.

CC It further relates to methods for determining whether a patient has an

CC increased risk for cardiovascular disease due to polymorphisms in the

CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat

CC or prevent cardiovascular disease, especially coronary artery disease,

CC cerebrovascular disease, coronary stenosis or peripheral vascular

CC disease. They may also be used in the treatment of diseases associated

CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick

CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

CC The invention specifically excludes proteins with the exact amino acid

CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic

CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The

CC present sequence represents a mutant human ABC1 cholesterol transporter

CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is

CC derived from the native human ABC1 shown on pages 152-157.

XX

XX Sequence 2143 AA;

XX

Query Match 100.0%; Score 1525; DB 21; Length 2143;

Best Local Similarity 100.0%; Pred. No. 4.7e-143;

Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 60

DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAEDTGTLELLNALTDPGFGTRCMGPNIPDTPCQ 1430

QY 61 AGEETWTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPCAGGLPPPPQRK 120

DB 1431 AGEETWTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPCAGGLPPPPQRK 1490

QY 121 QNTADILQDLTGRTSDYLKTYVQIITAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 180

DB 1491 QNTADILQDLTGRTSDYLKTYVQIITAKSLKNIWNEFRYGFSLGVSNTQALPPSOE 1550

QY 181 VNDATKQMKKHLKAKDSADRFNLGSRFTGLDTRNNYKVFNNKGWHAISSEFLNVIN 240

Db 1551 VNDATKQMKHKLAKDSSADREFLNSLGRFMTGLDTRNNKVFNNKGWHAISSEFLNVIN 1610
 QY 241 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 284
 Db 1611 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 1654

RESULT 3
 AAB38107
 ID AAB38107 standard; Protein; 2259 AA.
 XX AC AAB38107;
 XX 29-JAN-2001 (first entry)
 XX Human ABC1 FHA-3 mutant protein (delta-E1893, D1894).
 XX Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW muten.
 XX Homo sapiens.
 XX OS
 XX PN WO200055318-A2.
 XX 21-SEP-2000.
 XX PD
 XX 15-MAR-2000; 2000WO-IB00532.
 XX PF
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 XX Haydén MR, Wilson AR, Pimstone SN;
 XX WPI; 2000-587528/55.
 DR N-PSDB; AAC69388.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 XX Examples; Page -: 229pp; English.

The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (c69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression

CC vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: AJ012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2259 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2259;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFCRCMEGNPIPTPCQ 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1371 FKYPSELEQPMWYNEQYTFVSNDAPEDTGTLLELNALTKDPGFCRCMEGNPIPTPCQ 1430
 QY 61 AGESEWTTAPVPTIMDLFQNGNWTMONPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1431 AGESEWTTAPVPTIMDLFQNGNWTMONPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490
 QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNTQALPPSQE 180
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1491 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNTQALPPSQE 1550
 QY 181 VNDATKQMKHKLAKDSSADREFLNSLGRFMTGLDTRNNKVFNNKGWHAISSEFLNVIN 240
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1551 VNDATKQMKHKLAKDSSADREFLNSLGRFMTGLDTRNNKVFNNKGWHAISSEFLNVIN 1610
 QY 241 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 284
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1611 NAILRANLQKGENPSHYGITAFNHPNLNTKQOLSEVALMTTSVD 1654

RESULT 4
 AAB38106
 ID AAB38106 standard; Protein; 2260 AA.
 XX AC AAB38106;
 XX 29-JAN-2001 (first entry)
 XX Human ABC1 cholesterol transporter FHA-1 mutant protein (delta-L693).

XX Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW muten.

XX Homo sapiens.
 XX OS
 XX PN WO200055318-A2.
 XX 21-SEP-2000.
 XX PD

CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents the human ABC1 cholesterol transporter.
 XX
 SQ Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTELLNALT KDPGFTRCMGPNIPDTPCQ 60
 DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTELLNALT KDPGFTRCMGPNIPDTPCQ 1430

QY 61 AGEEWTTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPQPK 120
 DB 1431 AGEEWTTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPQPK 1490

QY 121 QNTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNFRYGGFSLGVSNTQALPPSQE 180
 DB 1491 QNTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNFRYGGFSLGVSNTQALPPSQE 1550

QY 181 VNDAIKQMKHLKLAKDSSADRFSLGFRMTGLDTRNNVKWFNKGWHAISFLNVLN 240
 DB 1551 VNDAIKQMKHLKLAKDSSADRFSLGFRMTGLDTRNNVKWFNKGWHAISFLNVLN 1610

QY 241 NATLRANLQGENPSHYGTAFNHPNLNLTQKQSEVALMTTSDV 284
 DB 1611 NATLRANLQGENPSHYGTAFNHPNLNLTQKQSEVALMTTSDV 1654

RESULT 6
 AAB38105
 ID AAB38105 standard; Protein; 2261 AA.
 XX
 AC AAB38105;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human ABC1 cholesterol transporter TD-2 mutant protein (Q597R).
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW Alzheimer's disease; Niemann-Pick disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutin.

OS Homo sapiens.

XX

PN WO200055318-A2.

XX

PD 21-SEP-2000.
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 PR 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX
 DR WPI; 2000-587528/55.
 DR N-PSDB; AAC69386.
 XX

New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer.

Examples; Page -: 229pp; English.

CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

SQ Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTELLNALT KDPGFTRCMGPNIPDTPCQ 60

DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTELLNALT KDPGFTRCMGPNIPDTPCQ 1430

QY 61 AGEEWTTAPVQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPQPK 120

```

Db 1431 AGESEWTTAPVQITMDLFGQNNWMTQNPSPACQSSDKIKMLPVCPPGAGGLPPQPK 1490
Qy 121 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 180
Db 1491 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 1550
Qy 181 VNDATKQMKHKLAKDSSADRFNSLGRFMTGLDTRNNKVVWNNKGWHAISFLNWIN 240
Db 1551 VNDATKQMKHKLAKDSSADRFNSLGRFMTGLDTRNNKVVWNNKGWHAISFLNWIN 1610
Qy 241 NAILRANLQKGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 284
Db 1611 NAILRANLQKGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 1654

RESULT 7
AAB38109
ID AAB38109 standard; Protein; 2261 AA.
XX
AC AAB38109;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter mutant, R219K.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
XX
OS Homo sapiens.
XX
PN WO2000055318-A2.
XX
PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
PI Hayden MR, Wilson AR, Pimstone SN;
XX
XX WPI; 2000-587528/55.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Examples; Page -: 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC

```

```

CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;
XX
Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 FGKYPSELQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPGFGRMCGNPIPDTPCQ 60
Db 1371 FGKYPSELQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPGFGRMCGNPIPDTPCQ 1430
Qy 61 AGESEWTTAPVQITMDLFGQNNWMTQNPSPACQSSDKIKMLPVCPPGAGGLPPQPK 120
Db 1431 AGESEWTTAPVQITMDLFGQNNWMTQNPSPACQSSDKIKMLPVCPPGAGGLPPQPK 1490
Qy 121 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 180
Db 1491 QNTADILQDLTGRNLSYLVKTYVQIIIAKSLKNIWNEFRYGGFSLGVSNQALPPSQE 1550
Qy 181 VNDATKQMKHKLAKDSSADRFNSLGRFMTGLDTRNNKVVWNNKGWHAISFLNWIN 240
Db 1551 VNDATKQMKHKLAKDSSADRFNSLGRFMTGLDTRNNKVVWNNKGWHAISFLNWIN 1610
Qy 241 NAILRANLQKGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 284
Db 1611 NAILRANLQKGENPSHYGITAFNHPNLTKQOLSEVALMTTSVD 1654

RESULT 8
AAB38110
ID AAB38110 standard; Protein; 2261 AA.
XX
AC AAB38110;
XX
DT 29-JAN-2001 (first entry)
XX
XX Human ABC1 cholesterol transporter mutant, V399A.
XX
XX Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW

```

KW mutein.
 OS Homo sapiens.
 XX WO200055318-A2.
 PN 21-SEP-2000.
 PD
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX
 DR WPI: 2000-587528/55.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary stenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary stenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of Genbank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as Genbank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 XX Sequence 2261 AA;
 SQ

Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. NO. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKPSLELPQWYMYNEQYTFVSNDAPEDTGTLELLNALTKDGFGRGTRCMEGNPIPTPCQ 60
 DB 1371 FGKPSLELPQWYMYNEQYTFVSNDAPEDTGTLELLNALTKDGFGRGTRCMEGNPIPTPCQ 1430
 QY 61 AGESEWTTAPVPTIMDLFONGNWTMONPSPACQSSDK1KKMLPVCPPGAGGLPPQPK 120
 DB 1431 AGESEWTTAPVPTIMDLFONGNWTMONPSPACQSSDK1KKMLPVCPPGAGGLPPQPK 1490
 QY 121 QNTADILQDITGRNISDYLVKTYVQIIIAKSLANKIWNNEFRYGGFSLGVSTQALPPSQE 180
 DB 1491 QNTADILQDITGRNISDYLVKTYVQIIIAKSLANKIWNNEFRYGGFSLGVSTQALPPSQE 1550
 QY 181 VNDAIKQMKKHLKLAKDSSADRELSLGRFMTGLDTRNNKVKWFNKGWHAISFLNWIN 240
 DB 1551 VNDAIKQMKKHLKLAKDSSADRELSLGRFMTGLDTRNNKVKWFNKGWHAISFLNWIN 1610
 QY 241 NAILRANLQGENPSHYGITAFNHNPLNLTQKQLSEVALMTTSD 284
 DB 1611 NAILRANLQGENPSHYGITAFNHNPLNLTQKQLSEVALMTTSD 1654
 RESULT 9
 AAB38111
 ID AAB38111 standard; Protein; 2261 AA.
 XX
 AC AAB38111;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human ABC1 cholesterol transporter mutant, V771M.
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary stenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutin.
 XX
 OS Homo sapiens.
 XX
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 PR 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX
 DR WPI: 2000-587528/55.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary stenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary stenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of Genbank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as Genbank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 XX Sequence 2261 AA;
 SQ

CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

Query Match 100.08; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.08; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FGKPSLELPQWYNEQTFVSNAPEDTGTLELLNALTDPGFGTRCMEGNPIDPTCQ 60
|||||
DB 1371 FGKPSLELPQWYNEQTFVSNAPEDTGTLELLNALTDPGFGTRCMEGNPIDPTCQ 1430
|||||
QY 61 AGEETWTPAVQTMDLFGNGNWTMNPSPACQSSDKTKKMLPVCPPGAGLPPQQR 120
|||||
DB 1431 AGEETWTPAVQTMDLFGNGNWTMNPSPACQSSDKTKKMLPVCPPGAGLPPQQR 1490
|||||
QY 121 QNTADILQDLTGRNISDYLVKTYVOITIAKSLKNIWNEFRYGFSLGVSNTOALPPSQE 180
|||||
DB 1491 QNTADILQDLTGRNISDYLVKTYVOITIAKSLKNIWNEFRYGFSLGVSNTOALPPSQE 1550
|||||
QY 181 VNDAIKQMKHLKLAKDSSAORFLNSLGRPMTGDTNRNNKVPNNKGWHAISFLNVIN 240
|||||
DB 1551 VNDAIKQMKHLKLAKDSSAORFLNSLGRPMTGDTNRNNKVPNNKGWHAISFLNVIN 1610
|||||
QY 241 NATLRANLQKGNPSHYGTTAFNHPNLTKQLSEVALMTTSVD 284
|||||
DB 1611 NATLRANLQKGNPSHYGTTAFNHPNLTKQLSEVALMTTSVD 1654
|||||

RESULT 10

AAB38112

ID AAB38112 standard; Protein: 2261 AA.

XX

XX AAB38112;

AC

DT 29-JAN-2001 (first entry)

XX

DE Human ABC1 cholesterol transporter mutant, T774P.

XX

XX Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW mutin.

OS Homo sapiens.

XX

PN WO200055318-A2.

XX

PD 21-SEP-2000.

XX

PF 15-MAR-2000; 2000WO-IB00532.

XX

PR 15-MAR-1999; 99US-0124702.

PR

PR 08-JUN-1999; 99US-0138048.

PR

PR 17-JUN-1999; 99US-0139600.

PR

PR 01-SEP-1999; 99US-0151977.

XX

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX (XENO-) XENON BIORESEARCH INC.

XX

XX Hayden MR, Wilson AR, Pimstone SN;

XX

XX WPI; 2000-587528/55.

XX

XX New ABC1 polypeptide is useful for treating diseases associated with
XX ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
XX disease and cancer -

XX Examples; Page -: 229pp; English.

CC The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;


```
Query Match          100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKYPSELELPWMYNEQYTFVSNDAPEDTGTTLELLNALT KDPGFTRCMENPIPDTPCQ 60
Db 1371 FGKYPSELELPWMYNEQYTFVSNDAPEDTGTTLELLNALT KDPGFTRCMENPIPDTPCQ 1430

Qy 61 AGESEWTTAPVPTIMDLFQNGWNTMNPSPACQCSSDKIKMLPVCPPGAGGLPPQPK 120
Db 1431 AGESEWTTAPVPTIMDLFQNGWNTMNPSPACQCSSDKIKMLPVCPPGAGGLPPQPK 1490

Qy 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1491 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550

Qy 181 VNDAIKMKKHLKLAQSSADREFLSLGRFMTGLDTRNNKVKWNNKQWHAISFLNWIN 240
Db 1551 VNDAIKMKKHLKLAQSSADREFLSLGRFMTGLDTRNNKVKWNNKQWHAISFLNWIN 1610

Qy 241 NAILRANLQGENPSHYGITAFNHNPLNLTQQOLSEVALMTTTSVD 284
Db 1611 NAILRANLQGENPSHYGITAFNHNPLNLTQQOLSEVALMTTTSVD 1654

RESULT 11
AAB38113
ID AAB38113 standard; Protein; 2261 AA.
XX AC AAB38113;
XX DT 29-JAN-2001 (first entry)
XX DE Human ABC1 cholesterol transporter mutant, K776N.
XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
XX OS Homo sapiens.
XX PN WO200005318-A2.
XX PD 21-SEP-2000.
XX PF 15-MAR-2000; 2000WO-IB00532.
XX PR 15-MAR-1999; 99US-0124702.
XX PR 08-JUN-1999; 99US-0138048.
XX PR 17-JUN-1999; 99US-0139600.
XX PR 01-SEP-1999; 99US-0151977.
XX XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (XENO-) XENON BIORESEARCH INC.
XX PI Hayden MR, Wilson AR, Pimstone SN;
XX DR WPI; 2000-587528/55.
XX XX New ABC1 polypeptide is useful for treating diseases associated with
XX PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
XX PT disease and cancer -
XX XX Examples; Page -, 229pp; English.
XX PS The invention relates to the human ABC1 cholesterol transporter protein
XX CC
```

DE Human ABC1 cholesterol transporter mutant, E1172D.
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary stenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutain.
 XX
 OS Homo sapiens.
 XX
 PN W0200055318-A2.
 XX
 XX 21-SEP-2000.
 XX
 XX 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 XX Hayden MR, Wilson AR, Pimstone SN;
 PI
 XX WPI; 2000-587528/55.
 DR
 XX
 XX
 PT New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 XX Examples; Page -: 229pp; English.
 PS
 XX
 XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary stenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary stenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 XX Sequence 2261 AA;
 SQ
 Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 FGKYPSELEQPMWYNEQYTFVNSDAPEDTGTLELNALTKDPGFGTRCMGNGNIPDPDPCQ 60
 DB 1371 FGKYPSELEQPMWYNEQYTFVNSDAPEDTGTLELNALTKDPGFGTRCMGNGNIPDPDPCQ 1430
 QY 61 AGEETWTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPPPQRK 120
 DB 1431 AGEETWTAPVPTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPGAGGLPPPPQRK 1490
 QY 121 QNTADTLQDLTGRNLSYLVKTYVOIIIAKSLKNKIWNNEFRYGGFSLGVSNTOALPPSOE 180
 DB 1491 QNTADTLQDLTGRNLSYLVKTYVOIIIAKSLKNKIWNNEFRYGGFSLGVSNTOALPPSOE 1550
 QY 181 VNDAIKQMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNKVKWNNKGWHAISSEFLNVIN 240
 DB 1551 VNDAIKQMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNKVKWNNKGWHAISSEFLNVIN 1610
 QY 241 NATLRANLQGENPNSHYGITAFNHPNLTKOOLSEVALMTTSVD 284
 DB 1611 NATLRANLQGENPNSHYGITAFNHPNLTKOOLSEVALMTTSVD 1654
 RESULT J3
 AAB38116
 ID AAB38116 standard; Protein; 2261 AA.
 XX
 AC AAB38116;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 XX Human ABC1 cholesterol transporter mutant, S1731C.
 DE
 XX
 XX Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary stenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutain.
 XX
 XX Homo sapiens.
 OS
 XX W0200055318-A2.
 PN
 XX 21-SEP-2000.
 XX
 XX 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 XX Hayden MR, Wilson AR, Pimstone SN;
 PI
 XX WPI; 2000-587528/55.
 DR
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer, e.g. Alzheimer's disease, Huntington's

CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPGFTRCMEGNPIDTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPGFTRCMEGNPIDTPCQ 1430
QY 61 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPQPK 120
DB 1431 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPQPK 1490
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550
QY 181 VNDATKQMKHKLKAKSSADRFNLNLTGRMTGLDTRNNVYKFNKGNHAISSFLNWIN 240
DB 1551 VNDATKQMKHKLKAKSSADRFNLNLTGRMTGLDTRNNVYKFNKGNHAISSFLNWIN 1610
QY 241 NAILRANLQKGNPSHYGITAFNHPNLTKQQLSEVALMTTSVD 284
DB 1611 NAILRANLQKGNPSHYGITAFNHPNLTKQQLSEVALMTTSVD 1654

RESULT 15
AAB71749
ID AAB71749 standard; protein; 2261 AA.
AC AAB71749;
XX
DT 17-MAY-2001 (first entry)
XX
DE Human ABC1 protein.
XX
KW High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1.
XX
OS Homo sapiens.
PN WO200115676-A2.
XX
PD 08-MAR-2001.
XX
PF 01-SEP-2000; 2000WO-IB01492.
XX
PR 01-SEP-1999; 99US-0151977.
PR 15-MAR-2000; 2000US-0526193.
PR 23-JUN-2000; 2000US-0213958.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON GENETICS INC.
XX
XX Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
XX WPI; 2001-244356/25.
XX
XX Treating a lower than normal high density lipoprotein-cholesterol
PT (HDL-C) level, a higher than normal triglyceride level, or a
PT cardiovascular disease, by administering a compound that modulates LXR-
PT or RXR-mediated transcriptional activity -
XX
PS Claim 16; Fig 2; 317pp; English.

XX The present invention relates to a method for treating a patient
CC diagnosed as having a lower than normal high density
CC lipoprotein-cholesterol (HDL-C) level, a higher than normal
CC triglyceride level, or a cardiovascular disease, involving
CC administering a compound that modulates LXR- or RXR-mediated
CC transcriptional activity or ABC1 expression or activity.
CC The LXR gene product may be used in an assay to identify
CC compounds useful for the treatment of a disease or condition selected a
CC lower than normal HDL cholesterol level, a higher than normal
CC triglyceride level, and a cardiovascular disease.

SQ Sequence 2261 AA;
Query Match 100.0%; Score 1525; DB 22; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143;
Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPGFTRCMEGNPIDTPCQ 60
DB 1371 FGKYPSELEQPMWYNEQYTFVSNDAPEDTGTLELLNALT KDPGFTRCMEGNPIDTPCQ 1430
QY 61 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPQPK 120
DB 1431 AGEETWTTAPVPQTIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGLPPQPK 1490
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLVKTYVQIIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550
QY 181 VNDATKQMKHKLKAKSSADRFNLNLTGRMTGLDTRNNVYKFNKGNHAISSFLNWIN 240
DB 1551 VNDATKQMKHKLKAKSSADRFNLNLTGRMTGLDTRNNVYKFNKGNHAISSFLNWIN 1610
QY 241 NAILRANLQKGNPSHYGITAFNHPNLTKQQLSEVALMTTSVD 284
DB 1611 NAILRANLQKGNPSHYGITAFNHPNLTKQQLSEVALMTTSVD 1654

Search completed: February 4, 2003, 09:39:19
Job time : 48 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:39:23 ; Search time 14 Seconds
(without alignments)
596.865 Million cell updates/sec

Title: US-09-704-272-6
Perfect score: 1525
Sequence: 1 FGKYPSELELQPMYNEQYTF.....PLNLTKQLSEVALMTTSVD 284

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA.*
1: /cgn2.6/ptodata/1/iaa/5A_COMB.pep.*
2: /cgn2.6/ptodata/1/iaa/5B_COMB.pep.*
3: /cgn2.6/ptodata/1/iaa/6A_COMB.pep.*
4: /cgn2.6/ptodata/1/iaa/6B_COMB.pep.*
5: /cgn2.6/ptodata/1/iaa/PCTUS_COMB.pep.*
6: /cgn2.6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1423	93.3	1375	3	US-08-665-259-26
2	1423	93.3	1375	3	US-08-762-500-26
3	257	16.9	1457	3	US-08-665-259-27
4	257	16.9	1457	3	US-08-762-500-27
5	94.5	6.2	884	6	5208144-8
6	92	6.0	2511	4	US-09-261-907-2
7	89.5	5.9	596	4	US-08-481-130-8
8	89.5	5.9	596	5	PCT-US93-00869-8
9	89	5.8	903	3	US-08-804-439A-22
10	89	5.8	903	3	US-08-720-229-22
11	88.5	5.8	903	1	US-08-220-151-8
12	88.5	5.8	903	1	US-08-413-118-8
13	88.5	5.8	903	3	US-08-473-446-8
14	88	5.8	888	2	US-08-861-464-5
15	88	5.8	888	2	US-08-396-001-5
16	88	5.8	888	4	US-09-323-433A-6
17	86.5	5.7	967	4	US-09-139-802-201
18	86	5.6	2509	1	US-08-469-005A-10
19	85.5	5.6	953	4	US-09-245-281-43
20	85.5	5.6	953	4	US-09-207-359B-43
21	83.5	5.5	339	4	US-09-125-619-14
22	83.5	5.5	969	4	US-09-206-942-32
23	83.5	5.5	975	4	US-09-206-942-30
24	83.5	5.5	3224	2	US-08-705-660-34
25	83.5	5.5	3224	3	US-08-989-045-34
26	83	5.4	913	1	US-08-220-151-6
27	83	5.4	913	1	US-08-413-118-6

28 83 5.4 913 3 US-08-473-446-6 Sequence 6, Appl
29 83 5.4 10182 4 US-09-134-001C-3159 Sequence 3159, Ap
30 82.5 5.4 736 1 US-07-688-352C-24 Sequence 24, Appl
31 82.5 5.4 736 2 US-08-474-379C-24 Sequence 24, Appl
32 82.5 5.4 736 3 US-09-146-249A-24 Sequence 24, Appl
33 82.5 5.4 736 3 US-08-208-188B-24 Sequence 24, Appl
34 82.5 5.4 736 5 PCT-US91-02714-23 Patent No. 5244792
35 82 5.4 904 6 5244792-4 Patent No. 5244792
36 82 5.4 913 6 5196516-8 Patent No. 5196516
37 81.5 5.3 820 4 US-09-173-914-2 Sequence 2, Appl
38 81.5 5.3 885 1 US-08-042-747A-8 Sequence 8, Appl
39 81.5 5.3 885 3 US-08-804-439A-23 Sequence 23, Appl
40 81.5 5.3 885 3 US-08-720-229-23 Sequence 23, Appl
41 80 5.2 464 4 US-09-025-580-28 Sequence 28, Appl
42 80 5.2 464 4 US-09-457-040B-5 Sequence 5, Appl
43 80 5.2 605 2 US-08-752-307B-8 Sequence 8, Appl
44 80 5.2 605 4 US-09-707-802-8 Sequence 8, Appl
45 80 5.2 605 4 US-09-991-326-8 Sequence 8, Appl

ALIGNMENTS

RESULT 1
US-08-665-259-26
; Sequence 26, Application US/08665259
; Patent No. 6028173
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dockowski, William R.
; APPLICANT: Van Raay, Terence J.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; TITLE OF INVENTION: COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 73
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/665,259
; FILING DATE: 17-JUN-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IG5-9.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1375 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-665-259-26

Query Match 93.3%; Score 1423; DB 3; Length 1375;
Best Local Similarity 93.0%; Pred. No. 6.2e-141;
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

Qy 1 FGKPSLEQPMYNEQYTFVSNDAPEDTGTLELLNALT KDGPGRGTRCMGSGNIPDTPCQ 60
Db 485 FGKPSLEQPMYNEQYTFVSNDAPEDTGTLELLNALT KDGPGRGTRCMGSGNIPDTPCQ 544
Qy 61 AGEEDWTAPVOTIMDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 120
Db 545 AGEEDWTISVPQSIVDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 604
Qy 121 QNTADILQDLTGRTNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNTQALPPSQE 180
Db 605 QXTADILQNLGTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNSQALPPSHE 664
Qy 181 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNKNGWHAISFLNVLN 240
Db 665 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNKNGWHAISFLNVLN 724
Qy 241 NAILRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTTSVD 284
Db 725 NAILRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTTSVD 768

RESULT 2
US-08-762-500-26
; Sequence 26, Application US/08762500
; Patent No. 6030806
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Raay, Terence J.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 83
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/762,500
; FILING DATE: 09-DEC-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/665,259
; FILING DATE: 17-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10469
; FILING DATE: 17-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IGS-9.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1375 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-762-500-26

Query Match 93.3%; Score 1423; DB 3; Length 1375;
Best Local Similarity 93.0%; Pred. No. 6.2e-141;
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;
Qy 1 FGKPSLEQPMYNEQYTFVSNDAPEDTGTLELLNALT KDGPGRGTRCMGSGNIPDTPCQ 60
Db 485 FGKPSLEQPMYNEQYTFVSNDAPEDTGTLELLNALT KDGPGRGTRCMGSGNIPDTPCQ 544
Qy 61 AGEEDWTAPVOTIMDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 120
Db 545 AGEEDWTISVPQSIVDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPGAGGLPPPPQK 604
Qy 121 QNTADILQDLTGRTNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNTQALPPSQE 180
Db 605 QXTADILQNLGTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGFSLGVSNSQALPPSHE 664
Qy 181 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNKNGWHAISFLNVLN 240
Db 665 VNDAIKQMKHKLAKDSSADRFSLGRTMTGLDTRNNKVVFNKNGWHAISFLNVLN 724
Qy 241 NAILRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTTSVD 284
Db 725 NAILRANLQGENPSHYGITAFNHPNLTKQOLSEVALMTTTSVD 768
RESULT 3
US-08-665-259-27
; Sequence 27, Application US/08665259
; Patent No. 6028173
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Raay, Terence J.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 73
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/665,259
; FILING DATE: 17-JUN-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IGS-9.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1457 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-665-259-27
Query Match 16.9%; Score 257; DB 3; Length 1457;
Best Local Similarity 24.9%; Pred. No. 8.6e-18;

```
Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15;
QY 2 GKYPSELEQPMWYNEQYT-----FVSNDAPE-----DTGTELLNALTCKDPGFGT 46
Db 504 GDLPLVLSPSOYH-NYTOPRGNFIPYANEERQYRLRLSPDASPOQLVSTFRUPSGVGA 562
QY 47 RCM-----EGNPI----- 54
Db 563 TCVLKSPANGSLGPMNLSSGESRLLAARFDSMCLESETQGLPLSNFVPPPPSPAPSDS 622
QY 55 ---PD-----TCQAGEEWTAP-VPQTIMDLFQNGNWTMNPSPACQSSDKI 100
Db 623 PVXPDEDSLQAWNSLPTAGPETWTSAPSLPRLVHEPVR-----CTCSAQGT 670
QY 101 KMLPVCPPGAGLPFPQRKONTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
Db 671 GFS---CPSSVGG-HPQMRVVTGDLTIDTGHNVSEYLLFTSDRF-----RLH 715
QY 161 RYGFSLGVSNTQALPPSQEVNDIAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNV 220
Db 716 RYGAITFG--NVQKSIFAS-----FGARVPPMVRKIAVRVA 750
QY 221 KWFENKCGHAISSFLVNNAILRANLQKE-NPSHYGITAFNHPNLTKOOLS-EVAL 278
Db 751 QVLYNNKGYHSMPTYLSNLNAILRANLPKSKGNPAAYXIYTNHPMKNKTSASLSLDYLL 810
QY 279 MTSV 283
Db 811 QGTDV 815

RESULT 4
US-08-762-500-27
; Sequence 27 Application US/08762500
; Patent No. 6030806
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William J.
; APPLICANT: Van Raay, Terence R.
; APPLICANT: Klinger, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; TITLE OF INVENTION: COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 83
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/762,500
; FILING DATE: 09-DEC-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/665,259
; FILING DATE: 17-JUN-1996
; PRIOR APPLICATION DATA: RCT/US96/10469
; APPLICATION NUMBER: 17-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IG5-9.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 872-8400
```

```
; TELEFAX: (508) 872-5415
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1457 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-762-500-27

Query Match 16.9%; Score 257; DB 3; Length 1457;
Best Local Similarity 24.9%; Pred. No. 8.6e-18;
Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15;
QY 2 GKYPSELEQPMWYNEQYT-----FVSNDAPE-----DTGTELLNALTCKDPGFGT 46
Db 504 GDLPLVLSPSOYH-NYTOPRGNFIPYANEERQYRLRLSPDASPOQLVSTFRUPSGVGA 562
QY 47 RCM-----EGNPI----- 54
Db 563 TCVLKSPANGSLGPMNLSSGESRLLAARFDSMCLESETQGLPLSNFVPPPPSPAPSDS 622
QY 55 ---PD-----TCQAGEEWTAP-VPQTIMDLFQNGNWTMNPSPACQSSDKI 100
Db 623 PVXPDEDSLQAWNSLPTAGPETWTSAPSLPRLVHEPVR-----CTCSAQGT 670
QY 101 KMLPVCPPGAGLPFPQRKONTADILQDITGRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
Db 671 GFS---CPSSVGG-HPQMRVVTGDLTIDTGHNVSEYLLFTSDRF-----RLH 715
QY 161 RYGFSLGVSNTQALPPSQEVNDIAIKOMKKHLKLAKDSSADRLNSLGRFMTGLDTRNNV 220
Db 716 RYGAITFG--NVQKSIFAS-----FGARVPPMVRKIAVRVA 750
QY 221 KWFENKCGHAISSFLVNNAILRANLQKE-NPSHYGITAFNHPNLTKOOLS-EVAL 278
Db 751 QVLYNNKGYHSMPTYLSNLNAILRANLPKSKGNPAAYXIYTNHPMKNKTSASLSLDYLL 810
QY 279 MTSV 283
Db 811 QGTDV 815

RESULT 5
5208144-8
; Patent No. 5208144
; APPLICANT: SMITH, JOHN A.; RAYCHOWHURY, RAKTIMA; NILES, JOHN L.
; TITLE OF INVENTION: METHOD FOR DETECTION OF HUMAN DNA
; CONTAINING THE GENE ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR
; NUMBER OF SEQUENCES: 42
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/396,697
; FILING DATE: 22-AUG-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 313,682
; FILING DATE: 22-FEB-1989
; APPLICATION NUMBER: 235,211
; FILING DATE: 23-AUG-1988
; SEQ ID NO: 8:
; LENGTH: 884
5208144-8

Query Match 6.2%; Score 94.5; DB 6; Length 884;
Best Local Similarity 23.6%; Pred. No. 0.57;
Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps 19;
QY 1 FCKYPS---LEQPMW-----YNEQYTFVSNDAPEDTGTELLNALTCKDPGFGT 47
Db 551 FGKENKEKVLVNPWLTVQVRIHQRLYNQS---VSNPKQVCVSHLCIL---RPGYSCA 603
QY 48 CMENGPNI---PDTQCAGEEWTAPVPQTIMDLFQNGN-WTMNPSPACQSSDKIKM 103
Db 604 CPOGSDFTVGTVCQDAASELPVTMPPPCRM---HGGNCYFDENELPKCKSSSYSGE- 659
```



```
;
; 104 LPVCPGP-AGGLPPQKONTADILQDLTGRTNISDYLVKTYVQIIAKSLNKIWNNEFRY 162
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 660 --YCEVGLSRGIPP-----GTTMA-VLLTFVVIIVGAL---VLVGLFHY 698
;
; 163 GGSFGLSVNTQALPPSQVNDIAIKOMKHLKLAKDSSADRFNLSLG-RWMTGLDTRNNVK 221
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 699 -----RKTGSLT-----LPKLPISLAKPSE-----NGNGVTRSGADV--NMD 738
;
; 222 VFNENKGNHAISSFLNVLNNAILRANLQKGNPSHYGITAFNHLPLNLTQQLSEVAL 278
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 739 IGVSPFGPETIDRSWANNEHFV---MEVGKQP-----VIFENPMYAAKDNISKVAL 787
;
RESULT 6
US-09-261-907-2
; Sequence 2, Application US/09261907A
; Patent No. 6294364
; GENERAL INFORMATION:
; APPLICANT: ELLIS, CATHERINE
; APPLICANT: LONSDALE, JOHN
; APPLICANT: BERGSMAN, DEBK J.
; APPLICANT: MOONEY, JEFFREY L.
; APPLICANT: DEPIERA, MEGAN E.
; APPLICANT: CHAPMAN, CONRAD
; TITLE OF INVENTION: HUMAN FAS
; FILE REFERENCE: GP-70603
; CURRENT APPLICATION NUMBER: US/09/261.907A
; CURRENT FILING DATE: 1999-03-03
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
;   LENGTH: 2511
;   TYPE: PRT
;   ORGANISM: HOMO SAPIENS
US-09-261-907-2
;
Query Match          6.0%; Score 92; DB 4; Length 2511;
Best Local Similarity 23.2%; Pred. No. 5.3;
Matches 39; Conservative 27; Mismatches 60; Indels 42; Gaps 7;

QY 107 CPPGAGLPPQKONTADILQDLTGRTNISDYLVKTYVQIIAKSLNKIWNNEFRYGGFS 166
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 634 CPPGV--VPACHNSKDTYI---SGQAPVF-----EFVEQLRKEGVFAKEVRUGNA 681
;
QY 167 LGVSNMTQALPPS--QEVNDATKQMK-----HLKLAKDSSADRFNLSLGR 209
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 682 FHSYFMEAIAPLLQELKKVIREPKRSARWLSTSIPEAQWHSSLARTSSAEYNVNVLVS 741
;
QY 210 FMTGLDTRNNVKVFNNGKWH--ISSFLNVLNNAILRANLQKGNPS 255
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 742 -----PVLQEQALWHPVHVVLEIAPHALLOAVLKRGLKPS 778
;
RESULT 7
US-08-481-190-8
; Sequence 8, Application US/08481190
; Patent No. 6160204
; GENERAL INFORMATION:
; APPLICANT: John C. Steffens
; TITLE OF INVENTION: Polyphenol Oxidase cDNA
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
```

```
;
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/481.190
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 203.533
; FILING DATE: 02-24-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26.824
; REFERENCE/DOCKET NUMBER: UA 816 CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 596 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-481-190-8
;
Query Match          5.9%; Score 89.5; DB 4; Length 596;
Best Local Similarity 23.0%; Pred. No. 1;
Matches 63; Conservative 32; Mismatches 128; Indels 51; Gaps 12;

QY 13 MYNEQYT-----FVSNDAPEDTGTELELNALTKDPGFGTRCMESNPIDPTPCQ 60
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 293 MYRQWVTNAPCLLFFGAPYVLGNVNEAPGTIETIPIPHVHWAGT--VRGSKFPGNDVS 350
;
QY 61 AGESEWTTAPVPTIMDLFQNGNWTMQNPSPACQCSDDIKKMLPVCPPGAGGLPPPPQR 120
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 351 YGED-----MGNEYSAGLDPVFYCHHGNVDRMNEW-KAIGG---KRRD 390
;
QY 121 QNTADILQD---LTGENISDYLVKTYVQIIAKSLKNKI-----WVNEFRYGGFSLGSN 171
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 391 ISBKDWLNSEFFYDEHKNRYKVRDCLDTKMGYDYAPMPTWRNFKPKSKASVGKVN 450
;
QY 172 TQALPPSQVNDIAIKOMKHLKLAKDSSADRFNLSLGRFMTGLDTRNNVKVFNNGKWH 231
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 451 TSTLPANVEVFFPLAK-MDKTISFAINRPASSRTOOEKNEQEMLTFNNIR--YDNRGYIR 507
;
QY 232 ISSFLNVLNNAILRAN-LQKGNPSHYGITAFNH 264
;   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
; 508 FDFVLNVDNN--VNANELDKAEFAGSY--TSLPH 537
;
RESULT 8
PCT-US93-00869-8
; Sequence 8, Application PC/TUS9300869
; GENERAL INFORMATION:
; APPLICANT: John C. Steffens
; TITLE OF INVENTION: Polyphenol Oxidase cDNAs: Cloning
; TITLE OF INVENTION: and Applications
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/00869
; FILING DATE: 19930129
; CLASSIFICATION:
```

ATTORNEY/AGENT INFORMATION:
 NAME: George M. Yahwak
 REGISTRATION NUMBER: 26,824
 REFERENCE/DOCKET NUMBER: CRF D-1057
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (203)268-1951
 TELEFAX: (203)268-1951
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 596 amino acids
 TYPE: AMINO ACID
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 PCT-US93-00869-8

Query Match 5.9%; Score 89.5; DB 5; Length 596;
 Best Local Similarity 23.0%; Pred. No. 1;
 Matches 63; Conservative 32; Mismatches 128; Indels 51; Gaps 12;
 QY 13 MYNQYT-----FVSDAPEDTGTLELNLTKDPGFGTRCMENPIPTPCQ 60
 DB 293 MYRQMTNAPCPLLFTGAPVILGNVNEAPGTIETIPHPVHWAGT--VRGSKFPNGDVS 350
 QY 61 AGESEWTAPVQTIIMDLFQNGNWTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
 DB 351 YGED-----MGNFYSAGLDPVFYCHGNVDKMNW-KAIGG---KRRD 390
 QY 121 QNTADILQD---LTGRNISDLYKTYVQIIAKSLNKI-----WVNEFYGFGSLGVS 171
 DB 391 ISEKDLNLSSEFFFYDEHKNPYRVKVRDCLDTKKMGYDYAPMPTWRNFKPKSKASVGKVN 450
 QY 172 TOALPPSQEYNDALIKMKKHLKLAQSSADRLNSLGRMTGLDTRNNVKNWNNKQWHA 231
 DB 451 TSTLPPANEVFLAK-MDKTISEFAINRPASSRTQOEKNEQEEMLTFFNNIR--YDNRGYIR 507
 QY 232 ISSFLNINNAILRAN-LOGENPSHYGITAFNH 264
 DB 508 FDVFLNVDNN--VNANELKAEPAGSY--TSLPH 537

RESULT 9
 US-08-804-439A-22
 Sequence 22, Application US/08804439A
 Patent No. 6015565

GENERAL INFORMATION:
 APPLICANT: Rose, Timothy M.
 APPLICANT: Bosch, Marnix L.
 TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
 NUMBER OF SEQUENCES: 113
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson P.C.
 STREET: 4225 Executive Square, Ste 1400
 CITY: La Jolla
 STATE: CA
 COUNTRY: USA
 ZIP: 92037
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/804,439A
 FILING DATE: February 21, 1997
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: Haile, Lisa A.
 REGISTRATION NUMBER: 38,347
 REFERENCE/DOCKET NUMBER: 09176/004001
 TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 678-5070
 TELEFAX: (619) 678-5099
 TELEX:
 INFORMATION FOR SEQ ID NO: 22:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 903 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-804-439A-22

Query Match 5.8%; Score 89; DB 3; Length 903;
 Best Local Similarity 20.2%; Pred. No. 2.2;
 Matches 57; Conservative 28; Mismatches 115; Indels 82; Gaps 11;
 QY 21 VSDAPEDTGTLELNLTKDPGFGTRCMENPIPTPCQAGESEWTAPVQTIIMDLFQ 80
 DB 26 VASAAFSSEGT-----ECVAAATQAAGGFATPA-----PPAPGPAPTGDTRP 68
 QY 81 NGNWTMNPSP-----ACQCSSDKIKKMLPVCPPGAGG----- 113
 DB 69 KKKKPKNPPPPRPGADNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVQFEQ 128
 QY 114 ---LPPQKQNTADILQDLTGRNISDLYKVT--YVQIIAKSLKNIWNEFYGFGSLG 168
 DB 129 PRCPTRPGEQNTGEGIAVVFVFKENIAPYKATWYKDVTVS---QVMFGH-RYSQF-MG 183
 QY 169 VSNQALPPSQEYNDAL-----KOMKKHLKLAQSSADRLNSLGRMTGLDTRN 218
 DB 184 IFEDRAPVPEEVIDKINAKGVCRSTAKYVRNNLETTAFHRDDH-----ETDMELKP 235
 QY 219 NVKWNWENKHAISSEFLNINNAILRANLOKGENPSHYGIT 260
 DB 236 ANAATRTSGWHTD-----LKNPNSRVEAFHRYGTT 267

RESULT 10
 US-08-720-229-22
 Sequence 22, Application US/08720229
 Patent No. 6022542
 GENERAL INFORMATION:
 APPLICANT: Rose, Timothy M.
 APPLICANT: Bosch, Marnix L.
 TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
 NUMBER OF SEQUENCES: 100
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Morrison & Foerster
 STREET: 755 Page Mill Road
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA
 ZIP: 94304-1018
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/720,229
 FILING DATE: 26-SEP-1996
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: Schiff, J. Michael
 REGISTRATION NUMBER: 40,253
 REFERENCE/DOCKET NUMBER: 29938-20002.00
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 813-5600
 TELEFAX: (415) 494-0792
 TELEX: 706141
 INFORMATION FOR SEQ ID NO: 22:

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-720-229-22
Query Match 5.8%; Score 89; DB 3; Length 903;
Best Local Similarity 20.2%; Pred. No. 2.2; Indels 82; Gaps 11;
Matches 57; Conservative 28; Mismatches 115;

Qy 21 VSDNAPEDTGTLELLNALT KDPCFGTRCMGNPIPDTPCOAGEEETAPVPQTIIMDLFQ 80
   || || || || || || || || || || || || || || || || || || || || ||
Db 26 VASAAPSPTG-----PGVAATQAANGGPAFA-----PPAPGAPTGTDP 68
   || || || || || || || || || || || || || || || || || || || || ||
Qy 81 NGNWTQNPSP-----ACQSSDKIKKMLPVCPPGAGG----- 113
   || || || || || || || || || || || || || || || || || || || || ||
Db 69 KKKKKKPNPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVQFEQ 128
   || || || || || || || || || || || || || || || || || || || || ||
Qy 114 ---LPPQRKQNTADILQDLTGRNISDYLVKT--YVQIIAKSLKNIWVNEFRYGGFSLG 168
   || || || || || || || || || || || || || || || || || || || || ||
Db 129 PRRCPTREPCQNTGEGIAVVFKEINAPIYKFKATMYKDVTVS---QVWFGH-RYSQF-MG 183
   || || || || || || || || || || || || || || || || || || || || ||
Qy 169 VSNTOALPPSQEVDNDAI-----KOMKKHLKLAKDSSADRLNSLGRFMTGLDTRN 218
   || || || || || || || || || || || || || || || || || || || || ||
Db 184 IFEDRAPVPFEEVIDKINAKGVCRTAKYVNNLTAFHRDDH-----ETDMELKP 235
   || || || || || || || || || || || || || || || || || || || || ||
Qy 219 NVKVFNNKGWHAISFLVINNALIRANLQKGENPSHYGTT 260
   || || || || || || || || || || || || || || || || || || || || ||
Db 236 ANAATRTSRGHTTD-----LKNPSRVEAFHRYGTT 267
   || || || || || || || || || || || || || || || || || || || || ||

RESULT 11
US-08-220-151-8
; Sequence 8, Application US/08220151
; Patent No. 5523780
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Limbach, Keith J.
; TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID SEQUENCES OF
; TITLE OF INVENTION: CANINE HERPESVIRUS gB, gC AND gD AND USES THEREFOR
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/220.151
; FILING DATE: 30-MAR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2540
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: N-terminal
US-08-220-151-8
Query Match 5.8%; Score 88.5; DB 1; Length 903;
Best Local Similarity 20.6%; Pred. No. 2.5;
Matches 58; Conservative 32; Mismatches 109; Indels 83; Gaps 13;

Qy 21 VSDNAPEDTGTLELLNALT KDPCFGTRCMGNPIPDTPCOAGEEETAPVPQTIIMDLFQ 80
   || || || || || || || || || || || || || || || || || || || || ||
Db 27 VASAAPSPTG-----PGVARDPG-GER-----GPCHSGAALGAAPTG---DPRP 68
   || || || || || || || || || || || || || || || || || || || || ||
Qy 81 NGNWTQNPSP-----ACQSSDKIKKMLPVCPPGAGG----- 113
   || || || || || || || || || || || || || || || || || || || || ||
Db 69 KKKKKKPNPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVQFEQ 128
   || || || || || || || || || || || || || || || || || || || || ||
Qy 114 ---LPPQRKQNTADILQDLTGRNISDYLVKT--YVOLIAKSLKNIWVNEFRYGGFSLG 168
   || || || || || || || || || || || || || || || || || || || || ||
Db 129 PRRCPTREPCQNTGEGIAVVFKEINAPIYKFKATMYKDVTVS---QVWFGH-RYSQF-MG 183
   || || || || || || || || || || || || || || || || || || || || ||
Qy 169 VSNTOALPPSQEVDNDAI-----KOMKKHLKLAKDSSADRLNSLGRFMTGLDTRN 218
   || || || || || || || || || || || || || || || || || || || || ||
Db 184 IFEDRAPVPFEEVIDKINAKGVCRTAKYVNNLTAFHRDDH-----ETDMELKP 235
   || || || || || || || || || || || || || || || || || || || || ||
Qy 219 NVKVFNNKGWHAISFLVINNALIRANLQKGENPSHYGTT 260
   || || || || || || || || || || || || || || || || || || || || ||
Db 236 ANAATRTSRGHTTD-----LKNPSRVEAFHRYGTT 267
   || || || || || || || || || || || || || || || || || || || || ||

RESULT 12
US-08-413-118-8
; Sequence 8, Application US/08413118
; Patent No. 5688920
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Limbach, Keith J.
; TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID SEQUENCES OF
; TITLE OF INVENTION: CANINE HERPESVIRUS gB, gC, AND gD AND USES THEREFOR
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CURTIS, MORRIS & SAFFORD, P.C.
; STREET: 530 FIFTH AVENUE, 25TH FLOOR
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/413.118
; FILING DATE: 29-MAR-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/220.151
; FILING DATE: 30-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: FROMMER, WILLIAM S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2670
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: N-terminal
```

US-08-413-118-8

Query Match 5.8%; Score 88.5; DB 1; Length 903;
Best Local Similarity 20.6%; Pred. No. 2.5;
Matches 58; Conservative 32; Mismatches 109; Indels 83; Gaps 13;

```
QY 21 VSDAPEDTGTLELLNALTDPGFGTRCMENPIPTPCQAGEEWTAPVPTIMDLFQ 80
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 27 VASAAPSSPGT-----PGVARDPG-GER-----GCHSGAALGAAPTG----DPKP 68
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 81 NGNWTQNPSP-----ACQSSDKIKMLPVCPPGAGG-----113
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 69 KKKKPKNPPTPRAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVOFEQ 128
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 114 ---LPPQRKQNTADILQDLTGRNISDYLVKT--YVQIIAKSLKNIWNEFRYGGFSLG 168
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 129 PRRCPTREGQNTYEGIAVFKENIAPYKFKATMYKDVTVS---QVWFGH-RYSQF-MG 183
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 169 VSNQALPPSQEVDNAT-----KOMKKHLKLAKDSSADRFNLGLRFTMTGLDTRN 218
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 184 IFEDRAPVPFEEVDKINAKGVCRSTAKYVRNNLETTAFHRDDH-----ETDMELKP 235
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 219 NVKWFNKGWHAISSEFLNINAILLANLOKGENPSHYGIT 260
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 236 ANAATRTSRGWHTD-----LKNPNSRVEAFHRYGTT 267
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

RESULT 13

```
US-08-473-446-8
; Sequence 8, Application US/08473446
; Patent No. 6017542
; GENERAL INFORMATION:
; APPLICANT: PAOLETTI, ENZO
; APPLICANT: LIMBACH, KEITH J.
; TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID SEQUENCES OF
; CANINE HERPESVIRUS 9B, 9C, AND 9D AND USES THEREFOR
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CURTIS, MORRIS & SAFFORD, P.C.
; STREET: 530 FIFTH AVENUE, 25TH FLOOR
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473.446
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/413,118
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FROMMER, WILLIAM S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2670
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 903 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: N-terminal
US-08-473-446-8
```

Query Match

Best Local Similarity 20.6%; Score 88.5; DB 3; Length 903;
Matches 58; Conservative 32; Mismatches 109; Indels 83; Gaps 13;

```
QY 21 VSDAPEDTGTLELLNALTDPGFGTRCMENPIPTPCQAGEEWTAPVPTIMDLFQ 80
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 27 VASAAPSSPGT-----PGVARDPG-GER-----GCHSGAALGAAPTG----DPKP 68
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 81 NGNWTQNPSP-----ACQSSDKIKMLPVCPPGAGG-----113
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 69 KKKKPKNPPTPRAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPTGATVVOFEQ 128
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 114 ---LPPQRKQNTADILQDLTGRNISDYLVKT--YVQIIAKSLKNIWNEFRYGGFSLG 168
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 129 PRRCPTREGQNTYEGIAVFKENIAPYKFKATMYKDVTVS---QVWFGH-RYSQF-MG 183
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 169 VSNQALPPSQEVDNAT-----KOMKKHLKLAKDSSADRFNLGLRFTMTGLDTRN 218
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 184 IFEDRAPVPFEEVDKINAKGVCRSTAKYVRNNLETTAFHRDDH-----ETDMELKP 235
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 219 NVKWFNKGWHAISSEFLNINAILLANLOKGENPSHYGIT 260
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 236 ANAATRTSRGWHTD-----LKNPNSRVEAFHRYGTT 267
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

RESULT 14

```
US-08-861-464-6
; Sequence 6, Application US/08861464
; Patent No. 5874210
; GENERAL INFORMATION:
; APPLICANT: Guarente, Leonard P.
; APPLICANT: Austriaco Jr., Nicanor
; APPLICANT: Kennedy, Brian
; TITLE OF INVENTION: Genes Determining Cellular Senescence
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/861,464
; FILING DATE: 22-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/396,001
; FILING DATE: 28-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/09351
; FILING DATE: 15-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/107,408
; FILING DATE: 16-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: MIT-6408A22
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 781-861-6240
; TELEFAX: 781-861-9540
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 888 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
```

; MOLECULE TYPE: protein
US-08-861-464-6

Query Match 5.8%; Score 88; DB 2; Length 888;
Best Local Similarity 19.4%; Pred. No. 2.8;
Matches 61; Conservative 36; Mismatches 105; Indels

[illegible]

RESULT 15

```

US-08-396-001-6
: Sequence 6, Application US/08396001
: Patent No. 5919618
: GENERAL INFORMATION:
: APPLICANT: Guarante, Leonard P.
: APPLICANT: Austriaco Jr., Nicanor
: APPLICANT: Claus, James
: APPLICANT: Cole, Francesca
: APPLICANT: Kennedy, Brian
: TITLE OF INVENTION: Genes Determining Cellular Senescence in
: TIME OF INVENTION: Yeast
: NUMBER OF SEQUENCES: 16
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
: STREET: Two Militia Drive
: CITY: Lexington
: STATE: MA
: COUNTRY: USA
: ZIP: 02173
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/396,001
: FILING DATE: 28-FEB-1995
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Granahan, Patricia
: REGISTRATION NUMBER: 32,227
: REFERENCE/DOCKET NUMBER: MIT-6408A2
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617-861-6240
: TELEFAX: 617-861-9540
: INFORMATION FOR SEQ ID NO: 6:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 888 amino acids
: TYPE: amino acid
: TOPOLOGY: linear

```

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:40:23 : Search time 13 Seconds
(without alignments)
484,314 Million cell updates/sec

Title: US-09-704-272-6
Perfect score: 1525
Sequence: 1 FGKPSLELPWMYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 129505 seqs, 22169297 residues
Total number of hits satisfying chosen parameters: 129505

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA.*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB pep.*
7: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB pep.*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB pep.*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB pep.*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB pep.*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	1513	99.2	2261	10	US-09-995-542-11
2	1513	99.2	2261	10	US-09-846-456-11
3	1423	93.3	2201	10	US-09-995-542-9
4	733.5	48.1	2273	10	US-09-995-542-12
5	724.5	47.5	2310	10	US-09-995-542-10
6	664	43.5	2121	10	US-09-995-542-3
7	664	43.5	2167	10	US-09-995-542-2
8	663.5	43.5	1550	10	US-09-995-542-8
9	663.5	43.5	2100	10	US-09-995-542-6
10	663.5	43.5	2146	10	US-09-995-542-5
11	662.5	43.4	2144	10	US-09-858-194-2
12	460.5	30.2	199	10	US-09-767-870-18
13	267	17.5	2001	9	US-10-072-621-8
14	267	17.5	2436	10	US-09-795-693-8
15	140	9.2	664	10	US-09-767-870-9
16	88	5.8	888	10	US-09-826-752-6
17	87.5	5.7	522	10	US-09-876-889-353
18	86.5	5.7	969	9	US-09-981-353-122
19	86.5	5.7	977	10	US-09-925-297-797
20					Sequence 11, Appl
21					Sequence 11, Appl
22					Sequence 9, Appl
23					Sequence 12, Appl
24					Sequence 10, Appl
25					Sequence 3, Appl
26					Sequence 2, Appl
27					Sequence 8, Appl
28					Sequence 6, Appl
29					Sequence 5, Appl
30					Sequence 2, Appl
31					Sequence 18, Appl
32					Sequence 8, Appl
33					Sequence 9, Appl
34					Sequence 6, Appl
35					Sequence 353, App
36					Sequence 122, App
37					Sequence 797, App

20	85.5	5.6	953	9	US-10-118-984-43	Sequence 43, Appl
21	85.5	5.6	953	10	US-09-728-721-43	Sequence 43, Appl
22	82.5	5.4	384	9	US-10-029-180-50	Sequence 50, Appl
23	81.5	5.3	172	10	US-09-764-847-551	Sequence 551, App
24	81.5	5.3	774	10	US-09-815-242-12046	Sequence 12046, A
25	81.5	5.3	972	10	US-09-924-154-16	Sequence 16, Appl
26	80	5.2	426	9	US-09-909-650A-24	Sequence 24, Appl
27	80	5.2	426	9	US-09-165-522-10	Sequence 10, Appl
28	80	5.2	464	9	US-09-165-522-2	Sequence 2, Appl
29	80	5.2	678	9	US-09-895-913A-4	Sequence 4, Appl
30	79.5	5.2	1242	10	US-09-903-248-5	Sequence 5, Appl
31	79.5	5.2	1242	10	US-09-859-604-5	Sequence 5, Appl
32	79.5	5.2	1242	10	US-09-903-063-5	Sequence 5, Appl
33	79.5	5.2	1242	10	US-09-903-216-5	Sequence 5, Appl
34	79.5	5.2	1242	10	US-09-903-199-5	Sequence 5, Appl
35	79.5	5.2	1242	10	US-09-903-023-5	Sequence 5, Appl
36	79.5	5.2	1242	12	US-10-085-027-1	Sequence 1, Appl
37	79	5.2	1848	9	US-09-839-996-6	Sequence 6, Appl
38	78.5	5.1	793	10	US-09-881-752A-362	Sequence 362, App
39	78.5	5.1	2434	10	US-09-815-242-5835	Sequence 5835, Ap
40	78.5	5.1	6281	10	US-09-815-242-12996	Sequence 12996, A
41	78	5.1	704	10	US-09-801-368-218	Sequence 218, App
42	77	5.0	315	10	US-09-764-853-793	Sequence 793, App
43	76.5	5.0	364	10	US-09-756-983-22	Sequence 22, Appl
44	76.5	5.0	378	10	US-09-801-574-38	Sequence 38, Appl
45	76.5	5.0	540	9	US-09-738-626-4450	Sequence 4450, Ap

ALIGNMENTS

RESULT 1
US-09-995-542-11
; Sequence 11, Application US/09995542
; Patent No. US20020127647A1

GENERAL INFORMATION:
APPLICANT: Shutter, John
APPLICANT: Ullas, Learni
TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
FILE REFERENCE: 00-658-A
CURRENT APPLICATION NUMBER: US/09/995,542
CURRENT FILING DATE: 2001-11-28
PRIOR FILING DATE: 2000-11-28
PRIOR APPLICATION NUMBER: 60/253,520
NUMBER OF SEQ ID NOS: 24
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 11
LENGTH: 2261
TYPE: PRT
ORGANISM: Homo sapiens
US-09-995-542-11

Query Match	99.2%	Score 1513;	DB 10;	Length 2261;
Best Local Similarity	99.3%	Pred. No. 2	6e-138;	
Matches	282;	Conservative	0;	Mismatches 2;
				Indels 0;
				Gaps 0;
QY	1	FGKPSLELPWMYNEQYTFVSNDA	PTDGTCTLELLNALTKD	PGFTRCMEGNPIDPTPCQ 60
Db	1371	FGKPSLELPWMYNEQYTFVSNDA	PTDGTCTLELLNALTKD	PGFTRCMEGNPIDPTPCQ 1430
QY	61	AGEEWTAPVPTIMDLFONGNWTQ	NPSACQCSDDIKKMLPVC	PGAGGLPPQPK 120
Db	1431	AGEEWTAPVPTIMDLFONGNWTQ	NPSACQCSDDIKKMLPVC	PGAGGLPPQPK 1490
QY	121	QNTADILQDLTGRNISDYLKTYV	QIIAKSLKKNKIVWNEFRY	GGFSLGVSNQALPPSQE 180
Db	1491	QNTADILQDLTGRNISDYLKTYV	QIIAKSLKKNKIVWNEFRY	GGFSLGVSNQALPPSQE 1550
QY	181	VNDAIKQMKHKLAKDSSADREF	LNSLGRFWTGLDTRNNV	KVWFKNKGWHAISSTLUNVN 240
Db	1551	VNDATKQMKHKLAKDSSADREF	LNSLGRFWTGLDTRNNV	KVWFKNKGWHAISSTLUNVN 1610

QY	241	NAILRANLQKGENPSHYGITAFNHPLNLTQQQLSEVALMTTSVD	284
QY	1611	NAILRANLQKGENPSHYGITAFNHPLNLTQQQLSEVAPMTTSVD	1654
pb			

RESULT 2

```

US-09-846-456-11
; Sequence 11, Application US/09846456
; Patent No. US20020146792A1
; GENERAL INFORMATION:
; APPLICANT: Rosier, Marie
; APPLICANT: Prades, Catherine
; APPLICANT: Lemoine, Cendrine
; APPLICANT: Naudin, Laurent
; APPLICANT: Denefle, Patrice
; APPLICANT: Duvergier, Nicolas
; APPLICANT: Brewer, Bryan
; APPLICANT: Remaley, Alan
; APPLICANT: Fojo, Silvia
; TITLE OF INVENTION: Regulatory Nucleic Acid Sequences
; DATE OF INVENTION: 2000-05-02
; FILE REFERENCE: 3806.0505
; CURRENT APPLICATION NUMBER: US/09/846-456-11
; CURRENT FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/201111
; PRIOR FILING DATE: 2000-05-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-846-456-11

```

Query Match	99.28;	Score 1513;	DB 10;	Length 2261;
Best Local Similarity	99.38;	Pred. No. 2.6e-138;		
Matches 282; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy	1	FGKPSLELQPMWYNEQYTFVSDNADPEDTGTTLELLNALT KDGFETRCMEGNIPDP	PCQ	60
Db	1371	FGKPSLELQPMWYNEQYTFVSDNADPEDTGTTLELLNALT KDGFETRCMEGNIPDP	IP	1430
Qy	61	AGEEWTTAPVPQITMDLFQNGNWTMQNPSACQSSDKIKKMLPVCPPGAGGLPP	QPK	120
Db	1431	AGEEWTTAPVPQITMDLFQNGNWTMQNPSACQSSDKIKKMLPVCPPGAGGLPP	QPK	1490
Qy	121	QNTADILODLTGRNISDYLVKTYVQIIAKSLKNKIWNFEFRYGGFSLGVSNTQAL	PPSQE	180
Db	1491	QNTADILODLTGRNISDYLVKTYVQIIAKSLKNKIWNFEFRYGGFSLGVSNTQAL	PPSQE	1550
Qy	181	VNDATKQMKHKLKAKDSSADRFNLNSLGRPMTGLDTRNNVKVWFNKNKGHAISS	FLNVIN	240
Db	1551	VNDATKQMKHKLKAKDSSADRFNLNSLGRPMTGLDTRNNVKVWFNKNKGHAISS	FLNVIN	1610
Qy	241	NAILRANTLQGENPSHYGITAFAHPLNLTKQQLSEVALMTT	SVD	284
Db	1611	NAILRANTLQGENPSHYGITAFAHPLNLTKQQLSEVALMTT	SVD	1654

RESULT 3

RES-001-3
 US-09-995-542-9
 ; Sequence 9, Application US/09995542
 ; Patent No. US20020127647A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Shutter, John
 ; APPLICANT: Ullas, Laarni
 ; TITLE OF INVENTION: Arp-Binding Cassette Transporter-Like Molecules and
 ; TITLE OF INVENTION: Uses Thereof
 ; FILE REFERENCE: 00-658-A
 ; CURRENT APPLICATION NUMBER: US/09/995,542
 ; CURRENT FILING DATE: 2001-11-28
 ; PRIOR APPLICATION NUMBER: 60/253,520
 ; PRIOR FILING DATE: 2000-11-28

```

: NUMBER OF SEQ ID NOS: 24
: SOFTWARE: PatentIn Ver. 2.0
: SEQ ID NO 9
: LENGTH: 2201
: TYPE: PRT
: ORGANISM: Mus musculus
: FEATURE:
: NAME/KEY: UNSURE
: LOCATION: (115)
: OTHER INFORMATION: amino acid at this position is unknown
: US-03-995-542-9

```

Query Match	93.3%;	Score 1423;	DB 10;	Length 2201;
Best Local Similarity	93.0%;	Pred. NO. 1.4e-129;		
Best Global Similarity	93.0%;	Pred. NO. 1.4e-129;		
Indels	0;			
Gaps	0;			

Qy	1	FGKYPSLELOPMWYNEOXYTFVSNDAPEDTGTELLNALT KDPGFGTRCMEGNPIPTPCQ	60
Db	1311	FGKYPSLELOPMWYNEOXYTFVSNDAPEDMGTQELLNALT KDPGFGTRCMEGNPIPTPCL	1370
Qy	61	AGBEEWTTAPVQOTIMDLFQNGNWTWMPSPACQSSDK IKKMLPVCPPCAGGLPPBPQR	120
Db	1371	AGBEDWTTISPVPOSIVDLFQNGNWTWMPSPACQSSDK IKKMLPVCPPCAGGLPPBPQR	1430
Qy	121	QNTADILQDLTGRTNSDYLVKTVYQIIAKSLUNKTWYNEFRYGFSLGVSNQTALPSQE	180
Db	1431	QKTADILQNLITGRNITSYLVKTVYQIIAKSLUNKTWYNEFRYGFSLGVSNQALPSHE	1490
Qy	181	VNDAIKOMKKHLKLAKDSSADRFSLSGRFMTGLDTRNNKVVFNKNGKWHAISSFLNVIN	240
Db	1491	VNDAIKOMKKLLKLTQDTSADRFSLSGRFMAGLDTRNNKVVFNKNGKWHAISSFLNVIN	1550
Qy	241	NATILRANLQGENPSHYGTTAFNHPNLNTKQOLSEVALMTTSD	284
Db	1551	NATILRANLQGENPSOYGTAFNHPNLNTKQOLSEVALMTTSD	1594

RESULT 4

```

RES001
US-09-995-542-12
; Sequence 12, Application US/09995542
; Patent No. US20020127847A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ulias, Learni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; TITLE OF INVENTION: Uses Thereof
; TITLE OF INVENTION: Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 12
; LENGTH: 2273
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-995-542-12

```

Query Match	48.1%;	Score 733.5;	DB 10;	Length 2273;
Best Local Similarity	48.2%;	Pred. No. 2e-62;		
		Models 39;		

Qy	1	FGKYPSELEQPMWNYQYTFVSNDAPEDTGTLLELNALTKDPPGRTGTCMEGNLPIDPQPC	60
Db	1397	FGEYPALTLPWYQGYTFESDPEGSQFTVLADVLINPGGKCLKEGWLPEYPC-	1455
Qy	61	AGEEWTAPVPQTIQDLTQNGWNTMONPSACQSSDKIKMLPVCPPGAGGLPPPPQR	120
Db	1456	GNSTPWTPTPSVSNITQLQKQKWTQVNPSPCRSTREKLTMLPECEPAGGLPPPQT	1515
Qy	121	QNTADIQLDLTGRNIDYLVKTVVQIIAKSLNKLITWNEFRYGGFSJGVSNQTALPSQE	180


```
Db 1516 QRSTEILDTRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIG-----GKLPVWPI 1571
QY 181 VNDAIKQMKHKLAKDSSADRELNSLGR-----FMWGLDTRNNVK 221
Db 1572 TGEALV-----GELSDLGRIMNYSGGPITREASKETPDLKHLKETEDNIK 1616
QY 222 VWFNKGWHAISSFLNINNAIRANLQKGNPSHYGITAFNHNPLNLTQKOLSEVALMTT 281
Db 1617 VWFNKGWHALVSLFNVAHNAIRASLPKDRSPPEYGITVISQPLNLTKEQLSDITVLT 1676
QY 282 SVD 284
Db 1677 SVD 1679

RESULT 5
US-09-995-542-10
; Sequence 10, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; PRIOR FILING DATE: 2001-11-28
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 2310
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-542-10

Query Match 47.5%; Score 724.5; DB 10; Length 2310;
Best Local Similarity 47.2%; Pred. No. 1.5e-61;
Matches 143; Conservative 39; Mismatches 82; Indels 39; Gaps 4;

QY 1 FGKPSLELQPMWYNEQYTFVSNDAPEDTGTLELLNALTQDPGFGTRCMEGNPIDTPCQ 60
Db 1396 FGEPFALTHPMWYGHQYTFVSNDAPEDTGTLELLNALTQDPGFGTRCMEGNPIDTPCQ 1454
QY 61 AGEERTTAPVQPTIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPGAGGLPPOR 120
Db 1455 INATSKTFSVSPNITLHFKQKWTAAHPSPCKSTREKLTMLPCEGAGGLPPOR 1514
QY 121 QNTADILQDLTGRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIG-GKLPALPISSE 180
Db 1515 QRSTEVLDLTRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIG-GKLPALPISSE 1573
QY 181 VNDAIKQMKHKLAKDSSADRELNSLGR-----FMWGLDTRNNVK 221
Db 1574 -----ALVGLSLGQMMNVSNGPVTREASKEMLDLFLKHLTTDNK 1615
QY 222 VWFNKGWHAISSFLNINNAIRANLQKGNPSHYGITAFNHNPLNLTQKOLSEVALMTT 281
Db 1616 VWFNKGWHALVSLFNVAHNAIRASLPKDRSPPEYGITVISQPLNLTKEQLSDITVLT 1675
QY 282 SVD 284
Db 1676 SVD 1678

RESULT 6
US-09-995-542-3
; Sequence 3, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ullas, Laarni
```

```
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; PRIOR FILING DATE: 2001-11-28
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 2121
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-542-3

Query Match 43.5%; Score 664; DB 10; Length 2121;
Best Local Similarity 45.3%; Pred. No. 1e-55;
Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

QY 1 FGKPSLELQPMWYNEQYTFVSNDAPEDTGTLELLNALTQDPGFGTRCMEGNPIDTPCQ 60
Db 1228 FGQYPLQLSPAMYGPQVSFFSEDAPGDPNRMKLLEALLGEAGLQEPSQDKDARGSECT 1287
QY 61 AGEERTTAPVQPTIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPGAGGLPPOR 119
Db 1288 HSLACYFTVPEVPPDVASILASGNWTPESPACQSQPGARRLLPDCPAGAGGPPPPQA 1347
QY 120 KONTADILQDLTGRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIGVSNLTQALPPSQ 179
Db 1348 VAGLGEVQNLTRNIDSLVKTYPALIRSLKSKFWNEQRYGGISIGVSNLTQALPPSQ 1406
QY 180 EVNDAIKQMKHKLAKDSSADRELNSLGRMTGLDTRNNVKNWNNKWHAISSFLNVI 239
Db 1407 EVRTLAEIRALLSPQGNALDRILNLTQWALGIDARNLSLKIFWNNKWHAMVAFVNR 1466
QY 240 NNAILRANLQKGNPSHYGITAFNHNPLNLTQKOLSEVALMTTSD 284
Db 1467 NGLLHALLSPGVRHAHSITLHNPLNLTKEQLSEATLIASSVD 1511

RESULT 7
US-09-995-542-2
; Sequence 2, Application US/09995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Ullas, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; PRIOR FILING DATE: 2001-11-28
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 2167
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-542-2

Query Match 43.5%; Score 664; DB 10; Length 2167;
Best Local Similarity 45.3%; Pred. No. 1.1e-55;
Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

QY 1 FGKPSLELQPMWYNEQYTFVSNDAPEDTGTLELLNALTQDPGFGTRCMEGNPIDTPCQ 60
Db 1274 FGQYPLQLSPAMYGPQVSFFSEDAPGDPNRMKLLEALLGEAGLQEPSQDKDARGSECT 1333
QY 61 AGEERTTAPVQPTIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPGAGGLPPOR 119
Db 1334 HSLACYFTVPEVPPDVASILASGNWTPESPACQSQPGARRLLPDCPAGAGGPPPPQA 1393
```



```

; NUMBER OF SEQ. ID NOS: 21
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 18
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-767-870-18

```

	Query, matched	Seq. ID#	Accession	Code	Length
	Best Local Similarity	41.08;	Pred. No.	2.4e-37;	
Matches	86; Conservative	40; Mismatches	73; Indels	11; Gaps	2;
QY	22	SNDAPDGTGLELNLALTKDPFGFTRCMEGNP	IPTDTPCOAGEEHWTTAPVQTIMDLFQN	81	
		: : : : :			
Db	1	SEDAGPDGRRALLEALLQEAG-----LEEPVQHSHRFSFAVEPAEKVLAS	50		
QY	82	GNWTQMNPSPACQSSDKIRKMLPVCPPGGGLPPPKQNTADILDLTGRNLSDYLVK	141		
Db	51	GNWTPESPSPACQSCRPGARLLPDCPAAAGGPPPPQAVTGSGEVQNLTLGRNLSDFLVK	110		
QY	142	TYVOIIAKSUKNTWNVEFRYGGFSLGVSNITQALPPSOEVNDATIKOMKHHLAKDSAD	201		
		: :			
Db	111	TYRLVRQGLTKKWINEVRIGGFSLC-GRDPGLPSQGELGRSVEELWALLSPPLPGGALD	169		
QY	202	RFLNSLGREMTGLDRNNKVWFNFKNKGWHA	231		
Db	170	RVLNLTAWAHSLLDAQDSLKIWFNKNKGWS	199		

```

US-10-072-621-8
; Sequence 8, Application US/10072621
; Patent No. US20020169137A1
; GENERAL INFORMATION:
; APPLICANT: Reiner, Peter B.
; APPLICANT: Connop, Bruce P.
; APPLICANT: Pollard, Michelle
; TITLE OF INVENTION: REGULATION OF AMYLOID PRECURSOR PROTEIN EXPRESSION
; TITLE OF INVENTION: BY MODIFICATION OF ABC TRANSPORTER EXPRESSION OR ACTIVATION
; FILE REFERENCE: 100103.402
; CURRENT APPLICATION NUMBER: US/10/072.621
; CURRENT FILING DATE: 2002-02-08
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 2001
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 30, 70, 280, 477, 558, 1471, 1651, 1689, 1724
; OTHER INFORMATION: Xaa = Any Amino Acid
; FEATURE:

```

```

; LOCATION: 507, OF 2867, 4779, 3367, 14747, 10031, 10033, 17424
; OTHER INFORMATION: Xaa = Adu Amino Acid
US-10-072-621-8

Query Match          17.5%; Score 267; DB 9; Length 2001;
Best Local Similarity 28.8%; Pred. No. 4.3e-17;
Matches 79; Conservative 41; Mismatches 68; Indels 86; Gaps 13;

Qy    44   FGTRCMEG-----NPIP-DTPCQ-----AGEEETAP-V 71
      :|::||:||||:
Db    1137 FDSMCLESFOTGLPLSNFVPPPPSPAPS DSPSDPDLQANVSILPTTAGEMWMTSAPSL 1196

Qy    72   PQTIMDLFQNGNWTHMNPDPACQSSDKIKMLPYCPGAGLPPQPORKONTADILQDLT 131
      :|::||:||||:
Db    1197 PRLVREPVR-----CTCSAQGTGS----CPNSVG-GHPQMRRVTGDTLTDIT 1240

Qy    132  GRNISDLVLKTYTQIIAAKSLKNKIWNREFRGFSGLVSNYQALPPSQEVNDAIKQMKKH 191
      :|::||:||||:
Db    1241 GHNYSEYLLETSDFR-----RHURHGATFTG-NVLKSTIPAS--FGTRAPPMWRK 1286

```


GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:27 ; Search time 19 Seconds

(without alignments)

1436.957 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKPSLELQPMWYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1423	93.3	2201	2	A54774	ATP binding casset
2	267	17.5	1529	2	A59189	ATP binding casset
3	257	16.9	1472	2	B54774	hypothetical prote
4	215.5	14.1	1447	2	T15200	glutamate-ammonia
5	108.5	7.1	432	2	T14292	glutamate-ammonia
6	100.5	6.6	434	1	AJBHQ	glutamate-ammonia
7	98	6.4	877	2	F90070	Clumping factor B
8	97	6.4	908	2	T16057	hypothetical prote
9	95.5	6.3	429	1	AJF8QD	glutamate-ammonia
10	94.5	6.2	263	2	C64339	hypothetical prote
11	94.5	6.2	430	2	S18600	glutamate-ammonia
12	94.5	6.2	4660	2	T42737	gp330 protein prec
13	92.5	6.1	428	1	AJR2QD	glutamate-ammonia
14	91	6.0	459	2	B83793	hypothetical prote
15	90.5	5.9	428	2	S32228	glutamate-ammonia
16	90	5.9	773	2	F90537	lipoprotein [impor
17	89.5	5.9	423	2	S39482	glutamate-ammonia
18	89.5	5.9	596	1	S33540	catechol oxidase (
19	89.5	5.9	649	2	B96729	hypothetical prote
20	89	5.8	903	1	VGBEK1	glycoprotein B pre
21	88.5	5.8	363	2	S38154	hypothetical prote
22	88.5	5.8	865	2	AG2023	hypothetical prote
23	88.5	5.8	903	1	VGBEK1	glycoprotein B pre
24	88.5	5.8	982	2	T43676	hunchback-related
25	88.5	5.8	1071	2	T18597	hypothetical prote
26	88.5	5.8	1650	2	S53457	dominant autoantig
27	88	5.8	678	2	S12456	vird3 protein - Ag
28	88	5.8	791	2	S67265	hypothetical prote
29	88	5.8	888	2	S64016	probable regulator

30	87.5	5.7	578	2	G84015	maltoogenic amylase
31	86.5	5.7	407	2	A85191	probable serine pr
32	86.5	5.7	944	2	D82926	hypothetical prote
33	86.5	5.7	967	2	A30325	membrane alanyl am
34	86	5.6	506	2	AB3411	cysteine-tRNA liga
35	86	5.6	633	2	S48956	hypothetical prote
36	86	5.6	739	2	I56187	transcription fact
37	86	5.6	1309	1	BVBYD9	RAD9 protein - yea
38	86	5.6	2509	2	G01880	fatty-acid synthas
39	85.5	5.6	430	1	AJPMQ2	glutamate-ammonia
40	85.5	5.6	2329	2	S44625	C50C3.6 protein -
41	85	5.6	770	1	S30293	transcription fact
42	85	5.6	1566	2	T20058	hypothetical prote
43	84.5	5.5	389	2	S75454	hypothetical prote
44	84	5.5	325	2	JC2008	actin homolog prot
45	83.5	5.5	283	2	D83948	hypothetical prote

ALIGNMENTS

RESULT 1

A54774

ATP binding cassette transporter ABC1 - mouse

C:Species: Mus musculus (house mouse)

C:Date: 05-Apr-1995 #sequence_revision 05-Apr-1995 #text_change 02-Feb-2001

C:Accession: A54774

R:Luciani, M.F.; Denizot, F.; Savary, S.; Mattei, M.G.; Chimini, G.

Genomics 21, 150-159, 1994

A:Title: Cloning of two novel ABC transporters mapping on human chromosome 9.

A:Reference number: A54774; MUID:94375008; PMID:8088782

A:Accession: A54774

A:Molecule type: mRNA

A:Residues: 1-2201 <LUC>

A:Cross-references: GB:X75926; NID:9495256; PIDN:CAA53530.1; PID:9495257

C:Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homolog

C:Keywords: ATP; duplication; nucleotide binding; P-loop

F:856-1047/Domain: ATP-binding cassette homology <ABC1>

F:873-880/Region: nucleotide-binding motif A (P-loop)

F:1869-2060/Domain: ATP-binding cassette homology <ABC2>

F:1886-1893/Region: nucleotide-binding motif A (P-loop)

Query Match

Best Local Similarity 93.3%; Score 1423; DB 2; Length 2201;

Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 1 FGKPSLELQPMWYNEQYTFVSNDAPEDTGTTLELNALTKDPCGTRMEGNPIPTPCQ 60

|||||

Db 1311 FGKPSLELQPMWYNEQYTFVSNDAPEDMGTQELLNALT KDPGFGTRCMEGNPIDTPCL 1370

QY 61 AGEETWTPVPQTMDFQNGNWTMONPSPACQSSDKIKKMLPVCPPGAGLPPQPK 120

|||||

Db 1371 AGEEDWTISFPQSVLDLFQNGNWTMKNPSPACQSSDKIKKMLPVCPPGAGLPPQPK 1430

QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180

|||||

Db 1431 QKTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNSQALPPSHE 1490

QY 181 VNDATKQMKHKHLKADSSADRFSLNSLGRFTGLDTRNNKVKVWFNNKGHAISSFLNVIN 240

|||||

Db 1491 VNDATKQMKHKHLKADSSADRFSLNSLGRFTGLDTRNNKVKVWFNNKGHAISSFLNVIN 1550

QY 241 NAILRANLQKGNPSHYGITAFAFNHPLNLTQKQQLSEVALMTTSVD 284

|||||

Db 1551 NAILRANLQKGNPSHYGITAFAFNHPLNLTQKQQLSEVALMTTSVD 1594

RESULT 2

A59189

ATP-binding cassette transporter - human (fragment)

N:Alternate names: KIAA1062 protein

C:Species: Homo sapiens (man)

C:Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 02-Jun-2000

Db 43 POEIKLYQNG-YTTTEIAIKMKCSHETIRRL-----RNNNIDI----- 81
QY 132 GRNISDYLVTYVQIIAKSKN--KIWNNEFRGGSLGVSNTQALPPSQEVN----- 182
Db 82 -RKSSSESLI-----IKNTKKINLNPSESILYLGLVINGDGSVNGKQESNYIELKV 130
QY 183 ---DAIKQMKKKHLKLAKDSADRLNSLGRFMTGLDTRNNVKVWENKNG---WHA---IS 233
Db 131 TDKDFIEEFRNLC---ENIGFYKINEYVRKFENKKDQYVVRV--RSKGFYIWKSLNVD 184
QY 234 SFLNVI--NNAILRANLOKQ 251
Db 185 YVMNVIGNNEKLMISWLKG 203

RESULT 11
S18600
glutamate-ammonia ligase (EC 6.3.1.2) precursor, chloroplast (clone lambdaaatgs11) - Arab
N;Alternate names: glutamine synthetase
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 22-Nov-1993 #sequence_revision 12-May-1995 #text_change 03-Jun-2002
C;Accession: S18600
R;Petersman, T.K.; Goodman, H.M.
Mol. Gen. Genet. 230, 145-154, 1991
A;Title: The glutamine synthetase gene family of Arabidopsis thaliana: light-regulation
A;Reference number: S18600; MUID:92079889; PMID:1684022
A;Accession: S18600
A;Molecule type: mRNA
A;Residues: 1-430 <PET>
A;Cross-references: EMBL:S69727; NID:9240069; PIDN:AAB20558.1; PID:g240070
A;Experimental source: clone lambdaaatgs11
C;Genetics:
A;Genome: nuclear
C;Superfamily: glutamate-ammonia ligase
C;Keywords: chloroplast; ligase
F;1-51/Domain: transit peptide (chloroplast) #status predicted <TNP>
F;52-430/Product: glutamate-ammonia ligase #status predicted <MAT>

Query Match 6.2%; Score 94.5; DB 2; Length 430;
Best Local Similarity 23.1%; Pred. No. 5.9;
Matches 67; Conservative 25; Mismatches 111; Indels 87; Gaps 14;
QY 5 PSLELPQWYNEQYTFVSNADP-EDTGTLELLNALT KDPGFG-----TRCMEGNPI 54
Db 105 PS-ELPKWNYDGSST---GQAPGEDSEVILYPQAFRDPFRGNNILVICDTWTTPAGEPI 160
QY 55 P-----DTPCQAGEEWTTPVPQTIMDLFQNGNWTMQNPSPACQCSSDKIKKM 103
Db 161 PTNKRKAAEIFSNKKVSGEVPWFGEQYETLLQ--QNVKWLGLWP----- 204
QY 104 LPVCPFGAGLPPQPRKQNTADILQDLTGRNISDYLVTYVQIIAKSKLNKIWNNEFRYG 163
Db 205 -----VGAFPGQPGPYCGVGADKIWGRDISDAHAKCL-----YA 240
QY 164 GFSLGVSNTQALPPSQEVN-----DAIKQMKKKHLKLAKDSADRFLNSLGRFMTGLDT 216
Db 241 GINISGTNGEVMFGQWFOGFSVGIDA---GDHWKCAR-YLLERITBQAGVILT-LDP 294
QY 217 RNNVKVWENKNGHATSSP-----LNVINNAILRANLOKGENPSHYG 258
Db 295 KPIEGDW-NGAGCHTNYTSKMRGGFEVTKKAILNLSLRHKEHSAYG 343

RESULT 12
T42737
gp330 protein precursor - rat
N;Alternate names: megalin
C;Species: Rattus norvegicus (Norway rat)
C;Date: 11-Jan-2000 #sequence_revision 11-Jan-2000 #text_change 04-Mar-2000
C;Accession: T42737
R;Saito, A.; Pietromonaco, S.; Loo, A.K.C.; Farquhar, M.G.
Proc. Natl. Acad. Sci. U.S.A. 91, 9725-9729, 1994
A;Title: Complete cloning and sequencing of rat gp330/megalin, a distinctive member of t

A;Reference number: A58173; MUID:95024033; PMID:7937880
A;Accession: T42737
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-4660 <SAI>
A;Cross-references: EMBL:L34049; NID:9561852; PID:g561853; PIDN:AAAS1369.1
A;Experimental source: strain Sprague-Dawley; kidney
C;Superfamily: alpha-2-macroglobulin receptor; EGF homology; LDL receptor ligand-bind
F;1-25/Domain: signal sequence #status predicted <SIG>
F;26-4660/Product: gp330 protein #status predicted <MAT>
Query Match 6.2%; Score 94.5; DB 2; Length 4660;
Best Local Similarity 23.6%; Pred. No. 1.4e+02;
Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps 19;
QY 1 FGKYPSS---LELQPMW-----YNEQYTFVSNADPDTGTLELLNALT KDPGFGTR 47
Db 4302 FGKENKEKVLVNVNPLTQVRIFHQLRYNQSS--VSNPCKQVCSHLCLL----RFGGYSCA 4354
QY 48 CMEGNPPI---PDTFCQAGEEWTTPVPQTIMDLFQNGN-WTMQNPSPACQCSSDKIKKM 103
Db 4355 CPQSGDFVTGSTVQCDAASELPVTMPPPCRM---HGGNCYFDENELPKCKCSCSGSGE- 4410
QY 104 LPVCPFG-AGGLPPQPRKQNTADILQDLTGRNISDYLVTYVQIIAKSKLNKIWNNEFRY 162
Db 4411 --YCEVGLSRGILPP-----GTMA-VLLTFVIVILVIGAL---VLVGLFHY 4449
QY 163 GGSFSGVSNTQALPPSQEVNDAIKQMKKKHLKLAKDSSADRFLNSLG-RFMTGLDTRNNVK 221
Db 4450 -----RKTGSLTPT-----LPKPLSLSLAKPSE-----NGNGVTFRSGADV--NMD 4489
QY 222 VWFNNKGWHAISSFLNVINNAILRANLOKGENPSHYGTAENHPLNLT KQOLSEVAL 278
Db 4490 IGVSPFGPETIDRSMAHNEHFV---MEVGKQP-----VIFENPMYAAKONTSKVAL 4538
RESULT 13
AJR20D
glutamate-ammonia ligase (EC 6.3.1.2) delta precursor, chloroplast - rice
N;Alternate names: glutamine synthetase delta
C;Species: Oryza sativa (rice)
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 03-Jun-2002
C;Accession: S07471
R;Sakamoto, A.; Ogawa, M.; Masumura, T.; Shibata, D.; Takeba, G.; Tanaka, K.; Fujii,
Plant Mol. Biol. 13, 611-614, 1989
A;Title: Three cDNA sequences coding for glutamine synthetase polypeptides in Oryza s
A;Reference number: S07469; MUID:91370845; PMID:2577497
A;Accession: S07471
A;Molecule type: mRNA
A;Residues: 1-428 <SAK>
A;Cross-references: GB:X14246; NID:g20369; PIDN:CAA32462.1; PID:g20370
C;Superfamily: glutamate-ammonia ligase
C;Keywords: chloroplast; ligase

Query Match 6.1%; Score 92.5; DB 1; Length 428;
Best Local Similarity 23.6%; Pred. No. 8.5;
Matches 67; Conservative 30; Mismatches 112; Indels 75; Gaps 14;
QY 5 PSLELPQWYNEQYTFVSNADP-EDTGTLELLNALT KDPGFG-----TRCMEGNPI 54
Db 103 PS-ELPKWNYDGSST---GQAPGEDSEVILYPQAFRDPFRGNNILVMCDTTPPAGEPI 158
QY 55 P-----DTPCQAGEEWTTPVP-----QTIMDLFQNGNWTMQNPSPACQCSSDKIKKM 105
Db 159 PTNKRRAAQVFSQPVKVSQVPMFGEIETLQRDVNWPLGWP----- 202
QY 106 VCPFGAGLPPQPRKQNTADILQDLTGRNISDYLVTYVQIIAKSKLNKIWNNEFRYGGF 165
Db 203 -----VGGYPGQPGPYCAVGSKDFGRDISDAHAKCL-----YAGI 240
QY 166 SLGVSNTQALPPSQE--VNDAIK-QMKKKHLKLAKDSSADRFLNSLGRFMTGLDTRNNVK 222
Db 241 NISGTNGEVMFGQWFOGFSVGIEAGDHIWISR-YILERITBQAGVILT-LDPKPIQGD 298

	Query Match	5.9%;	Score 90.5;	DB 2;	Length 429;
	Best Local Similarity	23.9%;	Pred. No. 12;		
	Matches 68;	Conservative 28;	Mismatches 113;	Indels 75;	Gaps 14;
Qy	5	PSLELOPMYNEQVTFYSNDAP-EDTGTLELLNALTWDPGFG-----TRCMEGNPI	54		
Db	103	PS-ELPKWNYDGSST---GOAPGEDSEVILYQPQAFIRDPFRGGNNILVICDITVTPAGEPI	158		
Qy	55	P-DTPCOAGE-----EEWTTAPVPQTIMDLFQNGNWTMQNPSPACQSSDKIKKMLP	105		
Db	159	PTNKRAAEALFSNKKVNEELPFGIEQEYTLQPNNVWPLGWP-----	202		
Qy	106	VCPPGAGLPPQQRKQNTADTLQDLTGRNTSDYLVKTVYQIIAKSLKNKIWNREFYGGF	165		
Db	203	----VGAYEPQPGPYCGVGAEKSWGDRISDAHYKACL-----YAGI	240		
Qy	166	SLGVSNTPQALPPSQE---VNDAIK--QMKHKHLKLAKDSSADRFNLSLGRFMTGLDTRNNVKV	222		

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:24 ; Search time 11 Seconds
(without alignments)
1070.843 Million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKPSLELPWMYNEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Swissprot_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Query %	ID	Description
1	1513	99.2	99.2	ABC1_HUMAN	O95477 homo sapien
2	1423	93.3	93.3	ABC1_MOUSE	P41233 mus musculus
3	733.5	48.1	27.3	ABC2_HUMAN	P78363 homo sapien
4	267	17.5	24.36	ABC2_HUMAN	Q9bzc7 homo sapien
5	264	17.3	24.34	ABC2_MOUSE	P41234 mus musculus
6	108.5	7.1	4.32	GLN2_DAUCA	O22506 daucus caro
7	98.5	6.5	4.34	GLN2_HORVU	P13564 hordeum vul
8	98.5	6.5	20.83	DYSF_MOUSE	Q9esd7 mus musculus
9	95.5	6.3	4.29	GLN4_PHAVU	P35102 phaseolus v
10	94.5	6.2	26.3	Y314_METJA	Q57762 methanococc
11	94.5	6.2	4.30	GLN2_ARATH	Q43127 arabidopsis
12	94.5	6.2	20.80	DYSF_HUMAN	O75923 homo sapien
13	94.5	6.2	4.660	LRP2_RAT	P98158 rattus norv
14	92.5	6.1	4.28	GLN2_ORYSA	P14655 oryza sativ
15	90.5	5.9	4.28	GLNC_BRANA	Q42624 brassica na
16	89.5	5.9	4.23	GLNC_MAIZE	P25462 zea mays (m
17	89.5	5.9	5.96	POB_LYCES	Q08304 lycopersico
18	89.5	5.8	9.03	VGLB_HSVIF	P06436 herpes simp
19	89.5	5.8	1.597	GTF1_STRDO	P11001 streptococc
20	88.5	5.8	3.63	YK57_YEAST	P36157 saccharomyc
21	88.5	5.8	9.82	HBL1_CAEEL	Q9xyd3 caenorhabdi
22	88	5.8	6.78	YD13_AGRHH	P13463 agrobacteri
23	88	5.8	8.88	YGB4_YEAST	P25339 saccharomyc
24	87.5	5.7	4.28	GLN2_MEDSA	Q9xq94 medicago sa
25	87.5	5.7	3.148	HD_FUGRU	P51112 fugu rubrip
26	87	5.7	27.68	THYG_HUMAN	P01266 homo sapien
27	86.5	5.7	9.44	Y166_UREPA	Q9pqq7 ureaplasma
28	86	5.6	6.33	BZL1_YEAST	P38822 saccharomyc
29	86	5.6	13.09	RAD9_YEAST	P14737 saccharomyc
30	85.5	5.6	4.30	GLN2_PEA	P08281 pisum sativ
31	85.5	5.6	2.212	RRPL_EBOZM	Q05318 ebola virus
32	85.5	5.6	2.329	YJ36_CAEEL	P34369 caenorhabdi
33	85	5.6	7.70	OCT1_MOUSE	P25425 mus musculus

RESULT 1

ABCL_HUMAN

ID ABC1_HUMAN STANDARD: PRT; 2261 AA.
AC O95477; Q9UN08; Q9UN07; Q9UN06; Q9NQV4; Q9UN09; Q96T85; Q96S56;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE ATP-binding cassette, sub-family A, member 1 (ATP-binding cassette transporter 1) (ABC-1) (Cholesterol efflux regulatory protein).
DE regulatory protein).
GN ABCA1 OR ABC1 OR CERP.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20345099; Pubmed=10884428;
RA Santamarina-Fojo S., Peterson K.M., Knapper C.L., Qiu Y., Freeman L.A., Cheng J.-P., Osorio J., Remaley A.T., Yang X.-P., Haudenschild C.C., Prades C., Chimini G., Blackmon E.E., Francos T.L., Duverger N., Rubin E.M., Rosier M., Deneffe P., Fredrickson D.S., Brewer H.B. Jr.;
RT "Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX Schwartz K., Lawn R.M., Wade D.P.;
RT "ABCA1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR.";
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=21251004; Pubmed=11352567;
RA Qiu Y., Cavellier L., Chiu S., Yang X., Rubin E., Cheng J.-F.;
RT "Human and mouse ABCA1 comparative sequencing and transgenesis studies revealing novel regulatory sequences.";
RL Genomics 73:66-76(2001).
RN [4]
RP SEQUENCE FROM N.A.
RA Tanaka A.R., Abe-Dohmae S., Arakawa R., Sadanami K., Kidera A., Kioka N., Amachi T., Yokoyama S., Ueda K.;
RT "A new topological model of functional human ABCA1-signal peptide cleavage and glycosylation of a large extracellular domain.";
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE OF 21-2261 FROM N.A.
RX MEDLINE=99194549; Pubmed=10092505;
RA Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., Kaminski W.E., Schmitz G.;
RT "Molecular cloning of the human ATP-binding cassette transporter 1 (ABCA1): evidence for sterol-dependent regulation in macrophages.";
RL Biochem. Biophys. Res. Commun. 257:29-33(1999).
RN [6]

ALIGNMENTS

34	84	5.5	322	1	ACT_PROCL	P45521 procambarus
35	83.5	5.5	353	1	VM17_BORHE	P32777 borrelia he
36	83.5	5.5	356	1	GLN3_ORYSA	P14656 oryza sativ
37	83.5	5.5	966	1	AMPN_HUMAN	P15144 homo sapien
38	83.5	5.5	1377	1	CID_DROME	P19538 drosophila
39	83.5	5.5	3224	1	RBP2_HUMAN	P49792 homo sapien
40	83	5.4	559	1	3BP2_MOUSE	Q06649 mus musculu
41	83	5.4	795	1	SYFB_BUCAI	P57230 buchnera ap
42	83	5.4	913	1	VGLB_PRVIF	P08355 pseudorabie
43	82.5	5.4	355	1	GLN4_MAIZE	P38562 zea mays (m
44	82.5	5.4	356	1	GLN3_MAIZE	P38561 zea mays (m
45	82.5	5.4	522	1	INA_DROME	P52235 drosophila

RP SEQUENCE OF 21-2261 FROM N.A.
RX MEDLINE=99364413; PubMed=10431238;
RA Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.-C.,
RA Deleuze J.-F., Brewer H.B., Duverger N., Deneffe P., Assmann G.,
RT "Tangier disease is caused by mutations in the gene encoding
RT ATP-binding cassette transporter 1";
RL Nat. Genet. 22:352-355(1999).
RN [7]
RP VARIANTS FHA THR-1091 AND 1893-GLU-ASP-1894 DEL.
RX MEDLINE=20001430; PubMed=10533863;
RA Marcell M., Brooks-Wilson A., Clee S.M., Roonp K., Zhang L.-H., Yu L.,
RA Collins J.A., van Dam M., Molhuizen H.O.F., Loubser O.,
RA Ouellette B.F.F., Senses C.W., Fichter K., Mott S., Denis M.,
RA Boucher B., Pinstone S., Genest J. Jr., Kastelein J.J.P., Hayden M.R.;
RT "Mutations in the ABC1 gene in familial HDL deficiency with defective
RT cholesterol efflux";
RL Lancet 354:1341-1346(1999).
RN [8]
RP VARIANTS TD ARG-597 AND ARG-1477, AND VARIANT FHA LEU-693 DEL.
RX MEDLINE=99364411; PubMed=10431236;
RA Brooks-Wilson A., Marcell M., Clee S.M., Zhang L.-H., Roonp K.,
RA van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F.,
RA Loubser O., Ouellette B.F.F., Fichter K., Ashbourne-Excoffon K.J.D.,
RA Senses C.W., Scherer S., Mott S., Denis M., Martindale D.,
RA Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P.,
RA Hayden M.R.;
RT "Mutations in ABC1 in Tangier disease and familial high-density
RT lipoprotein deficiency";
RL Nat. Genet. 22:336-345(1999).
RN [9]
RP VARIANTS TD SER-590; SER-935 AND VAL-937, AND VARIANTS ALA-399 AND
RP MET-883.
RX MEDLINE=99364412; PubMed=10431237;
RA Bodzioch M., Orso E., Klucken J., Langmann T., Boettcher A.,
RA Diederich W., Drobnik W., Barlage S., Buechler C.,
RA Porsch-Oezuermez M., Kaminski W.E., Hahmann H.W., Oette K.,
RA Rothe G., Aslanidis C., Lackner K.J., Schmitz G.;
RT "The gene encoding ATP-binding cassette transporter 1 is mutated in
RT Tangier disease";
RL Nat. Genet. 22:347-351(1999).
RN [10]
RP VARIANTS TD ILE-929; ARG-597 AND ARG-1477, AND VARIANTS FHA LEU-693
RP DEL; THR-1091; 1893-GLU-ASP-1894 DEL AND LEU-2150.
RX MEDLINE=20540002; PubMed=11086027;
RA Clee S.M., Kastelein J.J.P., van Dam M., Marcell M., Roonp K.,
RA Zwarts K.I., Collins J.A., Roelants R., Tamasawa N., Stulic T.,
RA Suda T., Ceska R., Boucher B., Rondeau C., Desouich C.,
RA Brooks-Wilson A., Molhuizen H.O.F., Frohlich J., Genest J. Jr.,
RA Hayden M.R.;
RT "Age and residual cholesterol efflux affect HDL cholesterol levels and
RT coronary artery disease in ABCA1 heterozygotes";
RL J. Clin. Invest. 106:1263-1270(2000).
RN [11]
RP VARIANTS TD ASN-1289 AND HIS-1800.
RX MEDLINE=20171564; PubMed=10706591;
RA Brousseau M.E., Schaefer E.J., Dupuis J., Eustace B.,
RA Van Berdevelde P., Goldkamp A.L., Thurston L.M., Fitzgerald M.G.,
RA Yasek-McKenna D., O'Neill G., Eberhart G.P., Weiffenbach B.,
RA Ordoas J.M., Freeman M.W., Brown R.H. Jr., Gu J.Z.;
RT "Novel mutations in the gene encoding ATP-binding cassette 1 in four
RT tangier disease kindreds";
RL J. Lipid Res. 41:433-441(2000).
RN [12]
RP VARIANT TD ASP-1046, VARIANT FHA CYS-230, AND VARIANTS LYS-219;
RX ILE-825; MET-883 AND LYS-1587.
RX MEDLINE=20396633; PubMed=10938021;
RA Wang J., Burnett J.R., Near S., Young K., Zinman B., Hanley A.J.G.,
RA Connelly P.W., Harris S.B., Hegde R.A.;
RT "Common and rare ABCA1 variants affecting plasma HDL cholesterol";
RL Arterioscler. Thromb. Vasc. Biol. 20:1983-1989(2000).
RN [13]
RP VARIANT TD TRP-587, AND VARIANT LEU-2168.
RX MEDLINE=21157002; PubMed=11257260;
RA Bertolini S., Pisciotto L., Seri M., Cusano R., Cantafora A.,
RA Calabresi L., Franceschini G., Ravazzolo R., Calandra S.;
RT "A point mutation in ABC1 gene in a patient with severe premature
RT coronary heart disease and mild clinical phenotype of Tangier
RT disease";
RL Atherosclerosis 154:599-605(2001).
RN [14]
RP VARIANTS LYS-219; MET-883 AND ASP-1172.
RX MEDLINE=21157003; PubMed=11257261;
RA Brousseau M.E., Bodzioch M., Schaefer E.J., Goldkamp A.L., Kiehl D.,
RA Probst M., Ordoas J.M., Aslanidis C., Lackner K.J.,
RA Bloomfield Rubins H., Collins D., Robins S.J., Wilson P.W.F.,
RA Schmitz G.;
RT "Common variants in the gene encoding ATP-binding cassette transporter
RT 1 in men with low HDL cholesterol levels and coronary heart disease";
RL Atherosclerosis 154:607-611(2001).
RN [15]
RP VARIANT TD LEU-1506.
RX MEDLINE=21369429; PubMed=11476961;
RA Lapicka-Bodzioch K., Bodzioch M., Kruehl M., Kiehl D., Probst M.,
RA Klec B., Andrikovics H., Boettcher A., Hubacek J., Aslanidis C.,
RA Suttorp N., Schmitz G.;
RT "Homogeneous assay based on 52 primer sets to scan for mutations of
RT the ABCA1 gene and its application in genetic analysis of a new
RT patient with familial high-density lipoprotein deficiency syndrome";
RL Biochim. Biophys. Acta 1537:42-48(2001).
RN [16]
RP VARIANTS TD ASN-1289 AND TRP-2081, AND VARIANT LYS-219.
RX MEDLINE=21369433; PubMed=11476965;
RA Huang W., Moriyama K., Koga T., Hua H., Ageta M., Kawabata S.,
RA Kawatari K., Imamura T., Eto T., Kawamura M., Teramoto T., Sasaki J.;
RT "Novel mutations in ABCA1 gene in Japanese patients with Tangier
RT disease and familial high density lipoprotein deficiency with
RT coronary heart disease";
RL Biochim. Biophys. Acta 1537:71-78(2001).
RN [17]
RP VARIANTS LYS-219; ALA-399; MET-771; PRO-774; ASN-776; ILE-825;
RP MET-883; ASP-1172; LYS-1587 AND CYS-1731.
RX MEDLINE=21138379; PubMed=11238261;
RA Clee S.M., Zwinderman A.H., Engert J.C., Zwarts K.Y.,
RA Molhuizen H.O.F., Roonp K., Jukema J.W., van Wijkland M., van Dam M.,
RA Hudson T.J., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P.,
RA Hayden M.R.;
RT "Common genetic variation in ABCA1 is associated with altered
RT lipoprotein levels and a modified risk for coronary artery disease";
RL Circulation 103:1198-1205(2001).
RN [18]
RP VARIANT TD THR-255, AND VARIANT ATHEROSCLEROSIS ASP-1611.
RX MEDLINE=21645894; PubMed=11785958;
RA Nishida Y., Hirano K., Tsukamoto K., Nagano M., Ikegami C., Roonp K.,
RA Ishihara Y., Sakane N., Zhang Z., Tsujii K., Matsuyama A., Ohama T.,
RA Matsura F., Ishigami M., Sakai N., Hiraoka H., Hattori H.,
RA Wellington C., Yoshida Y., Misugi S., Hayden M.R., Egashira T.,
RA Yamashita S., Matsuzawa Y.;
RT "Expression and functional analyses of novel mutations of ATP-binding
RT cassette transporter-1 in Japanese patients with high-density
RT lipoprotein deficiency";
RL Biochem. Biophys. Res. Commun. 290:713-721(2002).
CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
CC TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
CC TRANSPORT.
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED, BUT MOST ABUNDANT IN
CC MACROPHAGES.
CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
CC ATP BINDING CASSETTE (ABC) DOMAIN.
CC -1- DISEASE: DEFECTS IN ABCA1 ARE A CAUSE OF HIGH DENSITY LIPOPROTEIN
CC DEFICIENCY TYPE I (HDLI), ALSO KNOWN AS TANGIER DISEASE (TD). TD
CC IS A RECESSIVE DISORDER CHARACTERIZED BY ABSENCE OF HIGH DENSITY
CC LIPOPROTEIN (HDL) CHOLESTEROL FROM PLASMA, HEPATOSPLENOMEGALY,
CC PERIPHERAL NEUROPATHY, AND FREQUENTLY PREMATURE CORONARY ARTERY
CC DISEASE (CAD).
CC -1- DISEASE: Defects in ABCA1 are a cause of high density lipoprotein

```
Query Match          99.2%; Score 1513; DB 1; Length 2261;
Best Local Similarity 99.3%; Pred. No. 7.5e-120;
Matches 282; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 FGKPSLELPWMYNEQYTFVSNDAPEDTGTLLELNALTKDPGFCRCMEGNPIPDTPCQ 60
DB 1371 FGKPSLELPWMYNEQYTFVSNDAPEDTGTLLELNALTKDPGFCRCMEGNPIPDTPCQ 1430

QY 61 AGEEWTTAPVPTIMDLFQNGNWTQNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
DB 1431 AGEEWTTAPVPTIMDLFQNGNWTQNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490

QY 121 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550

QY 181 VNDIAIKMKKHLKAKDSSADRFNLNSLGRFMTGLDTRNNVKVFNKNGWHAISSFLNVIN 240
DB 1551 VNDIAIKMKKHLKAKDSSADRFNLNSLGRFMTGLDTRNNVKVFNKNGWHAISSFLNVIN 1610

QY 241 NAILRANLOKGENPSHYGITAFNHPNLTKQQLSEVALMTTSVD 284
DB 1611 NAILRANLOKGENPSHYGITAFNHPNLTKQQLSEVALMTTSVD 1654

RESULT 2
ID ABC1_MOUSE STANDARD; PRT; 2261 AA.
AC P41233;
DT 01-FEB-1995 (Rel. 31, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE ATP-binding cassette, sub-family A, member 1 (ATP-binding cassette
  transporter 1) (ATP-binding cassette 1) (ABC-1).
GN ABCA1 OR ABC1
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=DBA/2; TISSUE=Macrophage;
RX MEDLINE=94375008; PubMed=8068782;
RA Luciani M.F., Denizot F., Savary S., Mattei M.-G., Chimini G.;
RT "Cloning of two novel ABC transporters mapping on human chromosome
  9.";
RL Genomics 21:150-159(1994).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J;
RA Qiu Y., Cavelier L., Chiu S., Rubin E., Cheng J.-F.;
RT "Human and mouse ABCA1 comparative sequencing and transgenesis studies
  identify potential regulatory sequences.";
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
  TRANSPORT. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
  TRANSPORT (BY SIMILARITY).
CC -!- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST
  LEVELS ARE FOUND IN PREGNANT UTERUS AND UTERUS.
CC -!- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
  EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
  ATP BINDING CASSETTE (ABC) DOMAIN.
CC -!- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@lsb-sib.ch).
CC -----
```

```
DR EMBL; X75926; CAA53530.1; ALT_INIT.
DR EMBL; AF287263; AAG39073.1; ALT_INIT.
DR MGD; MGI:99607; Abcal.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transportr.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 1.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
KW ATP-binding; Glycoprotein; Transmembrane; Transport.
FT TRANSMEM 26
FT TRANSMEM 42
FT TRANSMEM 640
FT TRANSMEM 656
FT TRANSMEM 690
FT TRANSMEM 706
FT TRANSMEM 717
FT TRANSMEM 733
FT TRANSMEM 749
FT TRANSMEM 765
FT TRANSMEM 771
FT TRANSMEM 787
FT TRANSMEM 1041
FT TRANSMEM 1057
FT TRANSMEM 1351
FT TRANSMEM 1367
FT TRANSMEM 1661
FT TRANSMEM 1677
FT TRANSMEM 1708
FT TRANSMEM 1724
FT TRANSMEM 1737
FT TRANSMEM 1753
FT TRANSMEM 1775
FT TRANSMEM 1791
FT TRANSMEM 1854
FT TRANSMEM 1870
FT NP_BIND 933
FT NP_BIND 940
FT CARBOHYD 1946
FT CARBOHYD 1953
FT CARBOHYD 14
FT CARBOHYD 14
FT CARBOHYD 98
FT CARBOHYD 151
FT CARBOHYD 151
FT CARBOHYD 161
FT CARBOHYD 161
FT CARBOHYD 196
FT CARBOHYD 196
FT CARBOHYD 244
FT CARBOHYD 244
FT CARBOHYD 292
FT CARBOHYD 292
FT CARBOHYD 337
FT CARBOHYD 337
FT CARBOHYD 349
FT CARBOHYD 400
FT CARBOHYD 400
FT CARBOHYD 478
FT CARBOHYD 478
FT CARBOHYD 489
FT CARBOHYD 521
FT CARBOHYD 521
FT CARBOHYD 820
FT CARBOHYD 820
FT CARBOHYD 1144
FT CARBOHYD 1144
FT CARBOHYD 1294
FT CARBOHYD 1294
FT CARBOHYD 1453
FT CARBOHYD 1453
FT CARBOHYD 1499
FT CARBOHYD 1499
FT CARBOHYD 1504
FT CARBOHYD 1504
FT CARBOHYD 1637
FT CARBOHYD 1637
FT CARBOHYD 2044
FT CARBOHYD 2044
FT CARBOHYD 2238
FT CARBOHYD 2238
FT CONFLICT 1567
FT CONFLICT 1568
FT CONFLICT 2024
FT CONFLICT 2024
SQ SEQUENCE 2261 AA; 254011 MW; FAE62B21FD1D09F9 CRC64;

Query Match          93.3%; Score 1423; DB 1; Length 2261;
Best Local Similarity 93.0%; Pred. No. 3.2e-112;
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 1 FGKPSLELPWMYNEQYTFVSNDAPEDTGTLLELNALTKDPGFCRCMEGNPIPDTPCQ 60
DB 1371 FGKPSLELPWMYNEQYTFVSNDAPEDTGTLLELNALTKDPGFCRCMEGNPIPDTPCQ 1430

QY 61 AGEEWTTAPVPTIMDLFQNGNWTQNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
DB 1431 AGEEWTTAPVPTIMDLFQNGNWTQNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 1490

QY 121 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
DB 1491 QNTADILQDLTGRNISDYLVKTVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1550

QY 181 VNDIAIKMKKHLKAKDSSADRFNLNSLGRFMTGLDTRNNVKVFNKNGWHAISSFLNVIN 240
DB 1551 VNDIAIKMKKHLKAKDSSADRFNLNSLGRFMTGLDTRNNVKVFNKNGWHAISSFLNVIN 1610

QY 241 NAILRANLOKGENPSHYGITAFNHPNLTKQQLSEVALMTTSVD 284
DB 1611 NAILRANLOKGENPSHYGITAFNHPNLTKQQLSEVALMTTSVD 1654
```


RP I-959; K-1036; V-1038; P-1063; D-1087; C-1097; C-1108; L-1380; K-1399;
 RP P-1430; V-1440; L-1443; L-1486; X-1488; M-1537; P-1689; L-1705;
 RP T-1733; R-1748; P-1763; K-1885; H-1898; E-1961; R-1975; S-1977; G-2077
 RP W-2077 AND V-2241, AND VARIANTS Q-152; H-212; R-423; I-552; R-914;
 RP Q-943; T-1562; I-1868; M-1921; L-1948; F-1970; A-2059; N-2177 AND
 RP V-2216.
 RX MEDLINE-20442027; PubMed=10958763;
 RA Rivera A., White K., Stoehr H., Steiner K., Hemmrich N., Grimm T.,
 RA Jurklics B., Lorenz B., Scholl H.P.N., Apfelstedt-Sylla E.,
 RA Weber B.H.F.;
 RT "A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene
 RT in Stargardt disease and age-related macular degeneration.";
 RL Am. J. Hum. Genet. 67:800-813(2000).
 RN [15]
 RP VARIANTS CORD3 GLU-65; CYS-212; PRO-541; ALA-863; GLY-863 DEL;
 RP VAL-1038; LYS-1122; TYR-1490 AND ASP-1598.
 RX MEDLINE-20442040; PubMed=10958761;
 RA Maugeri A., Klevering B.J., Rohrschneider K., Blankenagel A.,
 RA Brunner H.G., Deutman A.F., Hoyng C.B., Cremers F.P.M.;
 RT "Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal
 RT recessive cone-rod dystrophy.";
 RL Am. J. Hum. Genet. 67:960-966(2000).
 RN [16]
 RP VARIANTS STGD ASP-340; GLN-572; ALA-863; SER-965; VAL-1038; ALA-1780
 RP AND HIS-1898, AND VARIANT GLN-943;
 RX MEDLINE-20208356; PubMed=10746567;
 RA Shroyer N.F., Lewis R.A., Lupski J.R.;
 RT "Complex inheritance of ABCR mutations in Stargardt disease: linkage
 RT disequilibrium, complex alleles, and pseudodominance.";
 RL Hum. Genet. 106:244-248(2000).
 RN [17]
 RP VARIANTS STGD.
 RX MEDLINE-20098082; PubMed=10634594;
 RA Papaioannou M., Oaka L., Bessant D., Lois N., Bird A.C., Payne A.,
 RA Bhattacharya S.S.;
 RT "An analysis of ABCR mutations in British patients with recessive
 RT retinal dystrophies.";
 RL Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).
 RN [18]
 RP VARIANTS STGD C-212; D-767; I-897; V-1038; K-1087; K-1399; Q-1640 AND
 RP E-1961, AND VARIANT HIS-212.
 RX MEDLINE-20174852; PubMed=10711710;
 RA Simonelli F., Testa F., de Crecchio G., Rinaldi E., Hutchinson A.,
 RA Atkinson A., Dean M., D'Urso M., Allikmets R.;
 RT "New ABCR mutations and clinical phenotype in Italian patients with
 RT Stargardt disease.";
 RL Invest. Ophthalmol. Vis. Sci. 41:892-897(2000).
 RN [19]
 RP CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLY-966; LYS-969;
 RP GLY-1975 AND LYS-1978.
 RX MEDLINE-20472331; PubMed=11017087;
 RA Sun H., Smallwood P.M., Nathans J.;
 RT "Biochemical defects in ABCR protein variants associated with human
 RT retinopathies.";
 RL Nat. Genet. 26:242-246(2000).
 RN [20]
 RP VARIANT STGD ASN-972, AND VARIANTS GLN-943; ILE-1868 AND LEU-1948.
 RX MEDLINE-21478761; PubMed=11594993;
 RA Eksandh L., Ekstroem U., Abrahamson M., Bauer B., Andreasson S.;
 RT "The ABCR gene encodes a protein with a high degree of homology to the
 RT ABC transporter family.";
 RL Hum. Genet. 106:244-248(2000).
 RN [21]
 RP Query Match 48.1%; Score 733.5; DB 1; Length 2273;
 RP Best Local Similarity 48.2%; Pred. No. 9.1e-54;
 RP Matches 146; Conservative 35; Mismatches 83; Indels 39; Gaps 4;
 QY 1 FGKPSLELOPMWYNQYTFVNDAPEDTGTELLNALTDPGFGTRCMGNPIPTPCQ 60
 DB 1397 FGEYPAITLHPWYQYQYTFVNDAPEDTGTELLNALTDPGFGTRCMGNPIPTPCQ 60
 QY 61 AGEBEWTPVPTIMDLFQNGWNTMNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
 DB 1456 GNSTPWKTPSVSNITQLFQKQKQVNPSPSCRCSTREKTLMLPECPGAGGLPPQPK 120
 QY 121 QNTADILQDUTGRNISDYLVKVTYQIIAASLKNKILWNEFRYGGFSLGSVNTQALPPSQE 180

RESULT 4

ABC2_HUMAN
 ID ABC2_HUMAN STANDARD; PRT; 2436 AA.
 AC Q9BZC7;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE ATP-binding cassette, sub-family A, member 2 (ATP-binding cassette
 DE transporter 2) (ATP-binding cassette 2).
 GN ABCA2 OR ABC2.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX PubMed=11178988;
 RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Ozcurumez M., Duong C.,
 RA Bared G.M., Buchler C., Schmitt G.;
 RT "Complete coding sequence, promoter region, and genomic structure of
 RT the human ABCA2 gene and evidence for sterol-dependent regulation in
 RT macrophages.";
 RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
 CC -1- FUNCTION: PROBABLE TRANSPORTER, ITS NATURAL SUBSTRATE HAS NOT BEEN
 CC FOUND YET. MAY HAVE A ROLE IN MACROPHAGE LIPID METABOLISM AND
 CC NEURAL DEVELOPMENT.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein (potential).
 CC -1- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF327705; AAK14335.1; JOINED.
 DR EMBL; AF327658; AAK14335.1; JOINED.
 DR EMBL; AF327659; AAK14335.1; JOINED.
 DR EMBL; AF327660; AAK14335.1; JOINED.
 DR EMBL; AF327661; AAK14335.1; JOINED.
 DR EMBL; AF327662; AAK14335.1; JOINED.
 DR EMBL; AF327663; AAK14335.1; JOINED.
 DR EMBL; AF327664; AAK14335.1; JOINED.
 DR EMBL; AF327665; AAK14335.1; JOINED.
 DR EMBL; AF327666; AAK14335.1; JOINED.
 DR EMBL; AF327667; AAK14335.1; JOINED.
 DR EMBL; AF327668; AAK14335.1; JOINED.
 DR EMBL; AF327669; AAK14335.1; JOINED.
 DR EMBL; AF327670; AAK14335.1; JOINED.
 DR EMBL; AF327671; AAK14335.1; JOINED.
 DR EMBL; AF327672; AAK14335.1; JOINED.
 DR EMBL; AF327673; AAK14335.1; JOINED.
 DR EMBL; AF327674; AAK14335.1; JOINED.
 DR EMBL; AF327675; AAK14335.1; JOINED.
 DR EMBL; AF327676; AAK14335.1; JOINED.

```
DR EMBL; AF327677; AAK14335.1; JOINED.
DR EMBL; AF327678; AAK14335.1; JOINED.
DR EMBL; AF327679; AAK14335.1; JOINED.
DR EMBL; AF327680; AAK14335.1; JOINED.
DR EMBL; AF327681; AAK14335.1; JOINED.
DR EMBL; AF327682; AAK14335.1; JOINED.
DR EMBL; AF327683; AAK14335.1; JOINED.
DR EMBL; AF327684; AAK14335.1; JOINED.
DR EMBL; AF327685; AAK14335.1; JOINED.
DR EMBL; AF327686; AAK14335.1; JOINED.
DR EMBL; AF327687; AAK14335.1; JOINED.
DR EMBL; AF327688; AAK14335.1; JOINED.
DR EMBL; AF327689; AAK14335.1; JOINED.
DR EMBL; AF327690; AAK14335.1; JOINED.
DR EMBL; AF327691; AAK14335.1; JOINED.
DR EMBL; AF327692; AAK14335.1; JOINED.
DR EMBL; AF327693; AAK14335.1; JOINED.
DR EMBL; AF327694; AAK14335.1; JOINED.
DR EMBL; AF327695; AAK14335.1; JOINED.
DR EMBL; AF327696; AAK14335.1; JOINED.
DR EMBL; AF327697; AAK14335.1; JOINED.
DR EMBL; AF327698; AAK14335.1; JOINED.
DR EMBL; AF327699; AAK14335.1; JOINED.
DR EMBL; AF327700; AAK14335.1; JOINED.
DR EMBL; AF327701; AAK14335.1; JOINED.
DR EMBL; AF327702; AAK14335.1; JOINED.
DR EMBL; AF327703; AAK14335.1; JOINED.
DR EMBL; AF327704; AAK14335.1; JOINED.
DR Genew; HGNC:32; ABCA2.
DR MIT; 600047; -.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transporter.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
KW ATP-binding; Transport; Transmembrane; Repeat; Glycoprotein.
FT TRANSMEM 21 40 POTENTIAL.
FT TRANSMEM 706 728 POTENTIAL.
FT TRANSMEM 749 771 POTENTIAL.
FT TRANSMEM 786 808 POTENTIAL.
FT TRANSMEM 813 835 POTENTIAL.
FT TRANSMEM 850 872 POTENTIAL.
FT TRANSMEM 892 914 POTENTIAL.
FT TRANSMEM 1793 1815 POTENTIAL.
FT TRANSMEM 1846 1865 POTENTIAL.
FT TRANSMEM 1875 1897 POTENTIAL.
FT TRANSMEM 1904 1926 POTENTIAL.
FT TRANSMEM 1988 2010 POTENTIAL.
FT NP_BIND 1025 1032 ATP (POTENTIAL).
FT NP_BIND 2088 2095 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 90 90 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 169 169 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 174 174 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 306 306 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 369 369 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 380 380 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 421 421 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 433 433 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 477 477 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 485 485 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 495 495 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 531 531 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 545 545 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 591 591 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 601 601 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 629 629 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1409 1409 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1497 1497 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1550 1550 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1558 1558 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1613 1613 N-LINKED (GLCNAC. .) (POTENTIAL).

FT CARBOHYD 1678 1678 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1776 1776 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2055 2055 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 2436 AA; 269971 MW; 9E6688D8615DE06D CRC64;

Query Match 17.5%; Score 267; DB 1; Length 2436;
Best Local Similarity 29.2%; Pred No. 3.5e-14;
Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIP-DTPQ-----AGEEWTPAP-V 71
| : | : |
Db 1572 FDSMCLESEFTQGLPLSNFVPPSPAPSDSPASPOEDLQAWNVLPTTAGPEMWTSA 1631
| : | : |
QY 72 POTIMDLFQNGWNTQNPSPACQSSDKIKMLPVCAGCAGLPPPOKONTADILDLT 131
| : | : |
Db 1632 PRUVREPVR-----CTCSAQGTGFS--CPSVVG-HPQMRVVVTGDIIDIT 1675
| : | : |
QY 132 GRNISDYLVKTVYQIIAKSLKNKWNEFRYGGFSLGVSNTQALPPSOEVNDAIKMKKH 191
| : | : |
Db 1676 GHNVSYLELLFTSDRF-----RLHRYGAITFG--NVLKSIPIASFGRAPPMVRK- 1721
| : | : |
QY 192 LKLAKDSSADREFLNSLGRFMTGLDTRNNVKNKNGHAISSPLNVNNAILRANLQKG 251
| : | : |
Db 1722 -----IARRAAQVFNKNGHSHMPTYLNSLNNAILRANLPKS 1759
| : | : |
QY 252 E-NPSHYGITAFNHLNLTQKQLS-EVALMTTSV 283
| : | : |
Db 1760 KGNPAAVYGITVTNHPMKNKTSASLSLDYLIQGTDV 1793

RESULT 5
ABCD_MOUSE STANDARD; PRT; 2434 AA.
ID ABC2_MOUSE AC P41234;
DT 01-FEB-1995 (Rel. 31, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE ATP-binding cassette, sub-family A, member 2 (ATP-binding cassette transporter 2) (ATP-binding cassette 2).
GN ABCA2 OR ABC2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
ON NCBI_TaxID=10090;
RX [1]
RP SEQUENCE FROM N.A., AND REVISIONS.
RC STRAIN=DBA/2;
RA Chimini G.;
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE OF 964-2434 FROM N.A.
RC STRAIN=DBA/2; TISSUE=Macrophage;
RX MEDLINE=94375008; PubMed=8088782;
RA Luciani M.F., Denizot F., Savary S., Mattei M.-G., Chimini G.;
RT "Cloning of two novel ABC transporters mapping on human chromosome 9.";
RL Genomics 21:150-159(1994).
CC -1- FUNCTION: PROBABLE TRANSPORTER, ITS NATURAL SUBSTRATE HAS NOT BEEN FOUND YET. MAY HAVE A ROLE IN MACROPHAGE LIPID METABOLISM AND NEURAL DEVELOPMENT.
CC -1- SUBCELLULAR LOCATION: Integral membrane protein (Potential).
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST LEVELS ARE FOUND IN BRAIN AND PREGNANT UTERUS.
CC -1- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/ or send an email to license@isb-sib.ch).
CC -----
```

```
DR EMBL; X75927; CAA53531.2; -.
DR MGD; MG1:99606; Abca2.
DR InterPro; IPR003593; AAA_AtpPase.
DR InterPro; IPR003439; ABC_transportr.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transp; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
KW ATP-binding; Transport; Transmembrane; Repeat; Glycoprotein.
FT TRANSMEM 21 40 POTENTIAL.
FT TRANSMEM 705 727 POTENTIAL.
FT TRANSMEM 748 770 POTENTIAL.
FT TRANSMEM 780 802 POTENTIAL.
FT TRANSMEM 809 831 POTENTIAL.
FT TRANSMEM 1793 1815 POTENTIAL.
FT TRANSMEM 1846 1865 POTENTIAL.
FT TRANSMEM 1875 1897 POTENTIAL.
FT TRANSMEM 1904 1926 POTENTIAL.
FT NP_BIND 1024 1031 ATP (POTENTIAL).
FT NP_BIND 2088 2095 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 89 89 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 168 168 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 173 173 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 305 305 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 368 368 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 379 379 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 420 420 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 432 432 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 476 476 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 484 484 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 494 494 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 530 530 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 548 548 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 589 589 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 599 599 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 627 627 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1408 1408 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1496 1496 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1549 1549 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1557 1557 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1613 1613 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1678 1678 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1776 1776 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2055 2055 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 2434 AA; 270582 MW; 3CEDD48ED5692005 CRC64;

Query Match 17.3%; Score 264; DB 1; Length 2434;
Best Local Similarity 25.2%; Pred. No. 6.3e-14;
Matches 92; Conservative 40; Mismatches 97; Indels 136; Gaps 15;

QY 2 GKPSLELPWMYNEQY-----FVSNDAPE-----DTGTELLNLTALTKDPGFGT 46
DB 1482 GDLPELVLPQYH-NVTPGRNFIPYAEERQYRLRLSPDASPQQLVSTFRLPSGVGA 1540
QY 47 RCM-----EGNPI----- 54
DB 1541 TCVLKSPANGSLGPMNLSSGESRLAARFFDSMCLESTQGLPLSNFVPPPPSPARSDS 1600
QY 55 ---PD-----TPCQAGEEWTAP-VPQIMDLFQNGNWTWQNPSPACQCSSDK1 100
DB 1601 PVXPDEDSLOANNLSLPTAGPETWTSAPSLPLVHEPYR-----CTCSAGGT 1648
QY 101 KMLPVCPPGAGLPPPPQKONTADILDTGRNISDYLVKTYVQIIAKSLKNKIWNNEF 160
DB 1649 GFS---CPSSVGG-HPPQMRVVTGDILDTIGHNVSEYLLFTSDFR-----RLH 1693
QY 161 RYGFSLGVSNTQALPPSOEVNDAIKQMKHLKLAKDSSADRLNSLGRFMTGLDTRNV 220
DB 1694 RGAITFG--NVQSIAS-----FGARVPMVRKTAVRVA 1728
QY 221 KYWFNKGWHAISSEFLVNNAILRANLPKSGKNPAAYGITVTNHPMNKTSASLSLDYLL 1788
DB 1729 QVLYNNKGYSHPMTYLSNLSNAILRANLPKSGKNPAAYGITVTNHPMNKTSASLSLDYLL 1788
QY 279 MTTSV 283
DB 1789 QGTDV 1793

RESULT 6
ID GLN2_DAUCA STANDARD; PRT; 432 AA.
AC 022506;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--
DE ammonia ligase) (GS2).
GN GLN2.
OS Daucus carota (Carrot).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; Core eudicots;
OC Asteridae; euasterids II; Apiales; Apiaceae; Daucus.
OX NCBI_TaxID=4039;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. US-Harumakigosun; TISSUE=Leaf;
RA Higashi K., Kanada H.;
RL Submitted (AUG-1997) to the EMBL/GenBank/DBJ databases
CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION
CC (BY SIMILARITY).
CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
CC L-glutamine.
CC -!- SUBUNIT: HOMODIMER (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Chloroplast (By similarity).
CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF019561; AAB71693.1; -.
DR InterPro; IPR001691; GLN_synth.
DR Pfam; PF00120; glb-synt; 1.
DR PROSITE; PS00180; GLNA_1; 1.
DR PROSITE; PS00181; GLNA_ATP; 1.
KW Ligase; Multigene family; Chloroplast; Transit peptide.
FT TRANSIT 1 ? CHLOROPLAST (POTENTIAL).
FT CHAIN 1 ? 432 GLUTAMINE SYNTHETASE.
SQ SEQUENCE 432 AA; 47763 MW; 20BC0A4CF8E35345 CRC64;

Query Match 7.1%; Score 108.5; DB 1; Length 432;
Best Local Similarity 24.5%; Pred. No. 0.092;
Matches 71; Conservative 26; Mismatches 110; Indels 83; Gaps 15;

QY 3 KYPSELPQWMYNEQYTFVSNDAPEDTGTLELL-NALTKDPGFG-----TRCMEGN 52
DB 105 EHPS-ELPKWYDGSST---GQAPGDDSEVILYPOAIFKDPFRGGNNILVICDTYTPQE 160
QY 53 PIPOTPCQ-----AGEEWTAPVPQIMDLFQNGNWTWQNPSPACQCSSDK1 101
DB 161 PIPTNKRHKAQFSDAKVLGVEYFWFGIEQYTLMO--ODVNW----- 201
QY 102 KMLPVCPPG--AGGLPPPPQKONTADILDTGRNISDYLVKTYVQIIAKSLKNKIWNNE 159
DB 202 -----PLGNVGVGPGQPGYYCAAGADKSGFRDISDAHYKACL----- 240
QY 160 FRYGFSLGVSNTQALPPSOE--VNDAIK-QMKHLKLAKDSSADRLNSLGRFMTGLDT 216
DB 160 FRYGFSLGVSNTQALPPSOE--VNDAIK-QMKHLKLAKDSSADRLNSLGRFMTGLDT 216
```

Db	241	--YAGINTSGTNGEVMQGFQVSGIEAGDHIWCAR-YLIERITEQAGVVLTF-LDP	258
QY	217	RNNVKWFNNKGWHAISF-----LNVINNAILLRANLOKGENPSHYG	258
Db	297	KPIDGW-NGACGHTNYSTKSMREGGFVKKAILNLSLRKHKEHSAYG	345
RESULT 7			
ID	GLN2_HORVU	STANDARD;	PRT; 434 AA.
AC	P13564;		
DT	01-JAN-1990 (Rel. 13, Created)		
DT	01-NOV-1990 (Rel. 16, Last sequence update)		
DT	15-JUN-2002 (Rel. 41, Last annotation update)		
DE	Glutamine synthetase leaf isozyme, chloroplast precursor (EC 6.3.1.2.)		
DE	(Glutamate-ammonia ligase) (Chloroplast GS2).		
OS	Hordeum vulgare (Barley).		
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;		
OC	Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae;		
OC	Triticeae; Hordeum.		
OX	NCBI_TaxID=4513;		
RP	[1]		
RP	SEQUENCE FROM N.A.		
RX	MEDLINE=91355850; PubMed=1983297;		
RA	Stroman P., Balma S., Casadoro G.;		
RT	"A cDNA sequence coding for glutamine synthetase in Hordeum vulgare		
RL	L.";		
RL	Plant. Mol. Biol. 15:161-163(1990).		
RP	[2]		
RP	SEQUENCE OF 9-434 FROM N.A.		
RC	STRAIN=cv. Maris Mink; TISSUE=Leaf;		
RX	MEDLINE=913446618; PubMed=1983286;		
RA	Freeman J., Marquez A.J., Wallisgrove R.M., Saarelainen R.,		
RA	Forde B.G.;		
RT	"Molecular analysis of barley mutants deficient in chloroplast		
RL	glutamine synthetase.";		
RL	Plant Mol. Biol. 14:297-311(1990).		
RP	[3]		
RP	SEQUENCE OF 48-434 FROM N.A.		
RX	MEDLINE=89322552; PubMed=2473765;		
RA	Balma S., Haegi A., Stroman P., Casadoro G.;		
RT	"Characterization of a cDNA clone for barley leaf glutamine		
RL	synthetase.";		
RL	Carlsberg Res. Commun. 54:1-9(1989).		
CC	-1- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A		
CC	NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR		
CC	THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION.		
CC	-1- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +		
CC	L-glutamine		
CC	-1- SUBUNIT: HOMOOCTAMER.		
CC	-1- SUBCELLULAR LOCATION: Chloroplast.		
CC	-1- MISCELLANEOUS: IN BARLEY, THERE ARE DISTINCT ISOZYMES IN THE		
CC	CHLOROPLAST, AND CYTOPLASM.		
CC	-1- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.		
CC	This SWISS-PROT entry is copyright. It is produced through a collabor		
CC	between the Swiss Institute of Bioinformatics and the EMBL outstat		
CC	the European Bioinformatics Institute. There are no restrictions on		
CC	use by non-profit institutions as long as its content is in no		
CC	modified and this statement is not removed. Usage by and for comm		
CC	entities requires a license agreement (See http://www.isb-sib.ch/anno		
CC	or send an email to license@isb-sib.ch).		
CC	EMBL; X53580; CAA37643.1; -		
CC	EMBL; X16000; CAA34131.1; -		
DR	PIR; S11865; AJBHQ		
DR	InterPro; IPR001691; GLN_synth.		
DR	Tram; PF00120; gln-synt; 1.		
DR	PROSITE; PS00180; GLNA_1; 1.		
DR	PROSITE; PS00181; GLNA_ATP; 1.		
KW	Ligase; Multigene family; Chloroplast; Transit peptide.		
FT	TRANSIT	1 54	
FT	CHAIN	55 434	GLUTAMINE SYNTHETASE LEAF ISOZYME.


```
DR InterPro: IPR001637; GlnA_adenyltn.
DR Pfam: PF00120; gln-synt; 1.
DR PROSITE: PS00180; GLNA_1; 1.
DR PROSITE: PS00181; GLNA_Atp; 1.
KW Nitrogen fixation; Ligase; Multigene family; Chloroplast;
KW Transist peptide.
FT TRANSIT 1 57 CHLOROPLAST.
SQ CHAIN 58 429 GLUTAMINE SYNTHETASE LEAF ISOZYME.
SQ SEQUENCE 429 AA; 47246 MW; 0CA55624B1118AF8 CRC64;

Query Match 6.3%; Score 95.5; DB 1; Length 429;
Best Local Similarity 24.1%; Pred. No. 1.2;
Matches 69; Conservative 26; Mismatches 116; Indels 75; Gaps 14;

QY 3 KPSLELPQWYNQYTFVNDAP-EDTGTLELLNALTKDPGFGTRCM-----EGN 52
DB 102 EHPG-ELPKWYDGSST---GQAPGEDSEVILYQAIKDFPRGNNLTLCVDATPAGE 157
QY 53 PIPDTPCAGPEEWT-----APVP-----QTMDLFQNGNWTMNPSPACQSSDKIKK 103
DB 158 PIPTNKRHRAAEVFSNRVIAEVPWFEGIEQYVTLQTNNVWPLGW----- 203
QY 104 LPVCPGAGGLPPQKQNTADILQDLTGRTSD--YLVKTVQIIIAKSLKNIWNEFR 161
DB 204 -----VGGYPGGQPYYSAGADRSFGDISDAHYKACLFAGINISGTNGEYMPGQWE 256
QY 162 YG-GFSLGVSNTQALPPSQEVDNAIKQMKKHLKLAKDSSADRLNSLGRFTGLDTRNNV 220
DB 257 YGVGPSVGI-----EAGDHIWASRYL-----ERITQAG-VVLSLDPKPIE 297
QY 221 KVFNNKGWHAISF-----LNVNNAILRANLKGKNSHYG 258
DB 298 GDW-NGACHTNYSTKSMREDGGFEVVKAILNLSLRKEHISAYG 342

RESULT 10
Y314_METJA
ID Y314_METJA STANDARD; PRT; 263 AA.
AC Q57762;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Hypothetical protein M30314.
GN M30314.
OS Methanococcus jannaschii.
OC Archaea; Euryarchaeota; Methanococci; Methanococcales;
OC Methanocaldococcaceae; Methanocaldococcus.
OX NCBI_TaxID=2190;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=JAL-1 / DSM 2661 / ATCC 43067;
RX MEDLINE=96337999; PubMed=8688087;
RA Bult C.J., White O., Olsen G.J., Zhou L., Fleischmann R.D.,
RA Sutton G.G., Blake J.A., Fitzgerald L.M., Clayton R.A., Gocayne J.D.,
RA Kerlavage A.R., Dougherty B.A., Tomb J.-F., Adams M.D., Reich C.I.,
RA Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Glodek A.,
RA Scott J.L., Geoghegan N.S.M., Weidman J.F., Fuhrmann J.L., Nguyen D.,
RA Uitterback T.R., Kelley J.M., Peterson J.D., Sadow P.W., Hanna M.C.,
RA Cotton M.D., Roberts K.M., Hurst M.A., Kaine B.P., Borodovsky M.,
RA Klenk H.-P., Fraser C.M., Smith H.O., Woese C.R., Venter J.C.;
RT "Complete genome sequence of the methanogenic archaeon, Methanococcus
jannaschii.";
RL Science 273:1058-1073(1996).
CC -I- SIMILARITY: SOME, TO M.JANNASCHII M30398.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
```

```
DR EMBL: U67486; AAB98310.1; -.
DR TIGR: MJ0314; -.
DR InterPro: IPR002197; HTH_Fis.
DR InterPro: IPR000792; HTH_LuxR.
DR InterPro: IPR004042; Intein_endonuc.
DR PROSITE: PS50819; INTEIN_ENDONUCLEASE; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 263 AA; 30804 MW; A7520A3BBE0CC5CD CRC64;

Query Match 6.2%; Score 94.5; DB 1; Length 263;
Best Local Similarity 24.6%; Pred. No. 0.73;
Matches 49; Conservative 32; Mismatches 61; Indels 57; Gaps 11;

QY 72 PQTMDLFQNGNWTMNPSPACQSSDKIKMLPVCPPGAGGLPPQKQNTADILQDLT 131
DB 43 PQTMDLFQNGNWTMNPSPACQSSDKIKMLPVCPPGAGGLPPQKQNTADILQDLT 131
QY 132 GRNISDYLVTYVQIIIAKSLKN--KIWNVEFRYGGFSLGVSNTQALPPSQEVN----- 182
DB 82 -RKSESLI-----IKNPKINLNPSESLAYILGLVNGDGSVNKQESNVIELKV 130
QY 183 ---DAIKQMKKHLKLAKDSSADRLNSLGRFTGLDTRNNKYVFNKNG---WHA---IS 233
DB 131 TDKDFIEEFARNL-----ENIGFKYINEYVKFENKKDQYVVRV---RSKGFYYWTKSLNVD 184
QY 234 SFLNVI--NNAILRANLKG 251
DB 185 YMVNVIGNNEKLMISMLKG 203

RESULT 11
GLN2_ARATH
ID GLN2_ARATH STANDARD; PRT; 430 AA.
AC Q43127;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--
DE ammonia ligase) (GS2).
GN GLN2 OR GS2L OR A75G35630 OR MJE4.9.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92079899; PubMed=1684022;
RA Peterman R.K., Goodman H.M.;
RT "The glutamine synthetase gene family of Arabidopsis thaliana: light-
RT regulation and differential expression in leaves, roots and seeds.";
RL Mol. Gen. Genet. 230:145-154(1991).
RN [2]
RP SEQUENCE FROM N.A.
RA Arimura G., Fujii M., Takahashi M., Goshima N., Morikawa H.;
RT "Nucleotide sequences of genes for cytosolic and chloroplastic
RT glutamine synthetase from Arabidopsis thaliana.";
RL Submitted (WAY-1998) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=98403884; PubMed=9734815;
RA Kotani H., Nakamura Y., Sato S., Asamizu E., Kaneko T., Miyajima N.,
RA Tabata S.;
RT "Structural analysis of Arabidopsis thaliana chromosome 5. VI.
RT Sequence features of the regions of 1,367,185 bp covered by 19
RT physically assigned pl and TAC clones.";
RL DNA Res. 5:203-216(1998).
CC -I- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION
CC (BY SIMILARITY).
CC -I- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) -> ADP + phosphate +
```

RA Hosler B.A., Schurr E., Arahata K., de Jong P.J., Brown R.H. Jr.;
 RT "dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi
 RT myopathy and limb girdle muscular dystrophy.";
 RL Nat. Genet. 20:31-36(1998).
 RN [2]
 RP
 RP SEQUENCE OF 303-2080 FROM N.A.
 RP TISSUE=Skeletal muscle, and Placenta;
 RC MEDLINE=98400253; PubMed=9731527;
 RX MEDLINE=98400253; PubMed=9731527;
 RA Bashir R., Britton S., Strachan T., Keers S., Vafiadaki E., Lako M.,
 RA Richard I., Marchand S., Bourq N., Argov Z., Sadeh M., Mahjneh I.,
 RA Marconi G., Passos-Bueno M.R., de Sa Moreira E., Zatz M.,
 RA Beckmann J.S., Bushby K.M.D.;
 RA "A gene related to Caenorhabditis elegans spermatogenesis factor fer-1
 RT is mutated in limb-girdle muscular dystrophy type 2B.";
 RT Nat. Genet. 20:37-42(1998).
 RL [3]
 RP
 RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
 RX MEDLINE=99214026; PubMed=10196375;
 RA Anderson L.V.B., Davison K., Moss J.A., Young C., Cullen M.J.,
 RA Walsh J., Johnson M.A., Bashir R., Britton S., Keers S., Argov Z.,
 RA Mahjneh I., Fougereousse F., Beckmann J.S., Bushby K.M.D.;
 RT "Dysferlin is a plasma membrane protein and is expressed early in
 RT human development.";
 RL Hum. Mol. Genet. 8:855-861(1999).
 RN [4]
 RP
 RP ERRATUM.
 RA Anderson L.V.B., Davison K., Moss J.A., Young C., Cullen M.J.,
 RA Walsh J., Johnson M.A., Bashir R., Britton S., Keers S., Argov Z.,
 RA Mahjneh I., Fougereousse F., Beckmann J.S., Bushby K.M.D.;
 RL Hum. Mol. Genet. 8:1141-1141(1999).
 RN [5]
 RP
 RP SUBCELLULAR LOCATION.
 RX MEDLINE=99424596; PubMed=10496277;
 RA Matsuda C., Aoki M., Hayashi Y.K., Ho M.F., Arahata K.,
 RA Brown R.H. Jr.;
 RT "Dysferlin is a surface membrane-associated protein that is absent in
 RT Miyoshi myopathy.";
 RL Neurology 53:1119-1122(1999).
 RN [6]
 RP
 RP SUBCELLULAR LOCATION, AND VARIANT MM AND LGMD2B ARG-791.
 RX MEDLINE=99214028; PubMed=10196377;
 RA Weiler T., Bashir R., Anderson L.V.B., Davison K., Moss J.A.,
 RA Britton S., Nylen E., Keers S., Vafiadaki E., Greenberg C.R.,
 RA Bushby K.M.D., Wrogemann K.;
 RA "Identical mutation in patients with limb girdle muscular dystrophy
 RT type 2B or Miyoshi myopathy suggests a role for modifier gene(s).";
 RT Hum. Mol. Genet. 8:871-877(1999).
 RL -!- SUBCELLULAR LOCATION: Type II
 CC Localizes to the sarcolemma.
 CC -!- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN SKELETAL MUSCLE, ALSO
 CC FOUND IN HEART, PLACENTA AND AT LOWER LEVELS IN LIVER, LUNG,
 CC KIDNEY AND PANCREAS.
 CC -!- DEVELOPMENTAL STAGE: Expression in limb tissue from 5-6 weeks
 CC embryos; persists throughout development.
 CC -!- DISEASE: DEFECTS IN DYSF ARE THE CAUSE OF AUTOSOMAL RECESSIVE LIMB
 CC GIRDLE MUSCULAR DYSTROPHY TYPE 2B (LGMD2B). TYPE 2 LIMB GIRDLE
 CC MUSCULAR DYSTROPHIES REPRESENT A GENETICALLY HETEROGENEOUS GROUP
 CC OF DISEASES WITH VARYING DEGREES OF SEVERITY DEPENDING ON AGE AT
 CC ONSET AND RATE OF PROGRESSION. LGMD2B IS CHARACTERIZED BY WEAKNESS
 CC AND ATROPHY STARTING IN THE PROXIMAL PELVIC/FEMORAL MUSCLES, WITH
 CC ONSET IN THE LATE TEENS OR LATER, MASSIVE ELEVATION OF SERUM
 CC CREATINE KINASE LEVELS AND SLOW PROGRESSION. SCAPULAR MUSCLE
 CC INVOLVEMENT IS MINOR AND NOT PRESENT AT ONSET. UPPER LIMB GIRDLE
 CC INVOLVEMENT FOLLOWS SOME YEARS AFTER THE ONSET IN LOWER LIMBS.
 CC -!- DISEASE: DEFECTS IN DYSF ARE THE CAUSE OF MIYOSHI MYOPATHY (MM).
 CC THIS TYPE OF AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY INVOLVES THE
 CC DISTAL LOWER LIMB MUSCULATURE. IT IS CHARACTERIZED BY WEAKNESS
 CC THAT INITIALLY AFFECTS THE GASTROCNEMIUS MUSCLE DURING EARLY
 CC ADULTHOOD. OTHERWISE THE PHENOTYPE OVERLAPS WITH LGMD2B,
 CC ESPECIALLY IN AGE AT ONSET AND CREATINE KINASE ELEVATION.
 CC -!- SIMILARITY: BELONGS TO THE FERLIN FAMILY.
 CC -!- DATABASE: NAME=Leiden Database Dystrophy pages; NOTE=Dysferlin;
 CC -!- SIMILARITY: CONTAINS 5 C2 DOMAINS.


```
WWW="http://www.dmd.nl/dysf_home.html".
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
CC EMBL; AF075575; AAC63519.1; -
CC EMBL; AJ007670; CAA07603.1; ALT_SEQ.
CC EMBL; AJ007973; CAA07800.1; -
CC HSSP; P21707; 1RSY.
CC Genew; HGNC:3097; DYSF.
CC MIM; 603009; -
CC MIM; 253601; -
CC MIM; 254130; -
CC MIM; 606768; -
CC InterPro; IPR000008; C2.
CC Pfam; PF00168; C2; 7.
CC SMART; SM00239; C2; 7.
CC PROSITE; PS00499; C2_DOMAIN_1; FALSE_NEG.
CC PROSITE; PS00004; C2_DOMAIN_2; 5.
CC Transmembrane; Repeat; Disease mutation.
KW DOMAIN 1 2046 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 2047 2067 POTENTIAL.
FT DOMAIN 2068 2080 EXTRACELLULAR (POTENTIAL).
FT DOMAIN 1 85 C2 DOMAIN 1.
FT DOMAIN 207 302 C2 DOMAIN 2.
FT DOMAIN 366 479 C2 DOMAIN 3.
FT DOMAIN 1139 1244 C2 DOMAIN 4.
FT DOMAIN 1565 1663 C2 DOMAIN 5.
FT DOMAIN 1038 1097 ARG-RICH.
FT VARIANT 791 791 P -> R (IN MM AND LGMD2B).
FT VARIANT 1298 1298 /FTID=VAR_012308.
FT VARIANT 1857 1857 I -> V (IN MM AND LGMD2B).
FT VARIANT 2042 2042 H -> R (IN MM).
FT VARIANT 2042 2042 /FTID=VAR_012310.
FT VARIANT 2042 2042 R -> C (IN MM AND LGMD2B).
FT VARIANT 2042 2042 /FTID=VAR_012311.
FT SEQUENCE 2080 AA; 237293 MW; 376E25A5A9B9B398 CRC64;
Query Match 6.2%; Score 94.5; DB 1; Length 2080;
Best Local Similarity 18.0%; Pred. No. 12;
Matches 65; Conservative 45; Mismatches 95; Indels 157; Gaps 15;
QY 1 FGKPSL-----ELQPMWYNEQYTFVSDNAPEDTGTLELLNALTKDPCFGTRCMGN 52
DB 1627 FGKMFELCTLPLEKDKITLYD--YDLISKDEKIGETVVDLENRLLSK--FGARC--- 1678
QY 53 PIPDPQOAGEW-----TTAPVPQTIMDLFQNGNWTMGN----- 88
DB 1679 GLPQYCYSGPNQWRDLRPSOLLHFCQQRHVKAPVYTRDVMFQDKKEYSIEETEAGRI 1738
QY 89 PSPAC-----QCSDKIKMLKPLVCPGAGGLP 115
DB 1739 PNPGLGPVEERLALHVOOGLVPEHVESRPLYSPLQPDIEQGLQMWVDLPFKALRGP 1798
QY 116 P-----PQRKQ-----NTADILQD--LTGRNISDYLKTVV----- 144
DB 1799 PPFNITPRARRRFFLCRIITWNRVLDLSDLTGKMSDIYVKGWGMIFEEHKQKTDVHY 1858
QY 145 -----QIIAKSLKNKIWNVEFRYGGFSLGVSNTQALPPSQEV 181
DB 1859 RSLGGEGNFRFIPFDYLPRAEQVCTIAKDAFW-----RLDKTESKIPARVY 1907
QY 182 -----NDA-----IKQMKHLKLKADSSADRFNLNL-GRFMTGLDTRNNKYV 222
DB 1908 FQIWDNKFSDFDLGLSLQDLNRMPPKPAKTAKGSLDQLDDAFHPFWSLFEQTKYKG 1967
QY 223 WF 224
```

```
Db 1968 WW 1969
RESULT 13
LRP2_RAT STANDARD; PRT; 4660 AA.
AC P98158;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Low-density lipoprotein receptor-related protein 2 precursor (Megalin)
DE (Glycoprotein 330).
GN LRP2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX MEDLINE=95024033; PubMed=7937880;
RA Saito A., Pietromonaco S., Loo A.K.C., Farquhar M.G.;
RT "Complete cloning and sequencing of rat gp330/megalin, a
RT distinctive member of the low density lipoprotein receptor gene
RT family";
RL Proc. Natl. Acad. Sci. U.S.A. 91:9725-9729(1994).
RN [2]
RP FUNCTION.
RX MEDLINE=95386696; PubMed=7544804;
RA Moestrup S.K., Cui S., Vorum H., Bregengaard C., Bjorn S.E.,
RA Norris K., Gliemann J., Christensen E.I.;
RT "Evidence that epithelial glycoprotein 330/megalin mediates uptake of
RT polybasic drugs.";
RL J. Clin. Invest. 96:1404-1413(1995).
RN [3]
RP TISSUE SPECIFICITY.
RX MEDLINE=94172242; PubMed=7510321;
RA Zheng G., Bachinsky D.R., Stamenkovic I., Strickland D.K., Brown D.,
RA Andres G., McCluskey R.T.;
RT "Organ distribution in rats of two members of the low-density
RT lipoprotein receptor gene family, gp330 and LRP/alpa 2MR, and the
RT receptor-associated protein (RAP).";
RL J. Histochem. Cytochem. 42:531-542(1994).
CC !- FUNCTION: BINDS PLASMINOGEN, EXTRACELLULAR MATRIX COMPONENTS,
CC PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE I
CC COMPLEX, APOLOPROTEIN E-ENRICHED BETA-VLDL, LIPOPROTEIN LIPASE,
CC LACTOFERRIN, CLUSTERIN AND CALCIUM.
CC !- FUNCTION: RECEPTOR-MEDIATED UPTAKE OF POLYBASIC DRUGS SUCH AS
CC APROTININ, AMINOGLYCOSIDES AND POLYMYXIN B.
CC !- SUBUNIT: FORMS A MULTIMERIC COMPLEX TOGETHER WITH A RECEPTOR-
CC ASSOCIATED PROTEIN (RAP).
CC !- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN. EXPRESSED IN
CC CLATHRIN-COATED PITS; A SOLUBLE FORM IS POSSIBLY DERIVED BY
CC CLEAVAGE AT THE CELL SURFACE.
CC !- TISSUE SPECIFICITY: EPITHELIAL CELLS OF KIDNEY GLOMERULUS AND
CC PROXIMAL TUBULE, LUNG, EPIDIDYMIS, YOLK SAC, AMONG OTHERS.
CC !- SIMILARITY: CONTAINS 36 LDL-RECEPTOR CLASS A DOMAINS.
CC !- SIMILARITY: CONTAINS 37 LDL-RECEPTOR CLASS B DOMAINS.
CC !- SIMILARITY: CONTAINS 17 EGF-LIKE DOMAINS.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
CC EMBL; L34049; AAA51369.1; -
CC HSSP; Q07954; 1CR8.
CC GlycoSuiteDB; P98158; -
CC InterPro; IPR000152; Asx_hydroxy1.
```


FT	DOMAIN	2432	2477	LDL-RECEPTOR CLASS B 25.
FT	DOMAIN	2479	2518	LDL-RECEPTOR CLASS B 26.
FT	DOMAIN	2520	2562	LDL-RECEPTOR CLASS B 27.
FT	DOMAIN	2564	2604	LDL-RECEPTOR CLASS B 28.
FT	DOMAIN	2605	2647	LDL-RECEPTOR CLASS B 29.
FT	DOMAIN	2652	2694	EGF-LIKE 10.
FT	DOMAIN	2699	2739	LDL-RECEPTOR CLASS A 16.
FT	DOMAIN	2740	2778	LDL-RECEPTOR CLASS A 17.
FT	DOMAIN	2779	2820	LDL-RECEPTOR CLASS A 18.
FT	DOMAIN	2821	2862	LDL-RECEPTOR CLASS A 19.
FT	DOMAIN	2863	2903	LDL-RECEPTOR CLASS A 20.
FT	DOMAIN	2906	2947	LDL-RECEPTOR CLASS A 21.
FT	DOMAIN	2948	2992	LDL-RECEPTOR CLASS A 22.
FT	DOMAIN	2993	3031	LDL-RECEPTOR CLASS A 23.
FT	DOMAIN	3032	3072	LDL-RECEPTOR CLASS A 24.
FT	DOMAIN	3075	3112	LDL-RECEPTOR CLASS A 25.
FT	DOMAIN	3113	3153	EGF-LIKE 11.
FT	DOMAIN	3154	3194	EGF-LIKE 12.
FT	DOMAIN	3194	3232	LDL-RECEPTOR CLASS B 30.
FT	DOMAIN	3241	3282	LDL-RECEPTOR CLASS B 31.
FT	DOMAIN	3284	3333	LDL-RECEPTOR CLASS B 32.
FT	DOMAIN	3335	3377	LDL-RECEPTOR CLASS B 33.
FT	DOMAIN	3379	3420	LDL-RECEPTOR CLASS B 34.
FT	DOMAIN	3421	3461	EGF-LIKE 13.
FT	DOMAIN	3467	3511	LDL-RECEPTOR CLASS A 26.
FT	DOMAIN	3512	3552	LDL-RECEPTOR CLASS A 27.
FT	DOMAIN	3553	3593	LDL-RECEPTOR CLASS A 28.
FT	DOMAIN	3594	3634	LDL-RECEPTOR CLASS A 29.
FT	DOMAIN	3635	3675	LDL-RECEPTOR CLASS A 30.
FT	DOMAIN	3678	3718	LDL-RECEPTOR CLASS A 31.
FT	DOMAIN	3719	3758	LDL-RECEPTOR CLASS A 32.
FT	DOMAIN	3759	3797	LDL-RECEPTOR CLASS A 33.
FT	DOMAIN	3798	3836	LDL-RECEPTOR CLASS A 34.
FT	DOMAIN	3842	3882	LDL-RECEPTOR CLASS A 35.
FT	DOMAIN	3883	3924	LDL-RECEPTOR CLASS A 36.
FT	DOMAIN	3928	3968	EGF-LIKE 14.
FT	DOMAIN	3968	4008	EGF-LIKE 15.
FT	DOMAIN	4009	4050	LDL-RECEPTOR CLASS B 35.
FT	DOMAIN	4156	4197	LDL-RECEPTOR CLASS B 36.
FT	DOMAIN	4199	4241	LDL-RECEPTOR CLASS B 37.
FT	DOMAIN	4244	4284	EGF-LIKE 16.
FT	DOMAIN	4332	4370	EGF-LIKE 17.
FT	DOMAIN	4379	4413	SH3-BINDING (POTENTIAL).
FT	SITE	4454	4460	SH3-BINDING (POTENTIAL).
FT	SITE	4457	4463	SH2-BINDING (POTENTIAL).
FT	SITE	4606	4609	SH3-BINDING (POTENTIAL).
FT	SITE	4619	4625	SH3-BINDING (POTENTIAL).
FT	SITE	4624	4630	CELL ATTACHMENT SITE (POTENTIAL).
FT	SITE	1743	1745	ENDOCYTOSIS SIGNAL (POTENTIAL).
FT	SITE	4522	4527	ENDOCYTOSIS SIGNAL (POTENTIAL).
FT	SITE	4601	4606	BY SIMILARITY.
FT	DISULFID	28	40	BY SIMILARITY.
FT	DISULFID	35	53	BY SIMILARITY.
FT	DISULFID	47	62	BY SIMILARITY.
FT	DISULFID	67	80	BY SIMILARITY.
FT	DISULFID	74	93	BY SIMILARITY.
FT	DISULFID	87	103	BY SIMILARITY.
FT	DISULFID	108	120	BY SIMILARITY.
FT	DISULFID	115	133	BY SIMILARITY.
FT	DISULFID	127	142	BY SIMILARITY.
FT	DISULFID	147	157	BY SIMILARITY.

Query Match 6.2%; Score 94.5; DB 1; Length 4660;
Best Local similarity 23.6%; Pred. No. 35;
Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps

Qy	1	FGKYPSS--LELOPHW-----YNQYTFVSNDAPEDTGTELLNALTKDPGFCTR	47
Db	4302	FGKENKEKVLVNPMLTQVRIHQIRYNOS---VSNPKQVCVSHCLL-----RPGYSCA	4354
Qy	48	CMEGNPIT---PDTPCQAGEEHWTTAPVOTIMDLFQNGN-WTMQNPSPACOCSSDKIKKM	103
Db	4355	CPOGSDFTVGTGQDAASELPVTPPPFCROM---HGGNCYFDENELPKCKCSGYSCE-	4410

QY 104 LPVCPGP-AGGLPPQKQNTADILQDLTGRNISDYLVKTYVOIIAKSLKNIWNEFRY 162
 Db 4411 --YCEVGLSRGIPP-----GTTWA-VLLTFVIVIGAL---VLVGLFHY 4449
 QY 163 GGFSLGVNTQALPPSQEVNDAIKQMKHLKLAKDSSADFLNSLG-REWTGLDTRNNVK 221
 Db 4450 -----RKTGSLLP-----LPKLPSJSLAKPSE-----NGNGVTRFSGADV--NMD 4489
 QY 222 VWFNNKGWHAISFLNINNAIRANLQKGNPSHYGITAFNHLNLTQKQSEVAL 278
 Db 4490 IGVSPFGPETIIDRSMANNEHFV---MEVGKQP-----VIFENPMYAARDNTSKVAL 4538
 RESULT 14
 GLN2_ORYSA
 ID GLN2_ORYSA STANDARD; PRT; 428 AA.
 AC P14655;
 DT 01-APR-1990 (Rel. 14, Created)
 DT 01-APR-1990 (Rel. 14, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Glutamine synthetase shoot isozyme, chloroplast precursor (EC 6.3.1.2)
 DE Glutamate--ammonia ligase (Clone lambda-GS31).
 OS Oryza sativa (Rice).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 OC Ehrhartoideae; Oryzeae; Oryza.
 OX NCBI_TaxID=4530;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Kinmaze; TISSUE=Shoot;
 RA MEDLINE=91370845; PubMed=2577497;
 RA Sakamoto A., Ogawa M., Masumura T., Shibata D., Takeba G.,
 Tanaka K., Fujii S.;
 RT "Three cDNA sequences coding for glutamine synthetase polypeptides in
 Oryza sativa L.";
 RL Plant Mol. Biol. 13:611-614(1989).
 CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
 CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
 CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION.
 CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
 CC L-glutamine.
 CC -!- SUBUNIT: HOMOOCTAMER.
 CC -!- SUBCELLULAR LOCATION: Chloroplast.
 CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; X12426; CAA32462.1; -;
 CC PIR; S07471; AJRZOD.
 CC InterPro; IPR001691; GLN_synth.
 CC Pfam; PF00120; gln-synt; 1.
 CC PROSITE; PS00180; GLNA.1; 1.
 CC PROSITE; PS00181; GLNA_ATP; 1.
 KW Ligase; Multigene family; Chloroplast; Transit peptide.
 FT TRANSIT 1 56 CHLOROPLAST (POTENTIAL).
 FT CHAIN 57 428 GLUTAMINE SYNTHETASE SHOOT ISOZYME.
 SQ SEQUENCE 428 AA; 46642 MW; DFF1B39BFC5921FE CRC64;
 Query Match 6.1%; Score 92.5; DB 1; Length 428;
 Best Local Similarity 23.6%; Pred. No. 2, 1;
 Matches 67; Conservative 30; Mismatches 112; Indels 75; Gaps 14;
 QY 5 PSLEQPMWYNEQYTFVSNADP-EDTGTLELLNALTKDPFG-----TRCMEGNPI 54
 Db 103 PS-ELPKWYDGSST---GQAPGDESEVILYPOAIFKDPFRGNNILVMCDTYTPAGEPI 158
 QY 55 P-----DTPCQAGEEETTPAVP-----QTIMDLFQNGNWTMONPSPACOCSSDKIKKMLP 105

Db 159 PTNKRNRQAQVSPKVSQVFWFCIEQEYTLQLDQVNWPLGW- 202
 QY 106 VCPPGAGGLPPQKQNTADILQDLTGRNISDYLVKTYVOIIAKSLKNIWNEFRYGGF 165
 Db 203 -----VCGYPGPQGPYCAVGSFGRDISDAHYKACL-----YAGI 240
 QY 166 SLGVSNTQALPPSQE--VNDALK-QMKHLKLAKDSSADFLNSLGRFMTGLDTRNNVKV 222
 Db 241 NISGTNGVMPQGWYQVGPVGIAGDHIIWSR-YILERITEQAGVVLT-LDPKPIQGD 298
 QY 223 WFNNGKWHAISSF-----LNVINNAIRANLQKGNPSHYG 258
 Db 299 W-NGAGCHTNTSKSMREDGGFEVKKAILNLSLRHDLHISAYG 341
 RESULT 15
 GLNC_BRANA
 ID GLNC_BRANA STANDARD; PRT; 428 AA.
 AC Q42624; Q9M429;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DE Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--
 DE ammonia ligase) (GS2).
 GN GLN2 OR GLN.
 OS Brassica napus (Rape).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
 OC eurosids II; Brassicales; Brassicaceae; Brassica.
 OX NCBI_TaxID=3708;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Leaf;
 RX MEDLINE=94269200; PubMed=7911583;
 RA Ochs G., Schock G., Wild A.;
 RT "Chloroplastic glutamine synthetase from Brassica napus.";
 RL Plant Physiol. 103:303-304(1993).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Drakkar; TISSUE=Leaf;
 RA Wojtyna S., Ochs G., Wild A.;
 RT "Cloning and Sequencing of genomic fragments coding for glutamine
 RT synthetase of Brassica napus.";
 RL Submitted (FEB-2000) to the EMBL/Genbank/DBJ databases.
 CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
 CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
 CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION
 CC (BY SIMILARITY).
 CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
 CC L-glutamine.
 CC -!- SUBUNIT: HOMOOCTAMER (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Chloroplast.
 CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; X72751; CAA51280.1; -;
 CC EMBL; AJ271909; CAB72423.1; -;
 CC InterPro; IPR001691; GLN_synth.
 CC Pfam; PF00120; gln-synt; 1.
 CC PROSITE; PS00180; GLNA.1; 1.
 CC PROSITE; PS00181; GLNA_ATP; 1.
 KW Ligase; Multigene family; Chloroplast; Transit peptide.
 FT TRANSIT 1 49 CHLOROPLAST (POTENTIAL).
 FT CHAIN 50 428 GLUTAMINE SYNTHETASE.
 FT CONFLICT 50 50 L -> I (IN REF. 2).


```
Db 1371 FGKYPSELEQPMWYDEQYTFISNDAPEDAGTOKLIDALLNKPFGTGRMCQGHISIPDTPTCT 1430
QY 61 AGESEWTTAPVPTIMDLFQNGWNTWNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1431 VQKEWTTASVPSVLEILR-GNWSMENSPSCSECSNEKIKKMLPVCPPGAGGLPPQPK 1489
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1490 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 1549
QY 181 VNDATKQMKHKLAKDSSADRELSNGRPMGLDPRNNKVMFNKNGHAISSFLVNLIN 240
Db 1550 VYDAIKQVKYLELAQSSGDRLENNLASFMKGLDPRNNKVMFNKNGHAISSFLVNLIN 1609
QY 241 NAILRANLQKGNPSHYGITAFNHPNLNLTQKQSEVALMTTSD 284
Db 1610 NAILRANLQKGNPSHYGITAFNHPNLNLTQKQSEVALMTTSD 1653

RESULT 2
002698 PRELIMINARY; PRT: 2281 AA.
AC 002698:
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ABC transporter.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN 1
RP SEQUENCE FROM N.A.
RC TISSUE=RETINAL ROD CELL;
RX MEDLINE=97248596; PubMed=9092582;
RA Illing M., Molday L.L., Molday R.S.;
RT "The 220-kDa rim protein of retinal rod outer segments is a member of
RT the ABC transporter superfamily."
RL J. Biol. Chem. 272:10303-10310(1997).
DR EMBL; U09126; AAC48716.1; -.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transporter.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 1.
DR TIGRFAMs; TIGR01257; rim_protein; 1.
KW ATP-binding.
SQ SEQUENCE 2281 AA; 257228 MW; 71CD404C98F7A079 CRC64;

Query Match 48.0%; Score 731.5; DB 6; Length 2281;
Best Local Similarity 47.2%; Pred. No. 1.4e-53;
Matches 143; Conservative 38; Mismatches 83; Indels 39; Gaps 4;

QY 1 FGKYPSELEQPMWYDEQYTFISNDAPEDGTLELLNALTQDPGFGTGRMGNPIPDTPCQ 60
Db 1395 FGCEYFALTLPFWMYGQYTFESMDQDSEWLSALADVLNKPFGNRCLEKWLPEYPC- 1453
QY 61 AGESEWTTAPVPTIMDLFQNGWNTWNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1454 GNSSPWKTSPVSPDVTLLQOQKQADQPSRCSTREKLTMLPECEGAGGLPPQRI 1513
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1514 QRSTELQDLTDRNVDFLVKTYPALIRSLSKSKFWNNEQRYGGSVG---GKLPAPPF 1569
QY 181 VNDATKQMKHKLAKDSSADRELSNGR-----FMTGLDTRNNVK 221
Db 1570 TGEALV-----GFLSDUGLQVMNVSGGPMTRAAKEMPAFLKQLETFEDNIK 1614
QY 222 VFNKNGHAISSFLVNLINAILRANLQKGNPSHYGITAFNHPNLNLTQKQSEVALMTT 281
Db 1615 VFNKNGHAISSFLVNLINAHAILRASLRKDKNPEYGITVISQPLNLTKEQLSEITVLT 1674
```

```
QY 282 SVD 284
Db 1675 SVD 1677

RESULT 3
035600 PRELIMINARY; PRT: 2310 AA.
AC 035600:
DT 01-JAN-1998 (TrEMBLrel. 05, Created)
DT 01-JAN-1998 (TrEMBLrel. 05, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ATP-binding cassette transporter.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN 1
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=97345663; PubMed=9202155;
RA Azarian S.M., Travis G.H.;
RT "The photoreceptor rim protein is an ABC transporter encoded by the
RT gene for recessive Stargardt's disease (ABCR).";
RL FEBS Lett. 409:247-252(1997).
RN 2
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Azarian S.M., Travis G.H.;
RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF000149; AAC23916.1; -.
DR MGD; MGI:109424; Abca4.
DR InterPro; IPR003439; ABC_transportr.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 1.
DR TIGRFAMs; TIGR01257; rim_protein; 1.
DR PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2310 AA; 260207 MW; 8370C6C8A62EF294 CRC64;

Query Match 47.5%; Score 724.5; DB 11; Length 2310;
Best Local Similarity 47.2%; Pred. No. 5.8e-53;
Matches 143; Conservative 39; Mismatches 82; Indels 39; Gaps 4;

QY 1 FGKYPSELEQPMWYDEQYTFISNDAPEDGTLELLNALTQDPGFGTGRMGNPIPDTPCQ 60
Db 1396 FGCEYFALTLPFWMYGQYTFESMDQDSEWLSALADVLNKPFGNRCLEKWLPEYPC- 1454
QY 61 AGESEWTTAPVPTIMDLFQNGWNTWNPSPACQSSDKIKKMLPVCPPGAGGLPPQPK 120
Db 1455 INATSWKTSPVSPNITLHFOKQKTAHPSPCGCKSTREKLTMLPECEGAGGLPPQRT 1514
QY 121 QNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQE 180
Db 1515 QRSTEVQDLTNRNISDYLVKTYPALIRSLSKSKFWNNEQRYGGSIG-GKLPALPISGE 1573
QY 181 VNDATKQMKHKLAKDSSADRELSNGR-----FMTGLDTRNNVK 221
Db 1574 -----ALVGLSLGOMNVSGPVITREASKEMDLEFLKHLETONIK 1615
QY 222 VFNKNGHAISSFLVNLINAILRANLQKGNPSHYGITAFNHPNLNLTQKQSEVALMTT 281
Db 1616 VFNKNGHAISSFLVNLINAHAILRASLRDRDPEYGITVISQPLNLTKEQLSDITVLT 1675

QY 282 SVD 284
Db 1676 SVD 1678
```

```

RESULT 4
Q91V24
ID Q91V24 PRELIMINARY; PRT: 2159 AA.
AC Q91V24;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ATP-binding cassette transporter sub-family A member 7.
GN ABCA7.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=O1129, AND DBA/2;
RX MEDLINE=21328888; PubMed=11435699;
RA Broccardo C., Osorio J., Luciani M.-F., Schriml L.M., Prades C.,
RA Shulenin S., Arnould I., Naudin L., Lafargue C., Rosier M., Jordan B.,
RA Mattei M.G., Dean M., Deneffe P., Chimini G.;
RT "Comparative analysis of the promoter structure and genomic
organization of the human and mouse ABCA7 gene encoding a novel ABCA
transporter."
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=O1129, AND DBA/2;
RX MEDLINE=21328888; PubMed=11435699;
RA Broccardo C., Osorio J., Luciani M.-F., Schriml L.M., Prades C.,
RA Shulenin S., Arnould I., Naudin L., Lafargue C., Rosier M., Jordan B.,
RA Mattei M.G., Dean M., Deneffe P., Chimini G.;
RT "Comparative analysis of the promoter structure and genomic
organization of the human and mouse ABCA7 gene encoding a novel ABCA
transporter."
RL CytoGenet. Cell Genet. 92:264-270(2001).
DR EMBL: AF287142; AAK56863.1; -.
DR EMBL: AF287141; AAK56862.1; -.
DR MGI: 1351646; Abca7.
DR InterPro: IPR003439; ABC_transportr.
DR InterPro: IPR002016; Peroxidase.
DR Pfam: PF00005; ABC_tran; 2.
DR ProDom: PD000006; ABC_transportr; 2.
DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE: PS00435; PEROXIDASE_1; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2159 AA; 236882 MW; CD2BE3FE0D8B822B CRC64;

Query Match 43.5%; Score 664; DB 11; Length 2159;
Best Local Similarity 45.3%; Pred. No. 8.3e-48;
Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

QY 1 FGKPSLELOPMWYNEQYTFVSDAPEDGTGLLELNALTKDPGFGTRCMEGNPIDTPCQ 60
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1266 FGQYPPQLSPAMYGPQVSPFSEDAPGDPNRMKLEALLGEAGLQEPSKDKARGSECT 1325

QY 61 AGESEWTAP-VPQTIMDLFQNGNWTMONPSPACQSSDKIKKMLPVCPPGAGLPPQR 119
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1326 HSLACFTVPVPPDVASILASGNWTPESPSPACQSQPGARRLLPDCPAGAGPPPPQA 1385

QY 120 KONTADILQDTGRNISDYLVKTYVQIIAKSLKNIWNEFRYGSFSLGVSNTQALPPSQ 179
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1386 VAGLGEVVQNLTGKRVNSDFLVKTYPSLVRRGLTKKKWDEVRYGGFSLG-GRDPDLPTGH 1444

QY 180 EVNDAIKOMKKHLKLAQSSADRFNSLGRFMTGLDTRNNKVNKNGWHAISFLNVI 239
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1445 EVVTRAEIRALSPQPGKDRILNNUQWALGIDARNLSUKINFNKNGWHAIVAFVNR 1504

QY 240 NNAILRANLQGENPSHYGTAFNHPNLTKQQLSEVALMTTSVD 284
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1505 NNGLIHALLPSGVRHARHSITTLNHPNLTKQQLSEVALMTTSVD 1549

RESULT 5
Q9BZC4
ID Q9BZC4 PRELIMINARY; PRT: 2146 AA.
AC Q9BZC4;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ABC transporter member 7.
GN ABCA7.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21328888; PubMed=11435699;
RA Broccardo C., Osorio J., Luciani M.-F., Schriml L.M., Prades C.,
RA Shulenin S., Arnould I., Naudin L., Lafargue C., Rosier M., Jordan B.,
RA Mattei M.G., Dean M., Deneffe P., Chimini G.;
RT "Comparative analysis of the promoter structure and genomic
organization of the human and mouse ABCA7 gene encoding a novel ABCA
transporter."
RL CytoGenet. Cell Genet. 92:264-270(2001).
DR EMBL: AF287142; AAK00959.1; -.
DR InterPro: IPR003593; AAA_ATPase.
DR InterPro: IPR003439; ABC_transportr.
DR InterPro: IPR001899; Gram_pos_anchor.
DR Pfam: PF00005; ABC_tran; 2.
DR ProDom: PD000006; ABC_transportr; 2.
DR SMART: SM00382; AAA; 2.
DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE: PS00343; GRAM_POS_ANCHORING; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2146 AA; 234306 MW; 2391728D5AD97E75 CRC64;

Query Match 43.4%; Score 662.5; DB 4; Length 2146;
Best Local Similarity 44.7%; Pred. No. 1.1e-47;
Matches 127; Conservative 50; Mismatches 96; Indels 11; Gaps 2;

QY 1 FGKPSLELOPMWYNEQYTFVSDAPEDGTGLLELNALTKDPGFGTRCMEGNPIDTPCQ 60
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1263 FGHPALRLSPTMYGAQVSPFSEDAPGDPGRARLEALLQLEAG-----LEEPVQ 1312

QY 61 AGESEWTAPVPQTIMDLFQNGNWTMONPSPACQSSDKIKKMLPVCPPGAGLPPQR 120
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1313 HSHRFSAPVPAEVAKVLASGNWTPESPSPACQSRPGARRLLPDCPAAAGGPPPOAV 1372

QY 121 QNTADILQDTGRNISDYLVKTYVQIIAKSLKNIWNEFRYGSFSLGVSNTQALPPSQ 180
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1373 TGSSEVQNLUTGRNLSDFLVKTYPRVLROGLTKRWNEVRVGGFSLG-GRDPGLPSGQ 1431

QY 181 VYNDAIKOMKKHLKLAQSSADRFNSLGRFMTGLDTRNNKVNKNGWHAISFLNVI 240
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1432 LGRSVEELWALLSPLPGGALDRVLKLNLTAWAHSLSAQDSLKIWFNKNKNGWHAIVAFNRAS 1491

QY 241 NNAILRANLQGENPSHYGTAFNHPNLTKQQLSEVALMTTSVD 284
. ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1492 NAILRAHLPPGPARHARHSITTLNHPNLTKQQLSEVALMTTSVD 1535

RESULT 6
Q96S58
ID Q96S58 PRELIMINARY; PRT: 2008 AA.
AC Q96S58;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ABCA-SSN.
GN ABCA7/ABCA-SSN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=2125283; PubMed=11355874;
RA Tanaka A., Ikeda Y., Abe-Dohmae S., Arakawa R., Sadanami K.,
RA Kidera A., Nakagawa S., Nagase T., Aoki R., Kioka N., Amachi T.,
RA Yokoyama S., Ueda K.;
RT "Human ABCA1 Contains a Large Amino-Terminal Extracellular Domain
Homologous to an Epitope of Sjogren's Syndrome."
RL Biochem. Biophys. Res. Commun. 283:1019-1025(2001).
DR EMBL: AB055390; BAB62294.1; -.
DR InterPro: IPR003439; ABC_transportr.
DR InterPro: IPR001899; Gram_pos_anchor.

```

Db	1313	HSHRFSAPEVPAEYAKVLASGNWTPESPACQCSOPGARRLLPCPAAAGPPPPQAV	1372
Qy	121	QNTADILQDLTGRNLSYLKVTYYVOIIIAKS LKNKIWNFRYGGFSLGVSNQAALPPSOE	180
Db	1373	TGSGEVVQMQLTGRNLSDFLVITYPRLVROGLKTKKWYNEVRYGGSFLG-GRPDGLPSGOE	1431
Qy	181	VNDATIKOMKHHLAKDSSARDLNSLGRRFMFTGLDTRNNKVVFNNKGHWAHSSEFLNVIN	240
Db	1432	LGRSVEELWALLSPPLPGCALDRVLKLNLTAWAHSLDQADS LKIFENKNGHWSVAFFNRAS	1491
Qy	241	NATLRANLOQGENSHYGIITAFNHPLNLTKOQJSEVALWTTSVD	284
Db	1492	NATLRAHLPPGARHAHSITTTLNHPLNLTKEOLEFAALMASSVD	1535
 RESULT 8 Q9UPU0 PRELIMINARY; PRT; 1529 AA.			
ID	Q9UPU0	PRELIMINARY;	PRT; 1529 AA.
DT	Q9UPU0; Q9NSL2;		
DT	01-MAY-2000 (TREMBLrel. 13; Created)		
DT	01-MAY-2000 (TREMBLrel. 13; Last sequence update)		
DT	01-JUN-2002 (TREMBLrel. 21; Last annotation update)		
DE	KIAA1062 protein (Fragment).		
GN	KIAA1062 OR DKFPZ547p193.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
NCBI_TaxID=9606;			
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	TISSUE=BRAIN;		
RC	MEDLINE=99397452; PubMed=10470851;		
RA	Kikuno T., Nagase T., Ishikawa K., Hirosewa M., Miyajima N.,		
RA	Tanaka A., Kotani H., Nomura N., Ohara O.		
RT	*Prediction of the coding sequences of unidentified human genes. XIV.		
RT	The complete sequences of 100 new cDNA clones from brain which code		
RL	for large proteins in vitro.;		
RL	Data Res. 6:197-205(1999).		
RN	[2]		
RP	SEQUENCE OF 1157-1529 FROM N.A.		
RC	TISSUE=BRAIN;		
RC	Bloecker H., Boecher M., Brandt P., Mewes H.W., Weil B., Wiemann S.;		
RL	Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.		
DR	EMBL; AB028985; BAB83014.1; .		
DR	EMBL; ALI62060; CAB82398.1; .		
DR	InterPro; IPR003439; ABC_transportr.		
DR	InterPro; IPR000561; EGF-like.		
DR	InterPro; IPR000566; Lipocaln_cytfABP.		
DR	Pfam; PF00005; ABC_tran; 2.		
DR	ProDom; PD000006; ABC_transporter; 2.		
DR	PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.		
DR	PROSITE; PS00022; EGF_1; UNKNOWN_1.		
DR	PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.		
KW	Hypothetical protei.		
FT	NON_TER 1		
SQ	SEQUENCE 1529 AA; 17005 MW; BCED65F5EAACAIA CRC64;		
 Query Match 17.5%; Score 267; DB 4; Length 1529; Best Local Similarity 29.2%; Pred. No. 6.3e-14; Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;			
Qy	44	FGTRCWEG-----NPID-DTPCQ-----AGEBWTAP-V	71
Db	665	FDSMCLSEFTQGLPLSNFVPPPPSPAPSDSPAPDELDQAWNVS LPTAGPMWMTSAPS	724
Qy	72	POTIMDLFONGNWTONSPACQSSDKIKMLPVGPPAGGLPPPKONTADILQDLT	131
Db	725	PLRVREPV-----CTCSAQGTGS---CPSSVGG-HPPQMRVTVTGDI LDTIT	768
Qy	132	GRNISDYLVKYVOIIIAKS LKNKIWNFRYGGFSLGVSNQAALPPSOEVNDAIKOMKH	191
Db	769	GHNVS YLLFTSDR-----RLHRGYAITFG--NVLKSIASFCTGRAPPVVRK-	814


```
QY 192 LKLAKSSADRFNSLGRFMTGLDTRNNVKYWFNNKGWHAISSFLNINNAILRANLQKG 251
Db 815 -----IAVRRAAQVFNKGYHSMPTYLNSLNNAILRANLPLKS 852
QY 252 E-NPSHYGITAFNHPNLNTKQOLS-EVALMTTSV 283
Db 853 KGNPAAYGITTNTNHPMKNKSASLSLDYLLQGTDV 886

RESULT 9
Q9HC28 PRELIMINARY; PRT; 2436 AA.
AC Q9HC28;
DT 01-MAR-2001 (TREMBlrel. 16, Created)
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
DE ATP-binding cassette sub-family A member 2 (ABC transporter ABCA2).
GN ABCA2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=BRAIN;
RA Vulevic B., Chen Z., Davis W. Jr., Walsh E.S., Tew K.D.;
RT "Cloning and characterization of human ABCA2.";
RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.
[2]
RN SEQUENCE FROM N.A.
RP PubMed=11178988;
RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Ozcurrence M., Duong C.,
RA Bared G.M., Buchler C., Schmitz G.;
RT "Complete Coding Sequence, Promoter Region, and Genomic Structure of the Human ABCA2 Gene and Evidence for Sterol-Dependent Regulation in Macrophages.";
RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
DR EMBL; AF178941; AAG09372.1; -.
DR EMBL; AF327657; AAK14334.1; -.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transportr.
DR InterPro; IPR000561; EGF-like.
DR InterPro; IPR000572; Euk_Mb_Oxred.
DR InterPro; IPR000566; Lipocln_cytFABP.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC_transportr; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.
DR PROSITE; PS00559; MOLYBDOTERIN_EUK; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2436 AA; 269955 MW; E04A43AF14EA25D1 CRC64;

Query Match 17.5%; Score 267; DB 4; Length 2436;
Best Local Similarity 29.2%; Pred. No. 1.2e-13;
Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIP-DTPCQ-----AGEEWTAP-V 71
Db 1572 FDSMCLESTQGLPLSNFVPPSPASDPEDLQAWNVSLLPPTAGPEMWTSPSL 1631
QY 72 POTIMDLFQNGNWTMONPSAPCQSSDKIKMLPVCPCGAGLPPPPORONTADILQDIT 131
Db 1632 PRLVREPVR-----CTCSAQGTGFS---CPSSVGG-HPQMRVVTGDIITDIT 1675
QY 132 GRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNTQALPPSOEVNDAIKMKKH 191
Db 1676 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPASFGTRAPPVVRK- 1721
QY 192 LKLAKSSADRFNSLGRFMTGLDTRNNVKYWFNNKGWHAISSFLNINNAILRANLQKG 251

Query Match 17.5%; Score 267; DB 4; Length 2436;
Best Local Similarity 29.2%; Pred. No. 1.2e-13;
Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIP-DTPCQ-----AGEEWTAP-V 71
Db 1572 FDSMCLESTQGLPLSNFVPPSPASDPEDLQAWNVSLLPPTAGPEMWTSPSL 1631
QY 72 POTIMDLFQNGNWTMONPSAPCQSSDKIKMLPVCPCGAGLPPPPORONTADILQDIT 131
Db 1632 PRLVREPVR-----CTCSAQGTGFS---CPSSVGG-HPQMRVVTGDIITDIT 1675
QY 132 GRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNTQALPPSOEVNDAIKMKKH 191
Db 1676 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPASFGTRAPPVVRK- 1721
QY 192 LKLAKSSADRFNSLGRFMTGLDTRNNVKYWFNNKGWHAISSFLNINNAILRANLQKG 251
```

```
Db 1722 -----IAVRRAAQVFNKGYHSMPTYLNSLNNAILRANLPLKS 1759
QY 252 E-NPSHYGITAFNHPNLNTKQOLS-EVALMTTSV 283
Db 1760 KGNPAAYGITTNTNHPMKNKSASLSLDYLLQGTDV 1793

RESULT 10
Q96HC2 PRELIMINARY; PRT; 867 AA.
AC Q96HC2;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE 01-MAR-2002 (TREMBlrel. 20, Last annotation update)
DE Similar to KIAA1062 protein (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=EYE;
RA Strausberg R.;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC008755; AAH08755.1; -.
DR InterPro; IPR003439; ABC_transportr.
DR InterPro; IPR000561; EGF-like.
DR Pfam; PF00005; ABC_tran; 1.
DR ProDom; PD000006; ABC_transportr; 1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR NON_TER; 1.
FT NON_TER.
SQ SEQUENCE 867 AA; 96734 MW; DCF6B6A90074C085 CRC64;

Query Match 17.2%; Score 262; DB 4; Length 867;
Best Local Similarity 28.8%; Pred. No. 8e-14;
Matches 79; Conservative 35; Mismatches 74; Indels 86; Gaps 12;

QY 44 FGTRCMEG-----NPIP-DTPCQ-----AGEEWTAP-V 71
Db 3 FDSMCLESTQGLPLSNFVPPSPASDPEDLQAWNVSLLPPTAGPEMWTSPSL 62
QY 72 POTIMDLFQNGNWTMONPSAPCQSSDKIKMLPVCPCGAGLPPPPORONTADILQDIT 131
Db 63 PRLVREPVR-----CTCSAQGTGFS---CPSSVGG-HPQMRVVTGDIITDIT 106
QY 132 GRNISDYLVKTYVQIIAKSLKNIWNEFRYGGFSLGVSNTQALPPSOEVNDAIKMKKH 191
Db 107 GHNVSLEYLLFTSDRF-----RLHRYGAITFG--NVLKSIPASFGTRAPPVVRK- 152
QY 192 LKLAKSSADRFNSLGRFMTGLDTRNNVKYWFNNKGWHAISSFLNINNAILRANLQKG 251
Db 153 -----IAVRRAAQVFNKGYHSMPTYLNSLNNAILRANLPLKS 190

QY 252 E-NPSHYGITAFNHPNLNTKQOLS-EVALMTTSV 283
Db 191 KGNPAAYGITTNTNHPMKNKSASLSLDYLLQGTDV 224

RESULT 11
Q9ESR9 PRELIMINARY; PRT; 2434 AA.
AC Q9ESR9;
DT 01-MAR-2001 (TREMBlrel. 16, Created)
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
DE ABC2.
GN ABC2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
```

```
RP SEQUENCE FROM N.A.
RC TISSUE=BRAIN;
RX MEDLINE=20427713; PubMed=10570803;
RA Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T.,
RT Shioda S., Ueda K., Inagaki N.;
RT "Cloning, characterization and tissue distribution of the rat ATP-
RL binding cassette (ABC) transporter ABC2/ABCA2.";
RL Biochem. J. 350:865-872(2000).
DR EMBL: AB037937; BAB16596.1; -.
DR InterPro: IPR003593; AAA_Atpase.
DR InterPro: IPR003439; ABC_transporter.
DR InterPro: IPR000561; EGF-like.
DR InterPro: IPR000566; Lipocin_cytfABP.
DR Pfam: PF00005; ABC_tran; 2.
DR ProDom: PD000006; ABC_transporter; 2.
DR SMART: SM00382; AAA; 2.
DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.
DR PROSITE: PS00022; EGF_1; UNKNOWN_1.
DR PROSITE: PS00213; LIPICALIN; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2434 AA; 270925 MW; CD424A9C4F63513F CRC64;

Query Match 17.0%; Score 259.5; DB 11; Length 2434;
Best Local Similarity 32.3%; Pred. No. 5,2e-13;
Matches 74; Conservative 29; Mismatches 71; Indels 55; Gaps 9;

QY 58 PCOAGEEWTAP-VPTQIMDLFQNGNWTMQNPSPACQSSDKIKKMLPVCPPGAGGLPP 116
DB 1617 PTAGPETWTWAPSLPRLVHEPVR-----CTCSAQGTGFS---CPSSVGG-HP 1660

QY 117 POKQNTADILDLTGRTNSDYLKTVYQIIAKSLKKNKIVNFEFFYGGFSLGVSNTQALP 176
DB 1661 -PQMRVVTGDLITDITGHNVSEYLLFTSDRF-----RLHRYGAITFG--NIQKSI 1707

QY 177 PSQEVNDIAIKQMKHLKLAKDSSADRFNLGLRGFTGLDTRNNVKNVFNKNGHAISSFL 236
DB 1708 PAPIGTRTLPWVRK-----IAVRVAQVLYNNKGYHSMPTYL 1744

QY 237 NVINNAILRANLQGE-NPSHYGITAFAFNHPLNLTKOQLS-EVALMTTSV 283
DB 1745 NSLNNAILRANLPKSGNPAAYGITVTNHPMKNKSASLSLDYLLQGTDV 1793

RESULT 12
Q96JT3 PRELIMINARY; PRT: 2277 AA.
AC Q96JT3;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE ATP-binding cassette transporter family A member 12.
GN ABCA12.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=RETINA;
RA Bonner T.I., Moses T., Detera-Wadleigh S.;
RT "A retinal cDNA for the ATP-binding cassette transporter ABCA12.";
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AV033486; AAK54355.1; -.
DR InterPro: IPR003439; ABC_transporter.
DR InterPro: IPR003583; HHH_1.
DR Pfam: PF00005; ABC_tran; 2.
DR ProDom: PD000006; ABC_transporter; 2.
DR SMART: SM00278; HHH1; 1.
DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.
KW ATP-binding.
SQ SEQUENCE 2277 AA; 256970 MW; EDA2F00280361E2D CRC64;

Query Match 16.4%; Score 250; DB 4; Length 2277;
```

```
Best Local Similarity 26.0%; Pred. No. 3.1e-12;
Matches 75; Conservative 49; Mismatches 81; Indels 84; Gaps 14;

QY 4 YPSLELOPMWY--NEQYTFVSNDAPEDTGTLLELLNALTKDPGFGTRCMEGNPIDTPC-- 59
DB 1456 YPIQISPLSYGTSEQTAFAYNHP---STEALVSAMWDFGIDNMCINTS---DLQCLN 1509

QY 60 QAGEEETWTTAPVPTQIMDLFQNGNWTMQNPSPACQSSDKIKKMLPVCPPGAGGLPPQQR 119
DB 1510 KDSLEKWNISGEPIINFGV-----CSCSEN-----VQECP---KENYSPPHR 1548

QY 120 KQNTADILDLTGRTNSDYLKTVYQIIAKSLKKNKIVNFEF---RYGGFSLGVSNTQALP 176
DB 1549 RYSSQVYIYNLTGQRVENYLIST-----ANEFVQKRYGWSFG----- 1586

QY 177 PSQEVNDIAIKQMKHLKLAKDSSADRFNLGLRGFTGLDTRNNVKNVFNKNGHAISSFL 235
DB 1587 -----LPLTKDLRF-----ITGVPANRTLAKVWYDGYHSLPAY 1622

QY 236 LVINNAILRANLQGENSPSHYGITAFNHPNLTKOQLSEVALMTTSVD 284
DB 1623 LNSLNNFLLRVNMKYDAARH-GIIMYSHPYPGVQDQ--EQATISSLID 1668

RESULT 13
Q01790 PRELIMINARY; PRT: 1547 AA.
AC Q01790;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Hypothetical 173.7 kDa protein.
GN Fl2B6.1.
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RX MEDLINE=99069613; PubMed=9851916;
RA Waterston R.;
RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology. The C. elegans Sequencing Consortium.";
RL Science 282:2012-2018(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RA Pauley A., Maggi L.;
RT "The sequence of C. elegans cosmid Fl2B6.";
RL Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RA Waterston R.;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF001318; AAK21369.2; -.
KW Hypothetical protein.
SQ SEQUENCE 1547 AA; 173682 MW; A532D93977006C67 CRC64;

Query Match 14.1%; Score 215.5; DB 5; Length 1547;
Best Local Similarity 24.2%; Pred. No. 1.7e-09;
Matches 86; Conservative 44; Mismatches 105; Indels 121; Gaps 15;

QY 5 PSLELOPMWYNEQYTFVSN--DAPEDTGTLLELLNALTKDPGFGTRCMEG--NPIDPT--- 57
DB 605 PPLPLETISMGNSDFYVNSWDTAENSTANDILHAFSSPGTGPACAKDVPNDLLDTMR 664

QY 58 -----PCQ--AGEEWT-----TAPVPTQIMDL- 78
DB 665 ELMFRNRYGFRNKPAGVYKDSVDNEYQCNIQIOGEFYDTEDISNATYNAPIYGCEDFG 724

QY 79 ----FQNGNWTMQNPSPACQSSDKIKKMLPVCPPGAGGLPPQQRKONTADILDLTGRTN 134
```



```
Qy 117 POKONTADILDLTGRN--ISDYLKTYVQIIAKSL-----KNKIWNNEFR 161
Db 698 -----DPIFKIGVNEIPGEHYLNNYLKRVILVSLACQVGSDDCYNQSANL--SEYL 747
Qy 162 YGFSLGVS-NTQALPPS--QEVNDAIKQMKHLKAKDSSADR--FLNSLG----- 208
Db 748 YNGTAIEATLKTQAYCAGLRSTTNEIYSRVQSDL-LSSDDSTDRSLFISSLGCGSTSQL 806
Qy 209 ---RFTWGLDTRNNYKVFNNKGWHAISSEFLNVINNALIRANLOKGENPSHYGITA 261
Db 807 LDFLRSLDTRNNSL-----SYSERTSLLNSAYS-----SEIGLTA 842
```

Search completed: February 4, 2003, 09:40:17
Job time : 43 secs